<SEC-DOCUMENT>0001104659-19-060804.txt : 20191107
<SEC-HEADER>0001104659-19-060804.hdr.sgml : 20191107
<ACCEPTANCE-DATETIME>20191107065956
ACCESSION NUMBER:		0001104659-19-060804
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191107
DATE AS OF CHANGE:		20191107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		191198065

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tm1919495d1_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(Mark One) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD STYLE="text-align: justify"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>For the quarterly period ended September 30, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></TD><TD STYLE="text-align: justify"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-33357 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission file number)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>PROTALIX
BIOTHERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center; width: 50%"><B><U>Delaware</U></B></TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 50%">&nbsp;<B>__<U>65-0643773</U>__</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of incorporation or organization)</B></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Snunit Street</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Science Park</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POB 455</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Carmiel, Israel</U></B></P></TD>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>20100</U></B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>+972-4-988-9488</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>N/A</U><BR>
<FONT STYLE="font-size: 10pt">(Former name, former address and former fiscal year, if changed since last report)</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 34%; font: bold 10pt Times New Roman, Times, Serif; padding: 2pt; text-align: center; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-indent: 2pt">Title of each class</TD>
    <TD STYLE="width: 33%; font: bold 10pt Times New Roman, Times, Serif; padding: 2pt; text-align: center; border-top: Black 1pt solid; border-right: Black 1pt solid; text-indent: 2pt">Trading Symbol(s)</TD>
    <TD STYLE="width: 33%; font: bold 10pt Times New Roman, Times, Serif; padding: 2pt; text-align: center; border-top: Black 1pt solid; border-right: Black 1pt solid; text-indent: 2pt">Name of each exchange on which registered</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center; padding: 2pt; border: Black 1pt solid; text-indent: 2pt">Common stock, $0.001 par value</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding: 2pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 2pt">PLX</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding: 2pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 2pt">NYSE American</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
subject to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&sect;
232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). Yes <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT>&nbsp; No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%">Large accelerated filer</TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 25%">Accelerated filer</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Non-accelerated filer</TD>
    <TD><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD>Smaller reporting company</TD>
    <TD><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings"></FONT></FONT></TD>
    <TD>Emerging growth company</TD>
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">On November&nbsp;1, 2019, approximately 148,382,299
shares of the Registrant&rsquo;s common stock, $0.001 par value, were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 10-Q</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Page</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center"><A HREF="#a_001">PART I &ndash; FINANCIAL INFORMATION</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_002">Item&nbsp;1.</A></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_002">Financial Statements</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 6%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.475in; text-indent: -0.125in; width: 82%"><A HREF="#a_003">Condensed Consolidated Balance Sheets &ndash; As of September&nbsp;30, 2019 (Unaudited) and December&nbsp;31, 2018</A></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center"><A HREF="#a_003">1</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.475in; text-indent: -0.125in"><A HREF="#a_004">Condensed Consolidated Statements of Operations (Unaudited) &ndash; For the Nine and Three Months Ended September&nbsp;30, 2019 and 2018</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_004">2</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.475in; text-indent: -0.125in"><A HREF="#a_005">Condensed Consolidated Statements of Changes in Capital Deficiency (Unaudited) &ndash;&nbsp;For the Nine and Three Months Ended September&nbsp;30, 2019 and 2018</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_005">3</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.475in; text-indent: -0.125in"><A HREF="#a_006">Condensed Consolidated Statements of Cash Flows (Unaudited) &ndash; For the Nine Months Ended September&nbsp;30, 2019 and 2018</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_006">4</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.475in; text-indent: -0.125in"><A HREF="#a_008">Notes to Condensed Consolidated Financial Statements</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_008">6</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_009">Item&nbsp;2.</A></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_009">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_009">13</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_010">Item&nbsp;3.</A></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_010">Quantitative and Qualitative Disclosures About Market Risk</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_010">24</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_011">Item&nbsp;4.</A></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_011">Controls and Procedures</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_011">25</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center"><A HREF="#a_012">PART II &ndash; OTHER INFORMATION</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_013">Item&nbsp;1.</A></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_013">Legal Proceedings</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_013">26</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_014">Item&nbsp;1A.</A></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_014">Risk Factors</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_014">26</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_015">Item&nbsp;2.</A></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_015">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_015">26</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_016">Item&nbsp;3.</A></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_016">Defaults Upon Senior Securities</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_016">26</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_017">Item&nbsp;4.</A></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_017">Mine Safety Disclosures</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_017">26</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_018">Item&nbsp;5.</A></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_018">Other Information</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_018">26</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#a_019">Item&nbsp;6.</A></TD>
    <TD STYLE="font-size: 10pt"><A HREF="#a_019">Exhibits</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_019">26</A></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><A HREF="#a_020">Signatures</A></TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><A HREF="#a_020">29</A></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B><A NAME="a_001"></A>PART I &ndash; FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_002"></A>Item&nbsp;1. Financial Statements</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>PROTALIX BIOTHERAPEUTICS, INC.<BR>
CONDENSED CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><DIV STYLE="padding: 0in 0in 1pt; border-bottom: Black 0.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September
                                         30, <BR>
                                         2019<BR>
                                         </B>(Unaudited)</P> </DIV></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><DIV STYLE="padding: 0in 0in 1pt; border-bottom: Black 0.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>December</B></FONT><B>&nbsp;<FONT STYLE="font-size: 10pt">31,
<BR>
2018&nbsp;</FONT></B></P> </DIV></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">ASSETS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left; padding-left: 0.125in">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">21,442</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">37,808</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Accounts receivable &ndash; Trade</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,716</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,729</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Other assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,756</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,877</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 0.125in">Inventories</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,525</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8,569</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">40,439</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">52,983</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><B>NON-CURRENT ASSETS:</B></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,953</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,758</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">PROPERTY AND EQUIPMENT, NET</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,573</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,390</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">OPERATING LEASE RIGHT OF USE ASSETS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,764</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">53,729</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">61,131</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">LIABILITIES NET OF CAPITAL DEFICIENCY</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Accounts payable and accruals:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0.25in">Trade</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7,755</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5,211</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0.25in">Other</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,730</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,274</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Operating lease liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,222</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Contracts liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,612</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,868</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">33,319</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">25,353</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">LONG TERM LIABILITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Convertible notes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">50,163</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">47,966</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Contracts liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28,586</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33,027</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Liability for employee rights upon retirement</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,606</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,374</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Operating lease liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,532</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Other long term liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,372</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,292</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total long term liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">91,259</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">88,659</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">124,578</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">114,012</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">COMMITMENTS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">CAPITAL DEFICIENCY</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(70,849</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(52,881</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total liabilities net of capital deficiency</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">53,729</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">61,131</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>The accompanying notes are an
integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="a_004"></A>PROTALIX
BIOTHERAPEUTICS, INC.<BR>
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
</B>(U.S. dollars in thousands, except per share data)<BR>
</FONT>(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, <BR>
2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30, <BR>
2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, <BR>
2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30, <BR>
2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-size: 10pt; font-weight: bold; text-align: left">REVENUES FROM SELLING GOODS</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">12,086</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">7,222</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,126</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">663</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -11pt; padding-left: 11pt">REVENUES FROM LICENSE AND R&amp;D
    SERVICES</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24,848</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,665</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,122</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,672</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">COST OF GOODS SOLD</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,945</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(7,024</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,205</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,917</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -11pt; padding-left: 11pt">RESEARCH AND DEVELOPMENT EXPENSES,
    NET(1)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(35,021</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(23,755</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(10,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(10,071</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -11pt; padding-left: 11pt">SELLING, GENERAL AND ADMINISTRATIVE
    EXPENSES (2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,885</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(8,744</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,587</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,088</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">OPERATING LOSS</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(12,917</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(15,636</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,544</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,741</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">FINANCIAL EXPENSES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,877</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,824</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,050</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,811</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">FINANCIAL INCOME</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">227</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">437</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">34</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">230</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">FINANCIAL EXPENSES, NET</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,650</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,387</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,016</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,581</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS FOR THE PERIOD</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(18,567</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(21,023</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,560</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,322</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -11pt; padding-left: 11pt">NET
    LOSS PER SHARE OF COMMON STOCK-BASIC AND DILUTED</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.13</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.14</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -11pt; padding-left: 11pt">WEIGHTED
    AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN     COMPUTING LOSS PER SHARE &ndash; BASIC AND DILUTED</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">148,382,299</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">146,752,355</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">148,382,299</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">148,187,513</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">(1) Includes share-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">426</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">54</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">110</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(14</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.3in">Includes grants</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(55</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,810</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(52</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(732</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">(2) Includes share-based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">173</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">42</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">86</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">8</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B><A NAME="a_005"></A>PROTALIX BIOTHERAPEUTICS,
INC. <BR>
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN<BR>
CAPITAL DEFICIENCY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands, except per share
data)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Common</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Common</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Additional<BR> Paid&ndash;In</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Stock (1)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-size: 10pt; font-weight: bold">Balance at January&nbsp;1, 2018</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">143,728,797</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">144</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">266,495</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(296,096</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(29,457</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Changes during the nine-month period ended September&nbsp;30, 2018:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Share-based compensation related to stock options</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">80</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">80</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Share-based compensation related to restricted stock award</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">29,898</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Convertible notes conversions</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,928,907</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,289</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,291</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Convertible notes exchange</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,613,636</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,148</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,150</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss for the period</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(21,023</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(21,023</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance at September&nbsp;30, 2018</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">148,301,238</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">148</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">269,028</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(317,119</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(47,943</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Balance at January&nbsp;1, 2019</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">148,382,299</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">148</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">269,524</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(322,553</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(52,881</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Changes during the nine-month period ended September&nbsp;30, 2019:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Share-based compensation related to stock options</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">599</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">599</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss for the period</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(18,567</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(18,567</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance at September&nbsp;30, 2019</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">148,382,299</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">148</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">270,123</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(341,120</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(70,849</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Balance at June&nbsp;30, 2018</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">148,183,591</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">148</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">268,907</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(311,797</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(42,742</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Changes during the three-month period ended September&nbsp;30, 2018:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Share-based compensation related to stock options</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Convertible notes conversions</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">117,647</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">99</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">99</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss for the period</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,322</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,322</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance at September&nbsp;30, 2018</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">148,301,238</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">148</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">269,028</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(317,119</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(47,943</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">Balance at June&nbsp;30, 2019</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">148,382,299</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">148</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">269,927</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(337,560</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">(67,485</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Changes during the three-month period ended September&nbsp;30, 2019:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Share-based compensation related to stock options</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">196</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">196</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss for the period</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font:  10pt Times New Roman, Times, Serif; text-align: right">(3,560</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: normal 10pt Times New Roman, Times, Serif; text-align: right">(3,560</TD><TD STYLE="padding-bottom: 1pt; font: normal 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance at September&nbsp;30, 2019</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">148,382,299</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">148</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">270,123</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(341,120</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(70,849</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px">*</TD>
    <TD STYLE="text-align: justify">Represents an amount less than $1.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="width: 24px">(1)</TD>
    <TD STYLE="text-align: justify">Common Stock, $0.001 par value; Authorized &ndash; as of September 30, 2019 and 2018 - 350,000,000 and 250,000,000, respectively.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>PROTALIX BIOTHERAPEUTICS, INC. <BR>
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,<BR>
2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,<BR>
2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left; padding-left: 0.25in">Net loss</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(18,567</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(21,023</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Adjustments required to reconcile net loss to net cash used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0.25in">Share based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">599</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">96</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0.25in">Depreciation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,205</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,257</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Financial expenses (income), net (mainly exchange
    differences)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">371</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(37</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Changes in accrued liability for employee rights upon retirement</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">51</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(86</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Gain on amounts funded in respect of employee rights upon retirement</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(45</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Net loss in connection with conversions of convertible notes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">204</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Amortization of debt issuance costs and debt discount</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,197</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,916</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Issuance of shares for interest payment in connection with conversions of convertible notes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">205</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Increase (decrease) in contracts liability (including non-current portion)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,697</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,264</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Increase in accounts receivable and other assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,767</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,661</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Changes in right of use assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(92</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt"></FONT></TD><TD STYLE="font-size: 10pt; text-align: left"></TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Decrease (increase) in inventories</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,044</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(126</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Increase (decrease) in accounts payable and accruals</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,905</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,805</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Increase in other long term liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">80</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,103</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Net cash used in operating activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(15,671</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,738</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Purchase of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(599</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(498</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Increase in restricted deposit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(254</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(247</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Amounts funded in respect of employee rights upon retirement, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(59</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">70</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Net cash used in investing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(912</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(675</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net payment for convertible notes</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,752</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net cash used in financing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,752</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">217</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(130</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">NET DECREASE IN CASH AND CASH EQUIVALENTS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(16,366</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(9,295</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">37,808</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">51,163</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">21,442</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">41,868</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="background-color: yellow"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Continued) - 2</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">September&nbsp;30,<BR>
2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,<BR>
2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 16.2pt">Purchase of property and equipment</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">14</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">237</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 16.2pt">Convertible notes conversions</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,236</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-indent: -0.1in; padding-left: 16.2pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.25in">Interest paid</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,172</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,411</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><A NAME="a_008"></A><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD><B>General</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Protalix BioTherapeutics, Inc. (collectively
with its subsidiaries, the &ldquo;Company&rdquo;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (the &ldquo;Subsidiaries&rdquo;),
are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the
Company&rsquo;s proprietary ProCellEx<SUP>&reg;</SUP> protein expression system (&ldquo;ProCellEx&rdquo;). To date, the Company
has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American
countries and Elelyso<SUP>&reg;</SUP> in the rest of the territories) for the treatment of Gaucher disease that has been approved
for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying
stages of the clinical development process. The Company&rsquo;s strategy is to develop proprietary recombinant proteins that are
therapeutically superior to existing recombinant proteins currently marketed for the same indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The Company&rsquo;s product pipeline
currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(1) pegunigalsidase alfa, or PRX-102,
a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(2) alidornase alfa, or PRX-110,
a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">(3) OPRX-106, the Company&rsquo;s
oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as
a natural capsule for the expressed protein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The Company, together with its commercialization
partner for PRX-102, Chiesi Farmaceutici S.p.A. (&ldquo;Chiesi&rdquo;), plans to file a biologics license application (&ldquo;BLA&rdquo;)
for PRX-102 for the treatment of Fabry disease by April 2020 through the Accelerated Approval pathway of the U.S. Food
and Drug Administration (&ldquo;FDA&rdquo;). This decision is the result of a series of meetings and correspondence between the
Company and Chiesi, on the one hand, and the FDA, on the other hand. The Company and Chiesi have initiated preparations for the
BLA submission based on clinical data generated in the one-year completed phase&nbsp;I/II clinical trials of PRX-102 and from the
ongoing phase&nbsp;III BRIDGE clinical trial, as well as safety data from all on-going studies. The BLA will also include extensive
data from the Company&rsquo;s completed nonclinical program, as well as information regarding production of PRX-102.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Obtaining marketing approval with
respect to any product candidate in any country is dependent on the Company&rsquo;s ability to implement the necessary regulatory
steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">On October&nbsp;19, 2017, Protalix
Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &ldquo;Chiesi Ex-US Agreement&rdquo;) pursuant to which
Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On
July&nbsp;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &ldquo;Chiesi US Agreement&rdquo;)
with respect to the commercialization of pegunigalsidase alfa in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Under each of the Chiesi Ex-US
Agreement and the Chiesi US Agreement (collectively, the &ldquo;Chiesi Agreements&rdquo;), Chiesi made an upfront payment to
Protalix Ltd. of $25.0&nbsp;million in connection with the execution of  each agreement. In addition, under the Chiesi Ex-US
Agreement, Protalix Ltd. is entitled to additional payments of up to $25.0&nbsp;million in pegunigalsidase alfa development
costs, capped at $10.0&nbsp;million per year, and to receive additional payments of up to $320.0&nbsp;million, in the
aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix Ltd. is entitled to
payments of up to a maximum of $20.0&nbsp;million to cover development costs for pegunigalsidase alfa, subject to a maximum
of $7.5&nbsp;million per year, and to receive an additional up to a maximum of $760.0&nbsp;million, in the aggregate, in
regulatory and commercial milestone payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
</B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Under the terms of both of the Chiesi
Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions,
and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement,
Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the
United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of
15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Since its approval by the FDA, taliglucerase
alfa has been marketed by Pfizer Inc. (&ldquo;Pfizer&rdquo;) in accordance with the exclusive license and supply agreement entered
into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and
Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement,
pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization
of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights
to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of
expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">On June&nbsp;18, 2013, the Company
entered into a Supply and Technology Transfer Agreement (the &ldquo;Brazil Agreement&rdquo;) with Funda&ccedil;&atilde;o Oswaldo
Cruz (&ldquo;Fiocruz&rdquo;), an arm of the Brazilian Ministry of Health (the &ldquo;Brazilian MoH&rdquo;), for taliglucerase alfa.
Fiocruz&rsquo;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and,
accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is,
at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated
with alfataliglicerase in Brazil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><I>Going Concern</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">Since the Company is engaged
in research and development activities, it has not derived significant income from its activities and has incurred
accumulated losses in the amount of $341.0&nbsp;million through September&nbsp;30, 2019 and cash outflows from operating
activities. As of September&nbsp;30, 2019, the Company has outstanding $57.9&nbsp;million aggregate principal amount of its
7.50% convertible promissory notes due 2021 (the &ldquo;2021 Notes&rdquo;) which are secured with a perfected lien on all of
the Company&rsquo;s assets. Under the terms of the indenture governing the 2021 Notes, the Company is required to maintain a
minimum cash balance of at least $7.5&nbsp;million. As of September 30, 2019, the Company had cash and cash equivalents of
$21.4&nbsp;million. Based on its current cash resources and commitments, the Company may not be able to meet its current
planned development activities and the corresponding level of expenditures for the next 12 months from the date of approval
of the financial statements as of September&nbsp;30, 2019 absent a refinancing or restructuring. These factors raise
substantial doubt as to the Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The Company&rsquo;s management is
in the process of evaluating refinancing and restructuring alternatives, including a restructuring of its outstanding convertible
notes, and related transactions. However, there is no certainty about the Company&rsquo;s ability to obtain such funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The financial information has been
prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities
in the normal course of business. If the Company does not complete a refinancing or restructuring, it will need to curtail or cease
operations. These financial statements do not include any adjustments that may be necessary should the Company be unable to continue
as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
</B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD STYLE="padding-right: 81.35pt"><B>Basis of presentation</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States (&ldquo;GAAP&rdquo;) for interim financial information. Accordingly, they do not include all of the information and notes
required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature)
considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results
for the interim period are not necessarily indicative of the results that may be expected for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">These unaudited condensed consolidated financial statements
should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year
ended December&nbsp;31, 2018, filed by the Company with the U.S Securities and Exchange Commission (the &ldquo;Commission&rdquo;).
The comparative balance sheet at December&nbsp;31, 2018 has been derived from the audited financial statements at that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>c.</B></TD><TD STYLE="padding-right: 81.35pt"><B>Net loss per share</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Basic and diluted
loss per share (&ldquo;LPS&rdquo;) are computed by dividing net loss by the weighted average number of shares of the Company&rsquo;s
common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), outstanding for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The calculation
of diluted LPS does not include 73,310,911 and 78,269,464 shares of Common Stock underlying outstanding options and restricted
shares of Common Stock and shares issuable upon conversion of outstanding convertible notes for the nine months ended September<FONT STYLE="font-size: 10pt">&nbsp;</FONT>30,
2018 and 2019, respectively, and 73,280,977 and 78,547,287 shares of Common Stock for the three months ended September&nbsp;30,
2018 and 2019, respectively, because the effect would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>d.</B></TD><TD STYLE="padding-right: 81.35pt"><B>Recently adopted standards </B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In February 2016, the Financial Accounting Standards
Board (&ldquo;FASB&rdquo;) issued ASU No. 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting,
Leases (Topic 840). The new standard requires a lessee to record assets and liabilities on its balance sheet for all leases with
terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern
of expense recognition in the lessee&rsquo;s income statement. The Company adopted this standard as of January&nbsp;1, 2019 on
a modified retrospective basis and will not restate comparative periods. The Company elected the package of practical expedients
permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the
historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months
or less off of its balance sheet. The Company recognized those lease payments in its statements of operations on a straight-line
basis over the lease period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">As of the adoption date, the Company recognized an
operating lease asset and liability of $5.9&nbsp;million and $5.7&nbsp;million, respectively, as of January&nbsp;1, 2019 on its
balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
</B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>e.</B></TD><TD STYLE="padding-right: 81.35pt"><B>Newly issued accounting pronouncements</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In June 2018, the FASB issued ASU 2018-07, &ldquo;Compensation
 &ndash; Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting&rdquo; that expands the scope
of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should
apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in ASU 2018-07. The guidance
is effective for fiscal years beginning after December&nbsp;15, 2018, including interim reporting periods within that fiscal year.
Early adoption is permitted, but no earlier than an entity&rsquo;s adoption date of Topic 606. The Company does not expect the
adoption of ASU 2018-07 to have a material impact on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 - INVENTORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Inventories at September<FONT STYLE="font-size: 10pt">&nbsp;</FONT>30, 2019 and December&nbsp;31, 2018 consisted of the following:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">(<I>U.S. dollars in thousands)</I></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left">Raw materials</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">3,691</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">3,792</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Work in progress</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">233</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,601</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,777</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total inventory</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,525</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,569</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>During the year ended December&nbsp;31, 2018 and the nine months ended September<FONT STYLE="font-size: 10pt">&nbsp;</FONT>30,
2019, the Company recorded approximately $1.1&nbsp;million and $29,000, respectively, for write-down of inventory under cost of
goods sold.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 &ndash; FAIR VALUE MEASUREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The Company measures fair value and discloses fair
value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale
of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The accounting standard establishes a fair value
hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 1: Quoted prices (unadjusted) in active markets
that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level
1 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 2: Observable prices that are based on inputs
not quoted on active markets, but corroborated by market data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 3: Unobservable inputs are used when little
or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">In determining fair value, the Company utilizes
valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible
and considers counterparty credit risk in its assessment of fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The fair value of the financial instruments included
in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible
notes derivative is based on Level 3 measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 3 &ndash; FAIR VALUE MEASUREMENT</B>
<FONT STYLE="font-family: Times New Roman, Times, Serif">(continued)<B>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The fair value of the $57.9&nbsp;million aggregate
principal amount of the <FONT STYLE="font-family: Times New Roman, Times, Serif">Company&rsquo;s outstanding 2021 Notes </FONT>as
of September<FONT STYLE="font-size: 10pt">&nbsp;</FONT>30, 2019 is approximately $57.7&nbsp;million based on a Level 3 measurement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company prepared a valuation of the fair value of the Company&rsquo;s outstanding 2021 Notes (a Level 3 valuation) as of September</FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">30,
2019. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the
Income Approach. The following parameters were used:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-right: 0">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">2021 Notes</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; font-size: 10pt; text-align: left">Stock price (USD)</TD><TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">0.21</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Expected term</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">2.13<FONT STYLE="color: White"></FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Risk free rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">1.62%</TD><TD STYLE="font-size: 10pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Volatility</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">74.99%</TD><TD STYLE="font-size: 10pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Yield</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">10.53%</TD><TD STYLE="font-size: 10pt; text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 4 &ndash; OPERATING LEASES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company is a party to a number of lease agreements
for its facilities, the latest of which has been extended until the end of 2021. The Company has the option to extend certain of
such agreements on two additional occasions for additional five-year periods each for a total of 10 additional years. During the
extended lease period, the aggregate monthly rental payments will increase by 7.5% - 10% for each option. The Company expects to
exercise these options in future periods. As of September<FONT STYLE="font-size: 10pt">&nbsp;</FONT>30, 2019, the Company provided
bank guarantees of approximately $437,000 in the aggregate, to secure the fulfillment of its obligations under the lease agreements.
As of December&nbsp;31, 2018, the future minimum lease payments required under the operating leases for such premises are approximately
$758,000, $758,000 and $621,000, for fiscal years 2019 through 2021, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company entered into several three-year leases
for vehicles which are regularly amended as new vehicles are leased. As of December&nbsp;31, 2018, the future minimum lease payments
for the years ending December&nbsp;31, 2019, 2020 and 2021 are approximately $474,000, $333,000 and $82,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following table sets forth data regarding
the Company&rsquo;s operating leases for the nine  and three months ended September<FONT STYLE="font-size: 10pt">&nbsp;</FONT>30,
2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-right: 0.5in; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Nine Months<BR>
 Ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Three Months<BR>
 Ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">(<I>U.S. dollars in thousands)</I></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30, 2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 62%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Operating lease costs</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"></TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">907</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">314</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for amounts included in the measurement of
    lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">999</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">337</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Right of use assets obtained in exchange for new
    operating lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">282</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">55</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following table sets forth data regarding the
Company&rsquo;s operating leases as of September<FONT STYLE="font-size: 10pt">&nbsp;</FONT>30, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 65%; font: 10pt Times New Roman, Times, Serif; margin-right: 0.5in; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt"></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,<BR>
 2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted average remaining lease term (in
    years)</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10.6</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Weighted average discount rate</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">12.55</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 4 - OPERATING LEASES</B> (continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following table sets forth a maturity analysis
of the Company&rsquo;s operating lease liabilities as of September<FONT STYLE="font-size: 10pt">&nbsp;</FONT>30, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">(<I>U.S. dollars in thousands)</I></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September 30, <BR>
2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font-size: 10pt; padding-left: 0.14in; text-indent: -0.14in">2019 (excluding the nine months ended &nbsp;September<FONT STYLE="font-size: 10pt">&nbsp;</FONT>30, 2019)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 25%; font-size: 10pt; text-align: right">300</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,128</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">949</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">2022</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">826</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">2023</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">803</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">After 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,656</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total undiscounted cash flows</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">10,662</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Less: imputed interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,908</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,754</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 5 &ndash; REVENUES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The following table summarizes the
Company&rsquo;s disaggregation of revenues:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-right: 0.5in; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-style: italic">(U.S. dollars in thousands)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 62%; font-size: 10pt">Pfizer</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">4,701</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">4,649</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Brazil</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">7,385</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,573</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total revenues from selling goods</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">12,086</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,222</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Revenues from license and R&amp;D services</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">24,848</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font:  10pt Times New Roman, Times, Serif; text-align: right">16,665</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The following table sets forth data
regarding the Company&rsquo;s contracts liability:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-right: 0.5in; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-style: italic; padding-bottom: 1pt">(U.S. dollars in thousands)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 62%; font-size: 10pt; text-align: left">Contracts liability at the beginning of the period</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">42,895</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">25,015</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Additions during the period </TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">22,151</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">34,929</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Revenue recognized during the period </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(24,848</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16,665</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Contracts liability at the end of the period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">40,198</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">43,279</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">The following table represents the
Company&rsquo;s unsatisfied performance obligation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-right: 0.5in; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">September&nbsp;30,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-style: italic; padding-bottom: 1pt">(U.S. dollars in thousands)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; width: 62%; padding-bottom: 2.5pt">Unsatisfied performance obligation</TD><TD STYLE="font-size: 10pt; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-size: 10pt; text-align: right; width: 12%; border-bottom: Black 2.5pt double">50,584</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-size: 10pt; text-align: right; width: 12%; border-bottom: Black 2.5pt double">76,969</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 6 - STOCK TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In September 2019, the Company granted to its new
chief financial officer 10-year options to purchase, in the aggregate, 800,000 shares of Common Stock under the Company&rsquo;s
2006 Employee Stock Incentive Plan, as amended (the &ldquo;Plan&rdquo;). The options have an exercise price equal to $0.2 per share
and vest over a four-year period in 16 equal quarterly increments. Vesting of the options is subject to acceleration in full upon
a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms
and conditions. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing
model to be approximately $97,000 based on the following weighted average assumptions: share price equal to $0.2; dividend yield
of 0% for all years; expected volatility of 66.48%; risk-free interest rates of 1.695%; and expected life of six years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>NOTE 7 &ndash; SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">On October 16, 2019, the Company received total proceeds
of approximately $2.6&nbsp;million from expense reimbursements in relation to its collaboration with Chiesi and on October 18,
2019, the Company received total proceeds of approximately $3.2&nbsp;million from sales of alfataliglicerase to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In accordance with ASC 855 &ldquo;Subsequent Events&rdquo;
the Company evaluated subsequent events through the date the condensed consolidated financial statements were issued. The Company
concluded that no other subsequent events have occurred that would require recognition or disclosure in the condensed consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><A NAME="a_009"></A><B>Item&nbsp;2. Management&rsquo;s Discussion and Analysis of
Financial Condition and Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>You should read the following discussion
and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial
statements and the related notes included elsewhere in this Form 10-Q and in our Annual Report on Form 10-K for the year ended
December</I>&nbsp;<I>31, 2018. Some of the information contained in this discussion and analysis, particularly with respect to
our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange
Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the
terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;can,&rdquo; &ldquo;continue,&rdquo;
 &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
 &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and words or phrases of similar import, as
they relate to our company or our management, are intended to identify forward-looking statements. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are only predictions and reflect our views as of the date they are made with respect to future events and financial
performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking
statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated
events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties
that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements
as a result of several factors including those set forth under &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for
the year ended December 31, 2018 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of the risks and uncertainties include, but are not
limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the risk that the FDA will not accept an application for Accelerated Approval of PRX-102 with the data generated to date
or will request additional data or other conditions of our submission, or that the FDA, the European Medicines Agency, or the EMA,
or other foreign regulatory authorities may not accept or approve a marketing application we file for any of our other product
candidates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>risks related to our ability to identify and complete strategic alternatives on attractive terms or at all within the time
period required to regain compliance with the continued listing standards of the NYSE American LLC, or the NYSE American, or to
otherwise maintain compliance with its continued listing standards;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>risks related to our ability to continue as a going concern absent a strategic transaction, refinancing or restructuring;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our
product candidates will not have the desired effects or will have undesirable side effects or other unexpected characteristics;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>risks relating to our ability to manage our relationship with our collaborators, distributors or partners;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>risks relating to our ability to make required payments under our outstanding convertible notes or any other indebtedness;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>our dependence on performance by third-party providers of services and supplies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the impact of development of competing therapies and/or technologies by other companies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>risks related to our supply of drug product to Pfizer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>risks related to our expectations with respect to the commercial value of our product and product candidates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>potential product liability risks, and risks of securing adequate levels of related insurance coverage; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the possibility of infringing a third-party&rsquo;s patents or other intellectual property rights and the uncertainty of
obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production and commercialization of improved
recombinant therapeutic proteins produced by its proprietary ProCellEx<SUP>&reg;</SUP> plant cell-based protein expression system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
We have recently undertaken many key transformational steps to strengthen the company and position our company to reemerge as a
leading Israeli pharmaceutical company including the appointment of Dror Bashan as President and Chief Executive Officer and Eyal
Rubin as Sr. Vice President and Chief Financial Officer. In addition, in August 2019, Zeev Bronfeld, a long-time member of our
Board of Directors and successful life sciences executive and investor, was elected as the new Chairman of the Board. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Our new management team has laid out the following key objectives for 2019-2021: improving our
capital structure, pursuing strategic partnerships and alliances, actively moving our pipeline towards commercialization
and performing a strategic and scientific review of our technology and assets with the goal of forming a research and
development plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Elelyso<SUP>&reg;</SUP> (taliglucerase alfa), our first commercial product for the treatment of Gaucher disease, was the first
plant cell derived recombinant protein therapeutic approved by major regulatory authorities, including the FDA and the EMA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pegunigalsidase alfa (PRX-102), our most advanced pipeline drug candidate, is produced through our ProCellEx technology and is
under development as a treatment for Fabry disease. We are currently running three phase&nbsp;III clinical trials and </FONT>we,
together with Chiesi, plan the submission of a BLA for PRX-102 via the FDA&rsquo;s Accelerated Approval pathway by April 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On July&nbsp;29, 2019, we appointed Eyal Rubin as our Senior Vice President and Chief Financial Officer, effective September&nbsp;22,
2019. Mr. Rubin is an experienced healthcare finance professional with over 20 years of diverse leadership experience including
his most recent role as Executive Vice President and Chief Financial Officer of BrainStorm Cell Therapeutics, Inc., a publicly
traded biotechnology company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On August&nbsp;13, 2019, we announced that our Board of Directors unanimously elected Zeev Bronfeld, a current independent director,
as Chairman of the Board. Mr. Bronfeld is one of the earliest investors in our company and has deep experience in the management
of biotechnology and life science companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On August&nbsp;22, 2019, we announced that we have engaged a first-tier financial advisory firm to assist us in evaluating
and pursuing strategic alternatives to maximize stakeholder value through financings and partnerships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On August&nbsp;30, 2019, we announced that we received a deficiency letter from NYSE American LLC stating that we are not in compliance
with the continued listing standards as set forth in Section 1003(a)(i)-(iii) of the NYSE American Company Guide as we have reported
a stockholders&rsquo; equity deficiency as of June&nbsp;30, 2019 and net losses in our five most recent fiscal years ended December&nbsp;31,
2018. The letter has no immediate effect on the listing of our common stock on the NYSE American. Subsequently, in accordance
with the NYSE American Company Guide, we submitted to the NYSE American a plan to regain compliance with the continued listing
standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On September&nbsp;24, 2019, we and Chiesi announced the completion of enrollment in the BALANCE study, one of our three Phase&nbsp;III
clinical trials of PRX-102 for the treatment of Fabry disease. The head-to-head Phase&nbsp;III BALANCE clinical study is designed
to evaluate the safety and efficacy of PRX-102 compared to agalsidase beta (Fabrazyme<SUP>&reg;</SUP>) on renal function in Fabry
patients with progressing kidney disease previously treated with agalsidase beta. To date, more than 66 patients are being treated
in our various extension studies after opting to continue treatment with PRX-102 after completion of an original study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On October&nbsp;17, 2019, we announced positive 12-month interim data from the first 16 out of the 22 adult patients (9 males and
7 females) enrolled in the BRIDGE Phase&nbsp;III open label switch-over study of PRX-102 for the treatment of Fabry disease. The
12 months on-treatment interim data demonstrate a mean improvement in kidney function, in both male and female patients, when switched
from agalsidase alfa (Replagal<SUP>&reg;</SUP>) to PRX-102, and will help to support the expected FDA BLA filing under Accelerated
Approval. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>ProCellEx: Our Proprietary Protein Expression
System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>ProCellEx is our proprietary platform used to produce proteins through plant cell cultures, which allows for unique advantages
in the areas of intellectual property, manufacturing enhancements and product candidate characteristics with reduced risks for
viral contaminations from mammalian components.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression. Our ProCellEx
platform uses flexible polyethylene disposable bioreactors and is optimized for plant cell cultures. As opposed to the large stainless-steel
bioreactors commonly used for recombinant protein production, our ProCellEx bioreactors are easy to use and maintain and allow
for the major advantage of rapid horizontal scale-up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Plant Cell Production Advantages Versus
Mammalian Cell Production</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="tm1919495d1_10qimg001.jpg" ALT="" STYLE="width: 830px"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="tm1919495d1_10qimg002.jpg" ALT="" STYLE="width: 830px"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry
Disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">PRX-102 is our proprietary, investigational,
plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant alpha-Galactosidase-A protein
under development for the treatment of Fabry disease. Fabry disease is an X-linked inherited disease that results from deficient
activity of the lysosomal enzyme alpha galactosidase A resulting in progressive accumulation of abnormal deposits of a fatty substance
called globotriaosylceramide (Gb3) in blood vessel walls throughout a person&rsquo;s body. Fabry disease occurs in one person per
40,000. Fabry patients inherit a deficiency of the enzyme alpha-galactosidase-A, which is normally responsible for the breakdown
of Gb3. The abnormal storage of Gb3 increases with time and, accordingly, Gb3 accumulates, primarily in the blood and in the blood
vessel walls. The ultimate consequences of Gb3 deposition range from episodes of pain and impaired peripheral sensation to end-organ
failure &ndash; particularly of the kidneys, but also of the heart and the cerebrovascular system. Global sales of Fabry treatments
exceeded $1.4&nbsp;billion in 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We, together with Chiesi, plan the submission of a BLA for PRX 102 by April 2020 through the FDA's Accelerated Approval pathway. This decision is the result of a series of
meetings and correspondence between our company and Chiesi, on the one hand, and the FDA, on the other hand. We and Chiesi have
initiated preparations for the BLA submission based on clinical data generated in the one-year completed phase&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">I/II
clinical trials of PRX-102 </FONT>and from the ongoing phase&nbsp;III BRIDGE clinical trial, as well as safety data from all on-going
studies<FONT STYLE="font-family: Times New Roman, Times, Serif">. </FONT>The BLA will also include extensive data from our
completed nonclinical program, as well as information regarding production of PRX-102.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2017, the European Commission granted Orphan Drug
Designation for <FONT STYLE="font-family: Times New Roman, Times, Serif">PRX-102</FONT> for the treatment of Fabry disease. Orphan
Drug Designation for <FONT STYLE="font-family: Times New Roman, Times, Serif">PRX-102</FONT> qualifies Chiesi for access to a centralized
marketing authorization procedure, including applications for inspections and for protocol assistance. If the orphan drug designation
is maintained at the time <FONT STYLE="font-family: Times New Roman, Times, Serif">PRX-102</FONT> is approved for marketing in
the European Union, if at all, we expect that <FONT STYLE="font-family: Times New Roman, Times, Serif">PRX-102</FONT> will benefit
from 10 years of market exclusivity within the European Union. The market exclusivity will not have any effect on Fabry disease
treatments already approved at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In January 2018, the FDA granted Fast
Track designation to PRX-102. Fast Track designation is a process designed to facilitate the development and expedite the review
of drugs and vaccines for serious conditions that fill an unmet medical need.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B><I>Key Trials and Design</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our phase&nbsp;III clinical program of PRX-102 of the treatment
of Fabry disease includes three individual studies; the BALANCE, BRIDGE and BRIGHT studies. In 2015, we completed a phase&nbsp;I/II
clinical trial of PRX-102. In the phase III clinical program, we are studying two alternative dosing regimens for PRX-102 with
the potential for improved efficacy and lower treatment burden versus existing treatments. The 1 mg/kg every two-weeks regimen
offers the potential for superior enzyme replacement therapy while the 2 mg/kg every four weeks regimen offers the potential for
better quality of life. Enrolment has been completed in each of the BALANCE, BRIDGE and BRIGHT studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Phase I/II Study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our phase&nbsp;I/II clinical trial of PRX<FONT STYLE="color: #333333">-</FONT>102,
which we completed in 2015, was a worldwide, multi-center, open label, dose ranging study to evaluate the safety, tolerability,
pharmacokinetics, immunogenicity and efficacy parameters of PRX<FONT STYLE="color: #333333">-</FONT>102 in adult Fabry patients.
Sixteen adult naive Fabry patients (9 male and 7 female) completed the trial, each in one of three dosing groups, 0.2 mg/kg, 1mg/kg
and 2mg/kg. Each patient received intravenous infusions of PRX<FONT STYLE="color: #333333">-</FONT>102 every two weeks for 12 weeks,
with efficacy follow-up after six-month and twelve-month periods. All patients that completed the trial opted to continue to receive
1 mg/kg of PRX<FONT STYLE="color: #333333">-</FONT>102 in an open-label, 60-month extension study under which all patients have
been switched to receive 1 mg/kg of the drug, the selected dose for our phase<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT>III
studies of PRX<FONT STYLE="color: #333333">-</FONT>102.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The data set forth below was recorded at 24 months from 11 patients
enrolled and treated in the long-term open-label extension trial. Patients who did not continue in the extension trial included
female patients who became or planned to become pregnant, and therefore were unable to continue in accordance with the study protocol,
and patients that relocated to a location where treatment was not available under the clinical study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lyso Gb3 levels decreased approximately 90% from baseline.
Renal function remained stable with mean eGRF levels of 108.02 and 107.20 at baseline and 24 months, respectively with a
modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and
frequency of abdominal pain and frequency of diarrhea, were noted. Cardiac parameters, including LVM, LVMI and EF, remained
stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown
as measured by the Mainz Severity Score Index (MSSI), a score compiling the different elements of the disease severity
including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the
individual parameters of the MSSI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The majority of adverse events were mild to moderate in severity,
and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed anti-drug antibodies
(ADA), of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative
for all three of these patients following 12&nbsp;months of treatment. The ADA positivity effect had no observed impact on the
safety, efficacy or continuous biomarker reduction of PRX-102.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>BALANCE Study </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The BALANCE Study is a
24-month, randomized, double blind, active control study of PRX-102 in Fabry disease patients with impaired renal function. Patients
previously treated with agalsidase beta for approximately one year and on a stable dose for at least six months were screened and
then randomized to be switched and treated with 1 mg/kg of PRX-102 or continue treatment with 1mg/kg of agalsidase beta. Patients
receive intravenous infusions of 1mg/kg administered every two weeks. Patients are randomized in a 2:1 ratio to PRX-102 or agalsidase
beta. In the study, randomization is being stratified by urinary protein to creatinine ratio (UPCR) of &lt; or &ge; 1 g/g by spot
urine sample. No more than 50% of the patients enrolled in the study are female. Patients participating in the study are being
evaluated to, among other disease parameters, determine if their renal function continues to deteriorate at the same rate while
being treated with agalsidase beta as measured by eGFR slope. Cardiac assessment, Lyso-Gb3, pain, quality of life, immunogenicity,
clinical events and pharmacokinetic and other parameters are also being evaluated. In addition, participating patients are being
evaluated to assess the safety and tolerability of PRX-102.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The primary endpoint for the BALANCE study, which was agreed
with both the FDA and the EMA, is the comparison in the rate of decline of eGFR slope between <FONT STYLE="color: #333333; background-color: white">agalsidase
beta</FONT> and PRX<FONT STYLE="color: #333333; background-color: white">-</FONT>102. At 12 months, we intend to conduct an interim
analysis to test for non-inferiority to support an anticipated regulatory filing with the EMA. At the same time, we intend to approach
the FDA to request its review of the then totality of data. Notwithstanding, patients enrolled in the study will continue to be
treated for a total of 24 months, at which point the data will be analyzed to test for superiority, which is the original guidance
we received from the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>BRIDGE Study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">The
BRIDGE study is an open label switch-over study evaluating the safety and efficacy of <FONT STYLE="background-color: white">PRX-102</FONT>,
1 mg/kg infused every two weeks, in up to 22 Fabry patients currently treated with agalsidase alfa for at least two years and
on a stable dose for at least six months. Patients are screened and evaluated over three months while continuing agalsidase alfa
treatment. Following the screening period, each patient was enrolled and switched from <FONT STYLE="background-color: white">agalsidase
alfa</FONT> treatment to receive intravenous (IV) infusions of <FONT STYLE="background-color: white">PRX-102</FONT> 1 mg/kg every
two weeks for 12 months. Patients have the option to receive <FONT STYLE="background-color: white">PRX-102</FONT> infusions in
a home care setting based on infusion tolerability and country regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">An
interim analysis of the BRIDGE study will be used to support the expected BLA filing under Accelerated Approval, and we anticipate
that the final analysis will be used to support a marketing authorization application (MAA) with the EMA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">The
12-month interim data from the first 16 of 22 adult patients enrolled (9 males and 7 females) demonstrated a mean improvement
in kidney function, in both male and female patients, when switched from agalsidase alfa to <FONT STYLE="background-color: white">PRX-102</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">One
hundred percent of the progressing patients, those with an estimated Glomerular Filtration Rate (eGFR) slope between -5 and -3
mL/min/1.73 m<SUP>2</SUP>/year, and 66.7% in the fast progressing group, with an eGFR slope &lt; -5 mL/min/1.73 m<SUP>2</SUP>/year,
achieved the proposed therapeutic goals (eGFR slope &ge; -3 mL/min/1.73 m<SUP>2</SUP>/year for progressing patients, and &ge;
-5 mL/min/1.73m<SUP>2</SUP>/year or more than 50% decrease in progression for fast progressing patients) after switching to <FONT STYLE="background-color: white">PRX-102</FONT>.
The majority of the patients who completed the study rolled over to a long-term extension study, continuing to be treated with
<FONT STYLE="background-color: white">PRX-102</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">In
the study, after one year, the mean annualized eGFR slope improved from -5.10 mL/min/1.73m<SUP>2</SUP>/year while on agalsidase
alfa to -0.23 mL/min/1.73m<SUP>2</SUP>/year on <FONT STYLE="background-color: white">PRX-102</FONT>. Baseline characteristics
of these patients, ages 27 to 60 years, were: mean eGFR 75.45 in males and 85.78 mL/min/1.73m<SUP>2</SUP> in females, annualized
pre-switching eGFR slope was -5.04 and -5.18 mL/min/1.73m<SUP>2</SUP>/year, in males and females respectively, mean residual leucocytes
enzymatic activity 5.9% of lab normal mean in males and 27.9% in females, and plasma lyso-Gb3 mean levels 53.6 and 13.8 nM, in
males and females, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black; background-color: white">PRX-102
</FONT><FONT STYLE="color: Black">was found to be well tolerated in the study, with all adverse events being transient in nature
without sequelae. Most of the patients who were eligible for home care therapy per country regulation were treated under a home
care arrangement in which certain of the scheduled infusions were performed at the patients&rsquo; home.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="color: Black"><B><I>BRIGHT
Study </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">The
BRIGHT study is a 12 month, open-label switchover study to assess the safety, efficacy and pharmacokinetics (PK) of <FONT STYLE="background-color: white">PRX-102
</FONT>2 mg/kg administered every 4 weeks in up to 30 Fabry patients previously treated with an enzyme replacement therapy (ERT):
agalsidase alfa or agalsidase beta. To determine eligibility for participation in the study, candidates were screened to identify
and select Fabry patients with stable kidney disease. Patients that matched the criteria were enrolled in the study and switched
from their current treatment of intravenous (IV) infusions every 2 weeks to 2 mg/kg of PRX-102 every 4 weeks for 12 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">Patients
participating in the study were evaluated to, among other disease parameters, determine if their kidney disease has not further
deteriorated while being treated with the four-week dosing regimen as measured by eGFR and Lyso Gb3, as well as other parameters.
In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><FONT STYLE="color: Black">To
date, substantially all patients that were enrolled in the BRIGHT study remain on the 4-week dosing regimen, and all of the patients
that completed the study opted, with the advice of the treating physician, to continue treatment under the 4-week dosing regimen
in a long-term extension study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #333333"><B><I>Commercialization
Agreements with Chiesi Farmaceutici</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
October</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">19, 2017, Protalix Ltd. and Chiesi entered into the
Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to
commercialize </FONT><FONT STYLE="color: #333333">PRX-102</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">. Under
the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
in connection with the execution of the agreement and Protalix Ltd. is entitled to additional payments of up to $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
in development costs in the aggregate, capped at $10.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
per year. Protalix Ltd. is also eligible to receive an additional up to a maximum of $320.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million,
in the aggregate, in regulatory and commercial milestone payments. Protalix Ltd. agreed to manufacture all of the PRX</FONT><FONT STYLE="color: #333333">-</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">102
needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase </FONT><FONT STYLE="color: #333333">PRX-102</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">from Protalix Ltd., subject to certain terms and conditions. Chiesi is
required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for
the supply of </FONT><FONT STYLE="color: #333333">PRX-102</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
July</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">23, 2018, Protalix Ltd. entered into the Chiesi US Agreement
with respect to the development and commercialization of </FONT><FONT STYLE="color: #333333">PRX-102</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">in
the United States. Protalix Ltd. is entitled to an upfront, non-refundable, non-creditable payment of $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
from Chiesi and additional payments of up to a maximum of $20.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million,
in the aggregate, to cover development costs for </FONT><FONT STYLE="color: #333333">PRX-102</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
subject to a maximum of $7.5</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million per year. Protalix Ltd.
is also eligible to receive an additional up to a maximum of $760.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million,
in the aggregate, in regulatory and commercial milestone payments. Chiesi will also make tiered payments of 15% to 40% of its net
sales under the Chiesi US Agreement to Protalix Ltd., depending on the amount of annual sales, subject to certain terms and conditions,
as consideration for product supply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Elelyso<SUP>&reg;</SUP> for the Treatment of Gaucher Disease
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elelyso (taliglucerase alfa), our first commercial product,
was approved by the FDA in 2012 for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients
with a confirmed diagnosis of type&nbsp;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric
patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease
and is now approved in over 20 markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gaucher disease is a $1.5&nbsp;billion global annual therapeutic
market that includes Sanofi&rsquo;s Cerezyme<SUP>&reg;</SUP>, Shire&rsquo;s (acquired by Takeda Pharmaceutical Company Limited)
Vpriv<SUP>&reg;</SUP> and Sanofi&rsquo;s Cerdelga<SUP>&reg;</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><I>Commercialization Agreements for Elelyso</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have licensed to Pfizer the global rights to Elelyso in all
markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs. We manufacture drug substance for
Pfizer, subject to certain terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the first 10-year period after the execution of our Amended
Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right
to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We maintain distribution rights to Elelyso in Brazil (marketed
as alfataliglicerase) through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian Ministry of Health.
Sales of alfataliglicerase in Brazil are expected to be $9.1&nbsp;million for 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>OPRX-106 for the Treatment of Inflammatory Bowel Disease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OPRX-106 is a plant cell-expressed recombinant human tumor necrosis
factor receptor II fused to an IgG1 Fc domain (TNFRII-Fc), for inhibiting TNF alpha. It is in development for oral administration.
When administered orally and while passing through the digestive tract, the plant cells function as a natural delivery vehicle,
having the unique attribute of a cellulose cell wall, which makes them resistant to degradation compared to proteins produced via
mammalian cell expression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Through oral administration, OPRX-106 is designed to work locally
in the gut, avoiding the systemic exposure that occurs when TNF alpha inhibitors are administered by injection or intravenous infusion.
Oral administration may potentially lead to a safer to use anti-TNF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OPRX-106 may also be less immunogenic which can potentially
result in longer-term efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that our oral delivery mechanism can potentially
prove to be a safer and more convenient method of protein administration and could be applied to additional proteins in certain
indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Alidornase Alfa (PRX-110)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alidornase alfa (PRX-110) is a proprietary
plant cell-expressed recombinant form of human deoxyribonuclease I (DNase&nbsp;I). In cystic fibrosis (CF) patients, the
accumulation of sputum in the lungs  exposes them to recurrent infections and compromises lung function. DNase
I therapy, or dornase alfa, is generally recommended for CF patients to improve lung function and reduce exacerbations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">However, DNase&nbsp;I activity is compromised by actin, a globular
multi-functional protein, found in high concentration in the sputum of CF patients, that is a potent inhibitor of DNase&nbsp;I.
As such, we believe that actin may decrease the enzyme&rsquo;s DNA degradation activity and potentially interfere with the effectiveness
of inhaled DNase I in the lungs of CF patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to reduce the actin-DNase&nbsp;I interaction and the
subsequent inhibition of DNase&nbsp;I activity by actin, we developed alidornase alfa by chemically modifying the enzyme forming
an actin inhibition resistant DNase I. This novel treatment candidate may result in improved lung function and decreased incidence
of recurrent infections in patients. Thus, we believe there is the potential that our recombinant form of the enzyme will demonstrate
significantly enhanced efficacy. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Intellectual Property 2019</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A key element of our overall strategy is to establish a broad
portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use.
We hold a broad portfolio of more than 75 patents in Europe, the United States, Israel and additional countries worldwide, as well
as more than 20 pending patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">During 2019, patents were granted in Canada,
India and the United States for the patent family named &ldquo;Large Scale Disposable Bioreactor,&rdquo; adding these to the 11
previously granted patents in this family. Patents were also granted in India and the United States for the patent family named
 &ldquo;Stabilized Alpha-Galactosidase and Uses Thereof&rdquo; adding these to the 18 previously granted patents in this family.
Another patent was granted in the United States for the patent family named &ldquo;Nucleic acid construct for expression of Alpha-Galactosidase
in plants and plant cells,&rdquo; adding these to the seven previously granted patents in this family. In addition, national phase filings
were performed in certain countries worldwide for the patent family named &ldquo;Therapeutic Regimen For The Treatment Of Fabry
using Stabilized Alpha-Galactosidase.&rdquo; An Israeli patent was granted for the patent family named &ldquo;Dry powder formulations
of DNAse&rdquo; adding to the already granted U.S. patent in this family.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Scientific Presentations 2019</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 7, 2019, Mr. Myrl D. Holida, PA, of the University
of Iowa Health Care in Iowa City, Iowa, a principal investigator in our phase&nbsp;III clinical trials of PRX-102, delivered an
oral presentation entitled &ldquo;Once every 4 weeks &ndash; 2 mg/kg of pegunigalsidase alfa for treating Fabry disease; Preliminary
results of a Phase 3 study,&rdquo; highlighting preliminary PK and safety data from our BRIGHT study. The presentation was delivered
at the 15<SUP>th</SUP> Annual WORLD<I>Symposium</I><SUP>TM</SUP> 2019, which took place February 4-8, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the oral presentation, the following poster presentations
were delivered at the conference with respect to PRX-102:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 &ldquo;Once every 4 weeks &ndash; 2 mg/kg of pegunigalsidase alfa for treating Fabry disease; Preliminary results of a phase 3
study,&rdquo; by Myrl D. Holida.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 &ldquo;Pegunigalsidase alfa for the treatment of Fabry disease: Preliminary results from a phase III open label, switch over study
from agalsidase alfa,&rdquo; by Prof. Ales Linhart of the V&scaron;eobecn&aacute; fakultn&iacute; nemocnice v Praze, Prague Czech
Republic, a principal investigator in our phase&nbsp;III clinical trials of PRX-102.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: left; text-indent: 35.95pt"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 &ldquo;Analysis of the baseline characteristics of Fabry disease patients screened for the pegunigalsidase alfa phase III BALANCE
study,&rdquo; by Prof. David Warnock, Professor of Nephrology at the University of Alabama Birmingham, Birmingham, Alabama, a consultant
to our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research &amp; Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0">We continuously work on the further development of our ProCellEx plant cell expression technology and
bioreactor system. In addition, we are working on the development of new products, each in different initial stages of development,
for specific products for which there are unmet needs in terms of efficacy and safety. Our development strategy focuses on the
utilization of different modification approaches and development improvements, customized for each protein product, in all stages
of expression and development.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Options: NewSection; Value: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes
to our critical accounting policies since we filed our Annual Report on Form 10-K for the year ended December&nbsp;31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and analysis of our financial condition and results
of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles.
The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well
as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments,
including those described in greater detail below. We base our estimates on historical experience and on various other factors
that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Three months ended September</I></B>&nbsp;<B><I>30, 2019
compared to the three months ended September</I></B>&nbsp;<B><I>30, 2018</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues from Selling Goods</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues from selling goods of $5.1&nbsp;million
during the three months ended September&nbsp;30, 2019, an increase of $4.5&nbsp;million,
or 673%, compared to revenues of $663,000
for the three months ended September&nbsp;30, 2018. The increase resulted primarily from an increase of $3.2&nbsp;million
in sales of drug product to Brazil as well as an increase of $1.3 million in sales of drug substance to Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues from License and R&amp;D Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues from license and R&amp;D services
of $9.1&nbsp;million for the three months ended September&nbsp;30, 2019, a decrease of $2.6&nbsp;million, or 22%, compared to
revenues of $11.7&nbsp;million for the three months ended September&nbsp;30, 2018. Revenues from the license agreements
represent the revenues we recognized in connection with the Chiesi Agreements. The decrease   resulted primarily from a
cumulative catch-up adjustment of $6.2 million in the third quarter of 2018 due to    the Chiesi
US Agreement, which we entered into on July&nbsp;23, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Goods Sold</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of goods sold was $3.2&nbsp;million
for the three months ended September&nbsp;30, 2019, an increase of $1.3&nbsp;million,
or 67%, from cost of goods sold of $1.9&nbsp;million
for the three months ended September&nbsp;30, 2018. The increase is primarily  due to an increase in sales of goods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $10.0&nbsp;million for
the three months ended September&nbsp;30, 2019, similar to the $10.1&nbsp;million of research and development expenses for the
three months ended September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect research and development expenses to continue to be
our primary expense<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Selling, general and administrative expenses were
$2.6&nbsp;million for the three months ended September&nbsp;30, 2019, a decrease of $1.5&nbsp;million, or 37%, compared to
$4.1&nbsp;million for the three months ended September&nbsp;30, 2018. The decrease is primarily due to costs related to the
Chiesi US Agreement we entered into in the third quarter of 2018, which were not incurred in the third quarter of 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Financial Expenses, net </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Financial expenses net were $2.0&nbsp;million
for the three months ended September&nbsp;30, 2019, an increase of $0.4&nbsp;million, or 28%, compared to financial expenses net
of $1.6&nbsp;million for the three months ended September&nbsp;30, 2018. Financial expenses are comprised primarily of interest
expense on our outstanding convertible notes of $1.1&nbsp;million for the three months ended September&nbsp;30, 2019 and 2018.
The increase is primarily due to exchange rate differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Nine months ended September</I></B>&nbsp;<B><I>30, 2019
compared to the nine months ended September 30, 2018</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues from Selling Goods</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues from selling goods of $12.1&nbsp;million
during the nine months ended September&nbsp;30, 2019, an increase of $4.9&nbsp;million, or 67%, compared to revenues of $7.2&nbsp;million
for the nine months ended September&nbsp;30, 2018. The increase resulted primarily from an increase of $4.8 million in sales of
drug product to Brazil as well as an increase of $52,000 in sales of drug substance to Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues from License and R&amp;D Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues from license and R&amp;D services of
$24.8&nbsp;million for the nine months ended September&nbsp;30, 2019, an increase of $8.1&nbsp;million, or 49%, compared to
revenues of $16.7&nbsp;million for the nine months ended September&nbsp;30, 2018. Revenues from the license agreements
represent the revenues we recognized in connection with the Chiesi Agreements. The increase is primarily due
to revenues recognized in connection with the Chiesi US Agreement which we entered into on July 23, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Goods Sold</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of goods sold was $7.9&nbsp;million for the nine months
ended September&nbsp;30, 2019, an increase of $0.9&nbsp;million, or 13%, from cost of goods sold of $7.0&nbsp;million for the nine
months ended September&nbsp;30, 2018. The increase is primarily due to an increase in sales of goods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $35.0 million
for the nine months ended September&nbsp;30, 2019, an increase of $11.3&nbsp;million, or 47%, compared to $23.8&nbsp;million
of research and development expenses for the nine months ended September&nbsp;30, 2018. The increase resulted primarily from
an increase of $8.5&nbsp;million in clinical trial related costs as well as a decrease of $1.8&nbsp;million in grants
received from the Israeli Innovation Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect research and development expenses to continue to be
our primary expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Selling, General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Selling, general and administrative expenses were $6.9&nbsp;million
for the nine months ended September&nbsp;30, 2019, a decrease of $1.9&nbsp;million, or 21%, compared to $8.7&nbsp;million for the
nine months ended September&nbsp;30, 2018. The decrease is primarily due to costs related to the Chiesi US Agreement we entered
into in the third quarter of 2018, which were not incurred in the third quarter of 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Financial Expenses, net </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Financial expenses net were $5.7&nbsp;million
for the nine months ended September&nbsp;30, 2019, an increase of $0.3&nbsp;million, or 5%, compared to financial expenses net
of $5.4&nbsp;million for the nine months ended September&nbsp;30, 2018. Financial expenses are comprised primarily of interest
expense on our outstanding convertible notes of $3.3&nbsp;million for the nine months ended September&nbsp;30, 2019 and 2018. The
increase is primarily due to exchange rate differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sources of Liquidity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our sources of liquidity include our cash balances. At September&nbsp;30,
2019, we had $21.4&nbsp;million in cash
and cash equivalents. We have primarily financed our operations through equity and debt financings, business collaborations, and
grant funding. <FONT STYLE="font-family: Times New Roman, Times, Serif">In the fourth quarter of 2017, Chiesi made a payment to
Protalix Ltd. of $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million in connection with the execution
of the Chiesi Ex-US Agreement and in the third quarter of 2018, Chiesi made a payment to Protalix Ltd. of $25.0</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million
in connection with the execution of the Chiesi US Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October&nbsp;16, 2019, we received total proceeds of approximately
$2.6&nbsp;million from expense reimbursements in relation to our collaboration with Chiesi and on October&nbsp;18, 2019, we received
total proceeds of approximately $3.2&nbsp;million from sales of alfataliglicerase to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Flows</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $15.7&nbsp;million
for the nine months ended September&nbsp;30, 2019. The net loss for the nine months ended September&nbsp;30, 2019 of $18.6&nbsp;million
was further increased by a $4.8&nbsp;million increase in accounts receivable,
but was partially offset by an increase of $4.9&nbsp;million in accounts payable
and accruals and by a decrease in inventories of $1.0&nbsp;million. Net cash
used in investing activities for the nine months ended September&nbsp;30, 2019 was $0.9&nbsp;million
and consisted primarily of purchases of property and equipment, and an increase in restricted deposit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $3.7&nbsp;million
for the nine months ended September&nbsp;30, 2018. The net loss for the nine months ended September&nbsp;30, 2018 of $21.0&nbsp;million
was partially offset by an increase of $18.3&nbsp;million in contracts liabilities representing an upfront payment and certain
expense reimbursements actually received from Chiesi in connection with our license agreements with Chiesi which we have not yet
recognized as revenues. Net cash used in investing activities for the nine months ended September 30, 2018 was $675,000 and consisted
primarily of purchases of property and equipment, and an increase in restricted deposit. Net cash used in financing activities
was $4.8&nbsp;million for the repayment of convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Future Funding Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As a result of our significant research
and development expenditures and the lack of significant revenue from sales of taliglucerase alfa, we have generated
operating losses from our continuing operations since our inception. We currently have outstanding $57.9&nbsp;million
aggregate principal amount of our <FONT STYLE="font-family: Times New Roman, Times, Serif">2021 Notes that are </FONT>secured
with a perfected lien on all of our assets<FONT STYLE="font-family: Times New Roman, Times, Serif">. Under the terms of the
indenture governing the 2021 Notes, we are required to maintain a minimum cash balance of at least $7.5</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">million. </FONT>These
factors raise substantial doubt as to our ability to continue as a going concern. In addition, as previously disclosed, we
have received a deficiency letter from the NYSE American stating that we are not in compliance with the continued listing
standards as set forth in Section 1003(a)(i) &ndash; (iii) of the NYSE American Company Guide as we have reported a
stockholders&rsquo; equity deficiency as of June 30, 2019 and net losses in our five most recent fiscal years ended December
31, 2018. The letter has no immediate effect on the listing of our common stock on the NYSE American. Our common stock will
trade on the NYSE American while we regain compliance with the continued listing standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect to continue to incur significant
expenditures in the near future, including significant research and development expenses related primarily to the clinical trials
of PRX-102. Our material cash needs for the next 24 months will include, among other expenses, (i) costs of preclinical and clinical
trials, (ii) employee salaries, (iii) payments for rent and operation of our manufacturing facilities, (iv) fees to our consultants
and legal advisors, patents and fees for service providers in connection with our research and development efforts and (v) payment
of principal and interest on our outstanding convertible promissory notes and other debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We will be required to raise a substantial
amount of capital in the future in order to develop and commercialize our product candidates and continue research and development
activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
our ability to maintain the listing of our common stock with the NYSE American;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>our efforts to commercialize PRX-102, and those of Chiesi;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>our progress in commercializing <FONT STYLE="font-family: Times New Roman, Times, Serif">alfataliglicerase</FONT> in Brazil;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the costs of commercialization activities, including product marketing, sales and distribution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the progress and results of our clinical trials, particularly our clinical trials of PRX-102;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product
candidates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>conversions of our 2021 Notes from time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the timing and outcome of regulatory review of our product candidates; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual
property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect to finance our future cash needs
through corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings.
We currently do not have any commitments for future external funding, except with respect to the development-related payments and
milestone payments that may become payable under the Chiesi Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our management is in the process of evaluating
refinancing and restructuring alternatives, including a restructuring of our outstanding convertible notes, and related transactions.
However, there is no certainty about our ability to obtain such funding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The financial information has been prepared
on a going concern basis, which assumes we will continue to realize our assets and discharge our liabilities in the normal course
of business. If we do not raise the requisite funds, we will need to curtail or cease operations. These financial statements do
not include any adjustments that may be necessary should we be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effects of Currency Fluctuations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currency fluctuations could affect us through
increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material
effect on our results of operations during the nine months ended September&nbsp;30, 2019 and September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have no off-balance sheet arrangements
as of each of September&nbsp;30, 2019 and September&nbsp;30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_010"></A>Item&nbsp;3. Quantitative and Qualitative
Disclosures About Market Risk</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Currency Exchange Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The currency of the primary economic environment
in which our operations are conducted is the U.S. dollar. We consider the currency of the primary economic environment to be the
currency in which we generate revenues and expend cash. Most of our revenues are denominated in U.S. dollars, approximately 50%
of our expenses and capital expenditures are incurred in U.S. dollars, and a significant source of our financing has been provided
in U.S. dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are
remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical
exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they
occur. Foreign currency translation gains or losses are recognized in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A portion of our costs, including salaries, expenses and office
expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations in
Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A devaluation of 1% of the NIS will affect our income before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-right: 0.75in; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="5" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><B>Nine Months Ended<BR> </B> <B>September</B>&nbsp;<B>30,</B></TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year Ended <BR> December&nbsp;31,</TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD>
<TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD>
<TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="width: 56%; font-size: 10pt">Average rate for period&#9;</TD>
<TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
<TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="width: 12%; font-size: 10pt; text-align: center">3.589</TD>
<TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
<TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="width: 12%; font-size: 10pt; text-align: center">3.558</TD>
<TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: center; width: 12%">3.595</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; text-align: left">Rate at period end&#9;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: center">3.482</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: center">3.627</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: center">3.748</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not engaged in hedging transactions. In the
future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange
rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due
to the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our exposure to market risk is confined to
our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible
to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while
maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily
in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest
rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in
the future as a result of changes in the financial markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_011"></A>Item&nbsp;4. Controls and Procedures</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted an evaluation of the effectiveness of the design
and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q.
The controls evaluation was conducted under the supervision and with the participation of management, including our Chief Executive
Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure
that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form 10-Q,
is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s rules and forms. Disclosure
controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management,
including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required
disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the controls evaluation, our Chief Executive Officer
and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our
disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in
our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and
that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief
Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their
costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company
have been detected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in Internal Control over Financial Reporting</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">There were no changes in our internal
control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter
ended September&nbsp;30, 2019 that have materially affected, or that are reasonably likely to materially affect, our internal control
over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_012"></A>PART II &ndash; OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_013"></A>Item&nbsp;1. Legal Proceedings</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are not involved in any material legal
proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_014"></A>Item&nbsp;1A. Risk Factors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; text-align: left">Except as set forth below, there have been
no material changes to the risk factors previously disclosed in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2018 and in our Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We have received a Deficiency Letter from the NYSE American
regarding our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: #333333">On August&nbsp;30, 2019, we announced
that we received a deficiency letter from the NYSE American stating that we are not in compliance with the continued listing standards
as set forth in Section 1003(a)(i) &ndash; (iii) of the NYSE American Company Guide as we have reported a stockholders&rsquo;
equity deficiency as of June</FONT>&nbsp;<FONT STYLE="color: #333333">30, 2019 and net losses in our five most recent fiscal years
ended December</FONT>&nbsp;<FONT STYLE="color: #333333">31, 2018, which may result in the delisting of our common stock from the
NYSE American. The letter has no immediate effect on the listing of our common stock on the NYSE American. Our common stock will
trade on the NYSE American while we regain compliance with the continued listing standards. Subsequently, we submitted a detailed
plan of compliance advising the NYSE American of the actions we have taken, or plan to take, that would bring our company into
compliance with the continued listing standards within 18 months of receipt of the letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_015"></A>Item&nbsp;2. Unregistered
Sales of Equity Securities and Use of Proceeds</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">There
were no unregistered sales of equity securities during the nine months ended September</FONT>&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">30,
2019.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_016"></A>Item&nbsp;3. Defaults
Upon Senior Securities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_017"></A>Item&nbsp;4. Mine Safety
Disclosure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">Not applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_018"></A>Item&nbsp;5. Other Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="a_019"></A>Item&nbsp;6. Exhibits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; vertical-align: bottom">Exhibit</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Incorporated by Reference</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">Filed or<BR>
 Furnished</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"> Number</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Exhibit Description</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Form</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">File Number</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Exhibit</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Date</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Herewith</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%; font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">Certificate of Incorporation of the Company<BR></A></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 8%; font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="width: 2%; font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">333-48677</A></TD><TD STYLE="width: 2%; font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD><TD STYLE="width: 2%; font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm" STYLE="-sec-extract: exhibit">April&nbsp;1, 2016</A></TD><TD STYLE="width: 2%; font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="width: 8%; font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">3.2</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">Amendment to Certificate of Incorporation of the Company</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">Def 14A</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">Appen. A</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm" STYLE="-sec-extract: exhibit">July&nbsp;1, 2016</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm" STYLE="-sec-extract: exhibit">3.3</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm" STYLE="-sec-extract: exhibit">Second Amendment to Certificate of Incorporation of the Company</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm" STYLE="-sec-extract: exhibit">Def 14A</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm" STYLE="-sec-extract: exhibit">Appen. A</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm" STYLE="-sec-extract: exhibit">October&nbsp;17, 2018</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">3.4</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">Bylaws of the Company</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">3.2</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm" STYLE="-sec-extract: exhibit">April&nbsp;1, 2016 <BR></A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">Form of Restricted Stock Agreement/Notice <BR></A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm" STYLE="-sec-extract: exhibit">July&nbsp;18, 2012 <BR></A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">4.2</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">Indenture, dated as of December&nbsp;7, 2016, between Protalix BioTherapeutics, Inc. the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent <BR></A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm" STYLE="-sec-extract: exhibit">December&nbsp;7, 2016</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">4.3</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Financing) <BR></A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">4.2</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm" STYLE="-sec-extract: exhibit">December&nbsp;7, 2016 <BR></A></TD><TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; width: 8%; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">4.4</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 32%"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Exchange) <BR></A></TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 8%; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 10%; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 10%; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">4.3</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm" STYLE="-sec-extract: exhibit">December&nbsp;7, 2016 <BR></A></TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 8%; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">4.5</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">First Supplemental Indenture, dated as of July&nbsp;24, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee, and Wilmington Savings Fund Society, FSB, as collateral agent</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">4.2</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm" STYLE="-sec-extract: exhibit">July&nbsp;25, 2017</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">4.6</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">Second Supplemental Indenture, dated as of November&nbsp;27, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee, registrar, paying agent and conversion agent <BR></A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">8-K <BR></A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm" STYLE="-sec-extract: exhibit">December&nbsp;1, 2017</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420419036350/tv526084_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420419036350/tv526084_ex10-1.htm" STYLE="-sec-extract: exhibit">Employment Agreement made effective as of July&nbsp;28, 2019 by and between Protalix Ltd. and Eyal Rubin</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420419036350/tv526084_ex10-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420419036350/tv526084_ex10-1.htm" STYLE="-sec-extract: exhibit">001-33357</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420419036350/tv526084_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1006281/000114420419036350/tv526084_ex10-1.htm" STYLE="-sec-extract: exhibit">July&nbsp;29, 2019</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="tm1919495d1_ex31-1.htm">31.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="tm1919495d1_ex31-1.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="tm1919495d1_ex31-1.htm">X</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="tm1919495d1_ex31-2.htm">31.2</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="tm1919495d1_ex31-2.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="tm1919495d1_ex31-2.htm">X</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="tm1919495d1_ex32-1.htm">32.1</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="tm1919495d1_ex32-1.htm">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="tm1919495d1_ex32-1.htm">X</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top"><A HREF="tm1919495d1_ex32-2.htm">32.2</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="tm1919495d1_ex32-2.htm">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top"><A HREF="tm1919495d1_ex32-2.htm">X</A></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; vertical-align: top">101.INS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">XBRL INSTANCE FILE</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; vertical-align: top">X</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; width: 8%">101.SCH</TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 32%">XBRL SHEMA FILE</TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 8%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 10%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 10%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 12%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 8%">X</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">101.CAL</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">XBRL CALCULATION FILE</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">101.DEF</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">XBRL DEFINITION FILE</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">101.LAB</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">XBRL LABEL FILE</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">101.PRE</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">XBRL PRESENTATION FILE</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">X</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_020"></A>SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 48%">PROTALIX BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Registrant)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: November&nbsp;7, 2019</TD>
    <TD>By:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Dror Bashan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dror Bashan</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President and Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: November&nbsp;7, 2019</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Eyal Rubin</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eyal Rubin</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Senior Vice President and Chief Financial Officer, Treasurer
        and Secretary</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial and Accounting Officer)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>tm1919495d1_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>EXHIBIT 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, Dror Bashan, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">Date: November&nbsp;7, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: Black 1pt solid">&nbsp;/s/ Dror Bashan</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 1pt"></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0">Dror Bashan <BR>President
and Chief Executive Officer</P></TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>tm1919495d1_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>EXHIBIT 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, Eyal Rubin, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-indent: -12pt; padding-left: 12pt">Date: November&nbsp;7, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-indent: -12pt; padding-left: 12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 50%; border-bottom: Black 1pt solid">/s/ Eyal Rubin</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Eyal Rubin <BR>Sr. Vice President &amp; Chief Financial Officer, Treasurer <BR></TD></TR>
</TABLE>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>tm1919495d1_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>EXHIBIT 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September&nbsp;30, 2019 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as
of the date hereof, solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best
of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt"></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">Date: November&nbsp;7, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: Black 1pt solid">&nbsp;/s/ Dror Bashan</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 1pt"></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Dror Bashan <BR>President and Chief Executive Officer <BR></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>tm1919495d1_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0"><B>EXHIBIT 32.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September&nbsp;30, 2019 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby
certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that
to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">Date: November&nbsp;7, 2019</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;/s/ Eyal Rubin</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Eyal Rubin <BR>Senior Vice President and Chief Financial Officer </TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>plx-20190930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.0.81 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/6/2019 11:41:50 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:plx="http://www.protalix.com/20190930" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="plx-20190930.xsd" />
  <!--Context Section-->
  <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_srt_StatementGeographicalAxis_plx_PfizerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_srt_StatementGeographicalAxis_country_BR">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018_srt_ProductOrServiceAxis_us-gaap_ProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_srt_ProductOrServiceAxis_us-gaap_ProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_srt_StatementGeographicalAxis_plx_PfizerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_srt_StatementGeographicalAxis_country_BR">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_1_1_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2019-01-01</instant>
    </period>
  </context>
  <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2019_plx_CommitmentsAndContingenciesAxis_us-gaap_LeaseAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2019_plx_CommitmentsAndContingenciesAxis_plx_VehicleLeaseAndMaintenanceAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="plx:CommitmentsAndContingenciesAxis">plx:VehicleLeaseAndMaintenanceAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_plx_Notes2021Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2021Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNoteMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2019_To_9_30_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="Duration_10_18_2019_To_10_18_2019_srt_ProductOrServiceAxis_plx_AlfataligliceraseToFiocruzMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:AlfataligliceraseToFiocruzMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-10-18</startDate>
      <endDate>2019-10-18</endDate>
    </period>
  </context>
  <context id="Duration_10_16_2019_To_10_16_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-10-16</startDate>
      <endDate>2019-10-16</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_srt_RangeAxis_srt_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_srt_RangeAxis_srt_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-07-23</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-07-23</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-10-01</startDate>
      <endDate>2017-10-19</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-10-01</startDate>
      <endDate>2017-10-19</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-10-31</instant>
    </period>
  </context>
  <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-07-23</instant>
    </period>
  </context>
  <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-10-19</instant>
    </period>
  </context>
  <context id="As_Of_11_1_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2019-11-01</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_9_30_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit14">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit13">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit12">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Unit1">
    <measure>xbrli:shares</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <dei:AmendmentFlag contextRef="Duration_1_1_2019_To_9_30_2019">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2019_To_9_30_2019">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2019_To_9_30_2019">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2019_To_9_30_2019">2019</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2019_To_9_30_2019">2019-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2019_To_9_30_2019">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2019_To_9_30_2019">0001006281</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_11_1_2019" unitRef="Unit1" decimals="0">148382299</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2019_To_9_30_2019">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="Duration_1_1_2019_To_9_30_2019">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2019_To_9_30_2019">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityInteractiveDataCurrent contextRef="Duration_1_1_2019_To_9_30_2019">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2019_To_9_30_2019">Protalix BioTherapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="Duration_1_1_2019_To_9_30_2019">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness contextRef="Duration_1_1_2019_To_9_30_2019">true</dei:EntitySmallBusiness>
  <dei:TradingSymbol contextRef="Duration_1_1_2019_To_9_30_2019">PLX</dei:TradingSymbol>
  <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember" unitRef="Unit12" decimals="-5">320000000</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
  <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember" unitRef="Unit12" decimals="-5">760000000</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
  <plx:AdditionalAmountsPayableToCoverDevelopmentCosts contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember" unitRef="Unit12" decimals="-5">25000000</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
  <plx:AdditionalAmountsPayableToCoverDevelopmentCosts contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember" unitRef="Unit12" decimals="-5">20000000</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
  <plx:ChangeInOperatingLeaseRightOfUseAssets contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">92000</plx:ChangeInOperatingLeaseRightOfUseAssets>
  <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage contextRef="As_Of_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember" unitRef="Unit13" decimals="2">1.00</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
  <plx:FairValueAssumptionsExpectedDividendRates contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit13" decimals="4">0.1053</plx:FairValueAssumptionsExpectedDividendRates>
  <plx:FairValueAssumptionsExpectedVolatilityRates contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit13" decimals="4">0.7499</plx:FairValueAssumptionsExpectedVolatilityRates>
  <plx:FairValueAssumptionsRiskFreeInterestRates contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit13" decimals="4">0.0162</plx:FairValueAssumptionsRiskFreeInterestRates>
  <plx:FairValueAssumptionsTerm contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">P2Y1M17D</plx:FairValueAssumptionsTerm>
  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">45000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
  <plx:GrantsAndReimbursementsReceivedOrReceivable contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">-1810000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">-732000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">-55000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">-52000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">237000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">14000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">205000</plx:IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes>
  <plx:MaintainOfMinimumCashBalance contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember" unitRef="Unit12" decimals="-5">7500000</plx:MaintainOfMinimumCashBalance>
  <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember" unitRef="Unit12" decimals="-5">10000000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
  <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember" unitRef="Unit12" decimals="-5">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
  <plx:NatureOfOperationsPolicyTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;a.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;General&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Protalix BioTherapeutics,&amp;nbsp;Inc. (collectively with its subsidiaries, the &amp;#x201C;Company&amp;#x201D;) and its wholly-owned subsidiaries, Protalix&amp;nbsp;Ltd. and Protalix B.V. (the &amp;#x201C;Subsidiaries&amp;#x201D;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#x2019;s proprietary ProCellEx&lt;/font&gt;&lt;font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;&amp;#xAE;&lt;/font&gt;&lt;font style="display:inline;"&gt; protein expression system (&amp;#x201C;ProCellEx&amp;#x201D;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;/font&gt;&lt;font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;&amp;#xAE;&lt;/font&gt;&lt;font style="display:inline;"&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&amp;#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s product pipeline currently includes, among other candidates:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (1)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;pegunigalsidase alfa, or PRX&amp;#8209;102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (2)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;alidornase alfa, or PRX&amp;#8209;110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase; and&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (3)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;OPRX&amp;#8209;106, the Company&amp;#x2019;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company, together with its commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&amp;#x201C;Chiesi&amp;#x201D;), plans to file a biologics license application (&amp;#x201C;BLA&amp;#x201D;) for PRX-102 for the treatment of Fabry disease by April 2020 through the Accelerated Approval pathway of the U.S. Food and Drug Administration (&amp;#x201C;FDA&amp;#x201D;). This decision is the result of a series of meetings and correspondence between the Company and Chiesi, on the one hand, and the FDA, on the other hand. The Company and Chiesi have initiated preparations for the BLA submission based on clinical data generated in the one-year completed phase I/II clinical trials of PRX-102 and from the ongoing phase III BRIDGE clinical trial, as well as safety data from all on-going studies. The BLA will also include extensive data from the Company&amp;#x2019;s completed nonclinical program, as well as information regarding production of PRX-102. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&amp;#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On October&amp;nbsp;19, 2017, Protalix&amp;nbsp;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &amp;#x201C;Chiesi Ex-US Agreement&amp;#x201D;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&amp;nbsp;23, 2018, Protalix&amp;nbsp;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &amp;#x201C;Chiesi US Agreement&amp;#x201D;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively,&amp;nbsp;the &amp;#x201C;Chiesi Agreements&amp;#x201D;), Chiesi made an upfront payment to Protalix&amp;nbsp;Ltd. of $25.0&amp;nbsp;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&amp;nbsp;Ltd. is entitled to additional payments of up to $25.0&amp;nbsp;million in pegunigalsidase alfa development costs, capped at $10.0&amp;nbsp;million per&amp;nbsp;year, and to receive additional payments of up to $320.0&amp;nbsp;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&amp;nbsp;Ltd. is entitled to payments of up to a maximum of $20.0&amp;nbsp;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&amp;nbsp;million per&amp;nbsp;year, and to receive an additional up to a maximum of $760.0&amp;nbsp;million, in the aggregate, in regulatory and commercial milestone payments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Under the terms of both of the Chiesi Agreements, Protalix&amp;nbsp;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. ("Pfizer") in accordance with the exclusive license and supply agreement entered into&amp;nbsp;between Protalix&amp;nbsp;Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October&amp;nbsp;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &amp;#x201C;Brazil Agreement&amp;#x201D;) with Funda&amp;#xE7;&amp;#xE3;o Oswaldo Cruz (&amp;#x201C;Fiocruz&amp;#x201D;), an arm of the Brazilian Ministry of Health (the &amp;#x201C;Brazilian MoH&amp;#x201D;), for taliglucerase alfa. Fiocruz&amp;#x2019;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 72pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Going Concern&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;"&gt;Since the Company is engaged in research and development activities, it has not derived significant income from its activities and has incurred accumulated losses in the amount of $341.0 million through September 30, 2019 and cash outflows from operating activities. As of September 30, 2019, the Company has outstanding $57.9 million aggregate principal amount of its 7.50% convertible promissory notes due 2021 (the &amp;#x201C;2021 Notes&amp;#x201D;) which are secured with a perfected lien on all of the Company&amp;#x2019;s assets. Under the terms of the indenture governing the 2021 Notes, the Company is required to maintain a minimum cash balance of at least $7.5 million. As of September 30, 2019, the Company had cash and cash equivalents of $21.4 million. Based on its current cash resources and commitments, the Company may not be able to meet its current planned development activities and the corresponding level of expenditures for the next 12 months from the date of approval of the financial statements as of September 30, 2019 absent a refinancing or restructuring. These factors raise substantial doubt as to the Company&amp;#x2019;s ability to continue as a going concern.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;"&gt;The Company&amp;#x2019;s management is in the process of evaluating refinancing and restructuring alternatives, including a restructuring of its outstanding convertible notes, and related transactions.&amp;nbsp;&amp;nbsp;However, there is no certainty about the Company&amp;#x2019;s ability to obtain such funding.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;"&gt;The financial information has been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business.&amp;nbsp;&amp;nbsp;If the Company does not complete a refinancing or restructuring, it will need to curtail or cease operations.&amp;nbsp;&amp;nbsp;These financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</plx:NatureOfOperationsPolicyTextBlock>
  <plx:PaymentOnNetSalesPercentage contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember" unitRef="Unit13" decimals="2">0.35</plx:PaymentOnNetSalesPercentage>
  <plx:PaymentOnNetSalesPercentage contextRef="Duration_10_1_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember" unitRef="Unit13" decimals="2">0.15</plx:PaymentOnNetSalesPercentage>
  <plx:PaymentOnNetSalesPercentage contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember" unitRef="Unit13" decimals="2">0.40</plx:PaymentOnNetSalesPercentage>
  <plx:PaymentOnNetSalesPercentage contextRef="Duration_7_1_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember" unitRef="Unit13" decimals="2">0.15</plx:PaymentOnNetSalesPercentage>
  <plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments contextRef="Duration_1_1_2019_To_9_30_2019_srt_RangeAxis_srt_MaximumMember" unitRef="Unit13" decimals="2">0.10</plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments>
  <plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments contextRef="Duration_1_1_2019_To_9_30_2019_srt_RangeAxis_srt_MinimumMember" unitRef="Unit13" decimals="3">0.075</plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments>
  <plx:ProceedsFromReimbursementOfExpenses contextRef="Duration_10_16_2019_To_10_16_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiMember" unitRef="Unit12" decimals="-5">2600000</plx:ProceedsFromReimbursementOfExpenses>
  <plx:ProceedsFromSaleOfProducts contextRef="Duration_10_18_2019_To_10_18_2019_srt_ProductOrServiceAxis_plx_AlfataligliceraseToFiocruzMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiMember" unitRef="Unit12" decimals="-5">3200000</plx:ProceedsFromSaleOfProducts>
  <plx:RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;d.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Recently adopted standards&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In February&amp;nbsp;2016, the Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) issued ASU No.&amp;nbsp;2016&amp;#8209;02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). The new standard requires a lessee to record assets and liabilities on its balance sheet for all leases with terms longer than 12&amp;nbsp;months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the lessee&amp;#x2019;s income statement. The Company adopted this standard as of January&amp;nbsp;1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company elected the package of practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12&amp;nbsp;months or less off of its balance sheet. The Company recognized those lease payments in its statements of operations on a straight-line basis over the lease period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of the adoption date, the Company recognized an operating lease asset and liability of $5.9&amp;nbsp;million and $5.7 million, respectively, as of January&amp;nbsp;1, 2019 on its balance sheet.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</plx:RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock>
  <plx:RevenueDisclosureTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;NOTE&amp;nbsp;5&amp;nbsp;&amp;#x2013; REVENUES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table summarizes the Company&amp;#x2019;s disaggregation of revenues:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Nine Months Ended September&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Pfizer&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 4,701&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 4,649&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Brazil&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 7,385&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 2,573&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Total revenues from selling goods&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 12,086&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 7,222&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Revenues from license and R&amp;amp;D services&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 24,848&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 16,665&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table sets forth data regarding the Company&amp;#x2019;s contracts liability:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Nine Months Ended September&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Contracts liability at the beginning of the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 42,895&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 25,015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Additions during the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 22,151&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 34,929&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Revenue recognized during the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; (24,848)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; (16,665)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Contracts liability at the end of the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 40,198&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 43,279&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table represents the Company&amp;#x2019;s unsatisfied performance obligation:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Unsatisfied performance obligation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 50,584&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 76,969&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</plx:RevenueDisclosureTextBlock>
  <plx:RevenueRemainingPerformanceObligationAmountTableTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table represents the Company&amp;#x2019;s unsatisfied performance obligation:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:26.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Unsatisfied performance obligation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 50,584&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 76,969&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</plx:RevenueRemainingPerformanceObligationAmountTableTextBlock>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue contextRef="As_Of_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit12" decimals="0">97000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">16000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">16000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures xsi:nil="true" id="Item-0001" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares id="Item-0003" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">29898</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
  <plx:StockIssuedDuringPeriodSharesConvertibleNoteExchange contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">2613636</plx:StockIssuedDuringPeriodSharesConvertibleNoteExchange>
  <plx:StockIssuedDuringPeriodSharesConvertibleNoteExchange contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">117647</plx:StockIssuedDuringPeriodSharesConvertibleNoteExchange>
  <plx:StockIssuedDuringPeriodValueConvertibleNoteExchange contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">1150000</plx:StockIssuedDuringPeriodValueConvertibleNoteExchange>
  <plx:StockIssuedDuringPeriodValueConvertibleNoteExchange contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">1148000</plx:StockIssuedDuringPeriodValueConvertibleNoteExchange>
  <plx:StockIssuedDuringPeriodValueConvertibleNoteExchange contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">2000</plx:StockIssuedDuringPeriodValueConvertibleNoteExchange>
  <plx:StockIssuedDuringPeriodValueConvertibleNoteExchange contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">99000</plx:StockIssuedDuringPeriodValueConvertibleNoteExchange>
  <plx:StockIssuedDuringPeriodValueConvertibleNoteExchange contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">99000</plx:StockIssuedDuringPeriodValueConvertibleNoteExchange>
  <plx:SupplementaryIncomeStatementInformationTableTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table summarizes the Company&amp;#x2019;s disaggregation of revenues:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Nine Months Ended September&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Pfizer&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 4,701&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 4,649&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Brazil&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 7,385&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 2,573&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Total revenues from selling goods&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 12,086&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 7,222&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Revenues from license and R&amp;amp;D services&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 24,848&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 16,665&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</plx:SupplementaryIncomeStatementInformationTableTextBlock>
  <plx:UpfrontNonrefundableNonCreditablePaymentReceivable contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember" unitRef="Unit12" decimals="-5">25000000</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
  <plx:UpfrontNonrefundableNonCreditablePaymentReceivable contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember" unitRef="Unit12" decimals="-5">25000000</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
  <us-gaap:AccountsPayableOtherCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">10274000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">12730000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableTradeCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">5211000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">7755000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">4729000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">8716000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">80000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">80000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">22000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">22000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">599000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">599000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">196000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">196000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">54000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3">42000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">-14000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3">8000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">426000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3">173000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">110000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="Unit12" decimals="-3">86000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCosts contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">1916000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">2197000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">73310911</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">73280977</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit1" decimals="0">78269464</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit1" decimals="0">78547287</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">61131000</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">53729000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">52983000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">40439000</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;b.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Basis of presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201C;GAAP&amp;#x201D;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full&amp;nbsp;year.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2018, filed by the Company with the U.S Securities and Exchange Commission (the &amp;#x201C;Commission&amp;#x201D;). The comparative balance sheet at December 31, 2018 has been derived from the audited financial statements at that date.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;NOTE&amp;nbsp;1&amp;nbsp;- SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;a.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;General&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Protalix BioTherapeutics,&amp;nbsp;Inc. (collectively with its subsidiaries, the &amp;#x201C;Company&amp;#x201D;) and its wholly-owned subsidiaries, Protalix&amp;nbsp;Ltd. and Protalix B.V. (the &amp;#x201C;Subsidiaries&amp;#x201D;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#x2019;s proprietary ProCellEx&lt;/font&gt;&lt;font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;&amp;#xAE;&lt;/font&gt;&lt;font style="display:inline;"&gt; protein expression system (&amp;#x201C;ProCellEx&amp;#x201D;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;/font&gt;&lt;font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;&amp;#xAE;&lt;/font&gt;&lt;font style="display:inline;"&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&amp;#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s product pipeline currently includes, among other candidates:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (1)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;pegunigalsidase alfa, or PRX&amp;#8209;102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (2)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;alidornase alfa, or PRX&amp;#8209;110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase; and&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (3)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;OPRX&amp;#8209;106, the Company&amp;#x2019;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company, together with its commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&amp;#x201C;Chiesi&amp;#x201D;), plans to file a biologics license application (&amp;#x201C;BLA&amp;#x201D;) for PRX-102 for the treatment of Fabry disease by April 2020 through the Accelerated Approval pathway of the U.S. Food and Drug Administration (&amp;#x201C;FDA&amp;#x201D;). This decision is the result of a series of meetings and correspondence between the Company and Chiesi, on the one hand, and the FDA, on the other hand. The Company and Chiesi have initiated preparations for the BLA submission based on clinical data generated in the one-year completed phase I/II clinical trials of PRX-102 and from the ongoing phase III BRIDGE clinical trial, as well as safety data from all on-going studies. The BLA will also include extensive data from the Company&amp;#x2019;s completed nonclinical program, as well as information regarding production of PRX-102. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&amp;#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On October&amp;nbsp;19, 2017, Protalix&amp;nbsp;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &amp;#x201C;Chiesi Ex-US Agreement&amp;#x201D;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&amp;nbsp;23, 2018, Protalix&amp;nbsp;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &amp;#x201C;Chiesi US Agreement&amp;#x201D;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively,&amp;nbsp;the &amp;#x201C;Chiesi Agreements&amp;#x201D;), Chiesi made an upfront payment to Protalix&amp;nbsp;Ltd. of $25.0&amp;nbsp;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&amp;nbsp;Ltd. is entitled to additional payments of up to $25.0&amp;nbsp;million in pegunigalsidase alfa development costs, capped at $10.0&amp;nbsp;million per&amp;nbsp;year, and to receive additional payments of up to $320.0&amp;nbsp;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&amp;nbsp;Ltd. is entitled to payments of up to a maximum of $20.0&amp;nbsp;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&amp;nbsp;million per&amp;nbsp;year, and to receive an additional up to a maximum of $760.0&amp;nbsp;million, in the aggregate, in regulatory and commercial milestone payments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Under the terms of both of the Chiesi Agreements, Protalix&amp;nbsp;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. ("Pfizer") in accordance with the exclusive license and supply agreement entered into&amp;nbsp;between Protalix&amp;nbsp;Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October&amp;nbsp;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &amp;#x201C;Brazil Agreement&amp;#x201D;) with Funda&amp;#xE7;&amp;#xE3;o Oswaldo Cruz (&amp;#x201C;Fiocruz&amp;#x201D;), an arm of the Brazilian Ministry of Health (the &amp;#x201C;Brazilian MoH&amp;#x201D;), for taliglucerase alfa. Fiocruz&amp;#x2019;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 72pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-style:italic;"&gt;Going Concern&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;"&gt;Since the Company is engaged in research and development activities, it has not derived significant income from its activities and has incurred accumulated losses in the amount of $341.0 million through September 30, 2019 and cash outflows from operating activities. As of September 30, 2019, the Company has outstanding $57.9 million aggregate principal amount of its 7.50% convertible promissory notes due 2021 (the &amp;#x201C;2021 Notes&amp;#x201D;) which are secured with a perfected lien on all of the Company&amp;#x2019;s assets. Under the terms of the indenture governing the 2021 Notes, the Company is required to maintain a minimum cash balance of at least $7.5 million. As of September 30, 2019, the Company had cash and cash equivalents of $21.4 million. Based on its current cash resources and commitments, the Company may not be able to meet its current planned development activities and the corresponding level of expenditures for the next 12 months from the date of approval of the financial statements as of September 30, 2019 absent a refinancing or restructuring. These factors raise substantial doubt as to the Company&amp;#x2019;s ability to continue as a going concern.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;"&gt;The Company&amp;#x2019;s management is in the process of evaluating refinancing and restructuring alternatives, including a restructuring of its outstanding convertible notes, and related transactions.&amp;nbsp;&amp;nbsp;However, there is no certainty about the Company&amp;#x2019;s ability to obtain such funding.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;"&gt;The financial information has been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business.&amp;nbsp;&amp;nbsp;If the Company does not complete a refinancing or restructuring, it will need to curtail or cease operations.&amp;nbsp;&amp;nbsp;These financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;b.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Basis of presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201C;GAAP&amp;#x201D;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full&amp;nbsp;year.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2018, filed by the Company with the U.S Securities and Exchange Commission (the &amp;#x201C;Commission&amp;#x201D;). The comparative balance sheet at December 31, 2018 has been derived from the audited financial statements at that date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;c.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Net loss per share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Basic and diluted loss per share (&amp;#x201C;LPS&amp;#x201D;) are computed by dividing net loss by the weighted average number of shares of the Company&amp;#x2019;s common stock, par value $0.001 per share (the &amp;#x201C;Common Stock&amp;#x201D;), outstanding for each period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The calculation of diluted LPS does not include 73,310,911 and 78,269,464 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes for the nine&amp;nbsp;months ended September 30, 2018 and 2019, respectively, and 73,280,977 and 78,547,287 shares of Common Stock for the three months ended September 30, 2018 and 2019, respectively, because the effect would be anti-dilutive.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 1pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;d.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Recently adopted standards&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In February&amp;nbsp;2016, the Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) issued ASU No.&amp;nbsp;2016&amp;#8209;02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). The new standard requires a lessee to record assets and liabilities on its balance sheet for all leases with terms longer than 12&amp;nbsp;months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the lessee&amp;#x2019;s income statement. The Company adopted this standard as of January&amp;nbsp;1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company elected the package of practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12&amp;nbsp;months or less off of its balance sheet. The Company recognized those lease payments in its statements of operations on a straight-line basis over the lease period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of the adoption date, the Company recognized an operating lease asset and liability of $5.9&amp;nbsp;million and $5.7 million, respectively, as of January&amp;nbsp;1, 2019 on its balance sheet.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;e.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Newly issued accounting pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In June&amp;nbsp;2018, the FASB issued ASU 2018&amp;#8209;07, &amp;#x201C;Compensation&amp;nbsp;&amp;#x2013; Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting&amp;#x201D; that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in ASU 2018&amp;#8209;07. The guidance is effective for fiscal&amp;nbsp;years beginning after December&amp;nbsp;15, 2018, including interim reporting periods within that fiscal&amp;nbsp;year. Early adoption is permitted, but no earlier than an entity&amp;#x2019;s adoption date of Topic 606. The Company does not expect the adoption of ASU 2018&amp;#8209;07 to have a material impact on its financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">51163000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="-3">41868000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">37808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">37808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">21442000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">21442000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-9295000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-16366000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2018" unitRef="Unit12" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_9_30_2019" unitRef="Unit12" />
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_9_30_2018" unitRef="Unit14" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_9_30_2019" unitRef="Unit14" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_9_30_2019" unitRef="Unit14" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">250000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_9_30_2019" unitRef="Unit1" decimals="0">350000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table sets forth data regarding the Company&amp;#x2019;s contracts liability:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Nine Months Ended September&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;(U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Contracts liability at the beginning of the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 42,895&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 25,015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Additions during the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 22,151&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 34,929&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Revenue recognized during the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; (24,848)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; (16,665)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Contracts liability at the end of the period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 40,198&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 43,279&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
  <us-gaap:ContractWithCustomerLiability contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">25015000</us-gaap:ContractWithCustomerLiability>
  <us-gaap:ContractWithCustomerLiability contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="-3">43279000</us-gaap:ContractWithCustomerLiability>
  <us-gaap:ContractWithCustomerLiability contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">42895000</us-gaap:ContractWithCustomerLiability>
  <us-gaap:ContractWithCustomerLiability contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">40198000</us-gaap:ContractWithCustomerLiability>
  <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">34929000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
  <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">22151000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
  <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">9868000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">11612000</us-gaap:ContractWithCustomerLiabilityCurrent>
  <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">33027000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">28586000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-16665000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-24848000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
  <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit12" decimals="-5">57700000</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">47966000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">50163000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:CostOfRevenue contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">7024000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">1917000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">7945000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">3205000</us-gaap:CostOfRevenue>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">2236000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember" unitRef="Unit12" decimals="-5">57900000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNoteMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit12" decimals="-5">57900000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember" unitRef="Unit13" decimals="4">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">1758000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">1953000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:Depreciation contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">1257000</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">1205000</us-gaap:Depreciation>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit14" decimals="2">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit14" decimals="2">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit14" decimals="2">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit14" decimals="2">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;c.&lt;font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"&gt;&lt;/font&gt;Net loss per share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Basic and diluted loss per share (&amp;#x201C;LPS&amp;#x201D;) are computed by dividing net loss by the weighted average number of shares of the Company&amp;#x2019;s common stock, par value $0.001 per share (the &amp;#x201C;Common Stock&amp;#x201D;), outstanding for each period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The calculation of diluted LPS does not include 73,310,911 and 78,269,464 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes for the nine&amp;nbsp;months ended September 30, 2018 and 2019, respectively, and 73,280,977 and 78,547,287 shares of Common Stock for the three months ended September 30, 2018 and 2019, respectively, because the effect would be anti-dilutive.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-130000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">217000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_plx_Notes2021Member">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company prepared a valuation of the fair value of the Company&amp;#x2019;s outstanding 2021 Notes&amp;nbsp;(a Level 3 valuation) as of September 30, 2019. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2021&amp;nbsp;Notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Stock price (USD)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 0.21&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Expected term&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 2.13&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Risk free rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 1.62&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 74.99&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 10.53&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;NOTE&amp;nbsp;3&amp;nbsp;&amp;#x2013; FAIR VALUE MEASUREMENT&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes derivative is based on Level 3 measurement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The fair value of the $57.9&amp;nbsp;million aggregate principal amount of the Company&amp;#x2019;s outstanding 2021 Notes as of September 30, 2019 is approximately $57.7&amp;nbsp;million based on a Level 3 measurement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company prepared a valuation of the fair value of the Company&amp;#x2019;s outstanding 2021 Notes&amp;nbsp;(a Level 3 valuation) as of September 30, 2019. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2021&amp;nbsp;Notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Stock price (USD)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 0.21&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Expected term&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 2.13&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Risk free rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 1.62&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 74.99&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 10.53&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">37000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-371000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-204000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-1805000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">4905000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">3661000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">4767000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">18264000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-2697000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
  <us-gaap:IncreaseDecreaseInInventories contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">126000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-1044000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">1103000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">80000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">247000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">254000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:InterestPaidNet contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">2411000</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">2172000</us-gaap:InterestPaidNet>
  <us-gaap:InventoryDisclosureTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;NOTE&amp;nbsp;2&amp;nbsp;- INVENTORIES&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; a.&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;Inventories at September 30, 2019 and December&amp;nbsp;31, 2018 consisted of the following:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;(&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,691&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,792&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Work in progress&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 233&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,601&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 4,777&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Total inventory&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 7,525&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 8,569&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; b.&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;During the&amp;nbsp;year ended December&amp;nbsp;31, 2018 and the nine&amp;nbsp;months ended September 30, 2019, the Company recorded approximately $1.1 million and $29,000, respectively, for write-down of inventory under cost of goods sold.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">4777000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">3601000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryNet contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">8569000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">8569000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">7525000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">7525000</us-gaap:InventoryNet>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">3792000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">3691000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">233000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWriteDown contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="-5">1100000</us-gaap:InventoryWriteDown>
  <us-gaap:InventoryWriteDown contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="0">29000</us-gaap:InventoryWriteDown>
  <us-gaap:LeaseCostTableTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table sets forth data regarding the Company&amp;#x2019;s operating leases for the nine and three&amp;nbsp;months ended September 30, 2019:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Nine Months Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Three Months Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;(&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:28.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Operating lease costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 907&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 314&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 999&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 337&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Right of use assets obtained in exchange for new operating lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 282&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 55&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table sets forth data regarding the Company&amp;#x2019;s operating leases as of September 30, 2019:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Weighted average remaining lease term (in years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Weighted average discount rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 12.55&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
  <us-gaap:LeasePracticalExpedientsPackage contextRef="Duration_1_1_2019_To_9_30_2019">true</us-gaap:LeasePracticalExpedientsPackage>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table sets forth a maturity analysis of the Company&amp;#x2019;s operating lease liabilities as of September 30, 2019:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;(&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;2019 (excluding the nine months ended September&amp;nbsp;30,&amp;nbsp;2019)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 300&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 1,128&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 949&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 826&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;2023&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 803&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;After 2023&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 6,656&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Total undiscounted cash flows&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 10,662&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Less: imputed interest&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 4,908&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Present value of&amp;nbsp;&amp;nbsp;operating lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 5,754&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">10662000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">6656000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="As_Of_9_30_2019_plx_CommitmentsAndContingenciesAxis_plx_VehicleLeaseAndMaintenanceAgreementsMember" unitRef="Unit12" decimals="0">474000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="As_Of_9_30_2019_plx_CommitmentsAndContingenciesAxis_us-gaap_LeaseAgreementsMember" unitRef="Unit12" decimals="0">758000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">803000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">826000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">949000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="As_Of_9_30_2019_plx_CommitmentsAndContingenciesAxis_plx_VehicleLeaseAndMaintenanceAgreementsMember" unitRef="Unit12" decimals="0">82000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="As_Of_9_30_2019_plx_CommitmentsAndContingenciesAxis_us-gaap_LeaseAgreementsMember" unitRef="Unit12" decimals="0">621000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">1128000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="As_Of_9_30_2019_plx_CommitmentsAndContingenciesAxis_plx_VehicleLeaseAndMaintenanceAgreementsMember" unitRef="Unit12" decimals="0">333000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="As_Of_9_30_2019_plx_CommitmentsAndContingenciesAxis_us-gaap_LeaseAgreementsMember" unitRef="Unit12" decimals="0">758000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
  <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">4908000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
  <us-gaap:LesseeOperatingLeasesTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;NOTE&amp;nbsp;4&amp;nbsp;&amp;#x2013; OPERATING LEASES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company is a party to a number of lease agreements for its facilities, the latest of which has been extended until the end of 2021. The Company has the option to extend certain of such agreements on two additional occasions for additional five-year periods each for a total of 10 additional&amp;nbsp;years. During the extended lease period, the aggregate&amp;nbsp;monthly rental payments will increase by 7.5%&amp;nbsp;- 10% for each option. The Company expects to exercise these options in future periods. As of September 30, 2019, the Company provided bank guarantees of approximately $437,000 in the aggregate, to secure the fulfillment of its obligations under the lease agreements. As of December&amp;nbsp;31, 2018, the future minimum lease payments required under the operating leases for such premises are approximately $758,000, &amp;nbsp;$758,000 and $621,000, for fiscal&amp;nbsp;years 2019 through 2021, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company entered into several three-year leases for vehicles which are regularly amended as new vehicles are leased. As of December&amp;nbsp;31, 2018, the future minimum lease payments for the&amp;nbsp;years ending December&amp;nbsp;31, 2019, 2020 and 2021 are approximately $474,000, &amp;nbsp;$333,000 and $82,000, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table sets forth data regarding the Company&amp;#x2019;s operating leases for the nine and three&amp;nbsp;months ended September 30, 2019:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Nine Months Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Three Months Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;(&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:28.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Operating lease costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 907&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 314&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 999&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 337&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Right of use assets obtained in exchange for new operating lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 282&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 55&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table sets forth data regarding the Company&amp;#x2019;s operating leases as of September 30, 2019:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Weighted average remaining lease term (in years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Weighted average discount rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 12.55&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table sets forth a maturity analysis of the Company&amp;#x2019;s operating lease liabilities as of September 30, 2019:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;(&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;2019 (excluding the nine months ended September&amp;nbsp;30,&amp;nbsp;2019)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 300&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 1,128&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 949&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 826&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;2023&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 803&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;After 2023&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 6,656&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Total undiscounted cash flows&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 10,662&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Less: imputed interest&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 4,908&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Present value of&amp;nbsp;&amp;nbsp;operating lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 5,754&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">114012000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">124578000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">61131000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">53729000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">25353000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">33319000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">88659000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">91259000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-4752000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-675000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-912000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-3738000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-15671000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-21023000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-21023000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-21023000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-21023000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-5322000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-5322000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-5322000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-18567000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-18567000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-18567000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-18567000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-3560000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-3560000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-3560000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;e.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Newly issued accounting pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In June&amp;nbsp;2018, the FASB issued ASU 2018&amp;#8209;07, &amp;#x201C;Compensation&amp;nbsp;&amp;#x2013; Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting&amp;#x201D; that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in ASU 2018&amp;#8209;07. The guidance is effective for fiscal&amp;nbsp;years beginning after December&amp;nbsp;15, 2018, including interim reporting periods within that fiscal&amp;nbsp;year. Early adoption is permitted, but no earlier than an entity&amp;#x2019;s adoption date of Topic 606. The Company does not expect the adoption of ASU 2018&amp;#8209;07 to have a material impact on its financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-5387000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-1581000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-5650000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-2016000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-15636000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-3741000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-12917000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">-1544000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeaseCost contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">907000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">314000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseLiability contextRef="As_Of_1_1_2019" unitRef="Unit12" decimals="-5">5700000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseLiability contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">5754000</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseLiabilityCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">0</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">1222000</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">4532000</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeasePayments contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">999000</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeasePayments contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">337000</us-gaap:OperatingLeasePayments>
  <us-gaap:OperatingLeaseRightOfUseAsset contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">0</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset contextRef="As_Of_1_1_2019" unitRef="Unit12" decimals="-5">5900000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">5764000</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="As_Of_9_30_2019" unitRef="Unit13" decimals="4">0.1255</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="As_Of_9_30_2019">P10Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OtherAssetsCurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">1877000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">2756000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">5292000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">5372000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherNonoperatingExpense contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">5824000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">1811000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">5877000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">2050000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingIncome contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">437000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">230000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">227000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">34000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-70000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">59000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">498000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">599000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">2374000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">2606000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">-86000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">51000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">6390000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">5573000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">4752000</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">23755000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">10071000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">35021000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">10000000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-5">341000000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRemainingPerformanceObligation contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="-3">76969000</us-gaap:RevenueRemainingPerformanceObligation>
  <us-gaap:RevenueRemainingPerformanceObligation contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">50584000</us-gaap:RevenueRemainingPerformanceObligation>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_9_30_2018_srt_StatementGeographicalAxis_country_BR" unitRef="Unit12" decimals="-3">2573000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_9_30_2018_srt_StatementGeographicalAxis_plx_PfizerMember" unitRef="Unit12" decimals="-3">4649000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_9_30_2018_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="Unit12" decimals="-3">16665000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_9_30_2018_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="Unit12" decimals="-3">16665000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_9_30_2018_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3">7222000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_9_30_2018_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3">7222000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_7_1_2018_To_9_30_2018_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="Unit12" decimals="-3">11672000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_7_1_2018_To_9_30_2018_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3">663000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2019_To_9_30_2019_srt_StatementGeographicalAxis_country_BR" unitRef="Unit12" decimals="-3">7385000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2019_To_9_30_2019_srt_StatementGeographicalAxis_plx_PfizerMember" unitRef="Unit12" decimals="-3">4701000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="Unit12" decimals="-3">24848000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="Unit12" decimals="-3">24848000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3">12086000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3">12086000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_7_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember" unitRef="Unit12" decimals="-3">9122000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_7_1_2019_To_9_30_2019_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="Unit12" decimals="-3">5126000</us-gaap:Revenues>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">282000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">55000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; a.&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;"&gt;Inventories at September 30, 2019 and December&amp;nbsp;31, 2018 consisted of the following:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;September&amp;nbsp;30,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;"&gt;(&lt;/font&gt;&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;"&gt;U.S. dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,691&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,792&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Work in progress&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 233&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 3,601&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 4,777&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;Total inventory&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 7,525&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"&gt; 8,569&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:SecurityDeposit contextRef="As_Of_9_30_2019_plx_CommitmentsAndContingenciesAxis_us-gaap_LeaseAgreementsMember" unitRef="Unit12" decimals="0">437000</us-gaap:SecurityDeposit>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">8744000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">4088000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">6885000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">2587000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">96000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit12" decimals="-3">599000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="4">0.6648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="5">0.01695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member" unitRef="Unit1" decimals="0">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit14" decimals="1">0.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member" unitRef="Unit14" decimals="1">0.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SharePrice contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit14" decimals="2">0.21</us-gaap:SharePrice>
  <us-gaap:SharesOutstanding id="Item-0002" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">143728797</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">148183591</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">148301238</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="Item-0005" contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">148301238</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="Item-0006" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">148382299</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">148382299</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">148382299</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="Item-0007" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">148382299</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">-29457000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">266495000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">144000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-296096000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_6_30_2018" unitRef="Unit12" decimals="-3">-42742000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">268907000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">148000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-311797000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="-3">-47943000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="-3">-47943000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">269028000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">269028000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">148000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">148000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-317119000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-317119000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">-52881000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="-3">-52881000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">269524000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">148000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-322553000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_6_30_2019" unitRef="Unit12" decimals="-3">-67485000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">269927000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">148000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-337560000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">-70849000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">-70849000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2019" unitRef="Unit12" decimals="-3">-70849000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">270123000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">270123000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">148000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">148000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-341120000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-341120000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;NOTE 6 - STOCK TRANSACTIONS&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In September 2019, the Company granted to its new chief financial officer 10-year options to purchase, in the aggregate, 800,000 shares of Common Stock under the Company&amp;#x2019;s 2006 Employee Stock Incentive Plan, as amended (the &amp;#x201C;Plan&amp;#x201D;).&amp;nbsp;&amp;nbsp;The options have an exercise price equal to $0.2 per share and vest over a four-year period in 16 equal quarterly increments.&amp;nbsp;&amp;nbsp;Vesting of the options is subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions.&amp;nbsp;&amp;nbsp;The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $97,000 based on the following weighted average assumptions: share price equal to $0.2; dividend yield of 0% for all years; expected volatility of 66.48%; risk-free interest rates of 1.695%; and expected life of six years.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="Item-0004" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">1928907</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="-3">1291000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">1289000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:SubsequentEventsTextBlock contextRef="Duration_1_1_2019_To_9_30_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;NOTE 7 &amp;#x2013; SUBSEQUENT EVENTS&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On October 16, 2019, the Company received total proceeds of approximately $2.6 million from expense reimbursements in relation to its collaboration with Chiesi and on October 18, 2019, the Company received total proceeds of approximately $3.2 million from sales of alfataliglicerase to Fiocruz.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In accordance with ASC 855 &amp;#x201C;Subsequent Events&amp;#x201D; the Company evaluated subsequent events through the date the condensed consolidated financial statements were issued. The Company concluded that no other subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">146752355</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">148187513</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2019_To_9_30_2019" unitRef="Unit1" decimals="0">148382299</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_7_1_2019_To_9_30_2019" unitRef="Unit1" decimals="0">148382299</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Footnote Section-->
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#Item-0001" xlink:label="Item-0001_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0001_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0003" xlink:label="Item-0003_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0003_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0002" xlink:label="Item-0002_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0002_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0005" xlink:label="Item-0005_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0005_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0006" xlink:label="Item-0006_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0006_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0007" xlink:label="Item-0007_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0007_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0004" xlink:label="Item-0004_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0004_lbl" xlink:to="Footnote-02" order="1" />
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">Represents an amount less than $1.</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">Common Stock, $0.001 par value; Authorized&#xA0;- as of September 30, 2019 and 2018&#xA0;- 350,000,000 and 250,000,000, respectively.</link:footnote>
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>plx-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.0.81 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/6/2019 11:42:04 PM-->
<!--Modified on: 11/6/2019 11:42:04 PM-->
<schema xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:plx="http://www.protalix.com/20190930" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.protalix.com/20190930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" id="DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails">
        <link:definition>40402 - Disclosure - OPERATING LEASES - Lessee, Operating Lease, Liability, Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails" id="DisclosureInventoriesAdditionalInformationDetails">
        <link:definition>40202 - Disclosure - INVENTORIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" id="DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesLeaseCostDetails" id="DisclosureOperatingLeasesLeaseCostDetails">
        <link:definition>40401 - Disclosure - OPERATING LEASES - Lease, Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" id="DisclosureOperatingLeasesAdditionalInformationDetails">
        <link:definition>40403 - Disclosure - OPERATING LEASES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesStatementsOfOperationsDetails" id="DisclosureRevenuesStatementsOfOperationsDetails">
        <link:definition>40501 - Disclosure - REVENUES - Statements of operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesContractWithCustomerAssetAndLiabilityDetails" id="DisclosureRevenuesContractWithCustomerAssetAndLiabilityDetails">
        <link:definition>40502 - Disclosure - REVENUES - Contract With Customer Asset And Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesUnsatisfiedPerformanceObligationsDetails" id="DisclosureRevenuesUnsatisfiedPerformanceObligationsDetails">
        <link:definition>40503 - Disclosure - REVENUES - Unsatisfied Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>40601 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40701 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeases" id="DisclosureOperatingLeases">
        <link:definition>10401 - Disclosure - OPERATING LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10501 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>10601 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10701 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesTables" id="DisclosureOperatingLeasesTables">
        <link:definition>30403 - Disclosure - OPERATING LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30503 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_DocumentAndEntityInformationAbstract" substitutionGroup="xbrli:item" />
  <element id="plx_GrantsAndReimbursementsReceivedOrReceivable" name="GrantsAndReimbursementsReceivedOrReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="NatureOfOperationsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <element name="RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" substitutionGroup="xbrli:item" />
  <element name="Notes2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_Notes2021Member" substitutionGroup="xbrli:item" />
  <element id="plx_SupplementaryIncomeStatementInformationTableTextBlock" name="SupplementaryIncomeStatementInformationTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" name="RevenueRemainingPerformanceObligationAmountTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <element name="AmendedPfizerAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ChiesiUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ChiesiExUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ProtalixBioTherapeuticsIncorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <element name="CollaborativeArrangementRevenuesExpensesSharingPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" substitutionGroup="xbrli:item" />
  <element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PaymentOnNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <element name="SevenPointFivePercentageConvertibleNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
  <element name="FairValueAssumptionsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsTerm" substitutionGroup="xbrli:item" />
  <element name="FairValueAssumptionsRiskFreeInterestRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsRiskFreeInterestRates" substitutionGroup="xbrli:item" />
  <element name="FairValueAssumptionsExpectedVolatilityRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsExpectedVolatilityRates" substitutionGroup="xbrli:item" />
  <element name="FairValueAssumptionsExpectedDividendRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_FairValueAssumptionsExpectedDividendRates" substitutionGroup="xbrli:item" />
  <element name="SevenPointFivePercentageConvertibleNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNoteMember" substitutionGroup="xbrli:item" />
  <element name="DisclosureOfLeasesOperatingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_DisclosureOfLeasesOperatingTable" substitutionGroup="xbrldt:hypercubeItem" />
  <element name="DisclosureOfLeasesOperatingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_DisclosureOfLeasesOperatingLineItems" substitutionGroup="xbrli:item" />
  <element name="PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" substitutionGroup="xbrli:item" />
  <element name="CommitmentsAndContingenciesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_CommitmentsAndContingenciesAxis" substitutionGroup="xbrldt:dimensionItem" />
  <element name="CommitmentsAndContingenciesDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_CommitmentsAndContingenciesDomain" substitutionGroup="xbrli:item" />
  <element name="VehicleLeaseAndMaintenanceAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_VehicleLeaseAndMaintenanceAgreementsMember" substitutionGroup="xbrli:item" />
  <element name="PfizerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_PfizerMember" substitutionGroup="xbrli:item" />
  <element id="plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" name="StockIssuedDuringPeriodValueConvertibleNoteExchange" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" name="StockIssuedDuringPeriodSharesConvertibleNoteExchange" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_EmployeeStockIncentivePlan2006Member" name="EmployeeStockIncentivePlan2006Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_MaintainOfMinimumCashBalance" name="MaintainOfMinimumCashBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_ProceedsFromReimbursementOfExpenses" name="ProceedsFromReimbursementOfExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_ProceedsFromSaleOfProducts" name="ProceedsFromSaleOfProducts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" name="UpfrontNonrefundableNonCreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_AlfataligliceraseToFiocruzMember" name="AlfataligliceraseToFiocruzMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>plx-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.0.81 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/6/2019 11:42:04 PM-->
<!--Modified on: 11/6/2019 11:42:04 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637086805237648240" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637086805237648240" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637086805237668227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637086805237648240" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637086805237668227" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637086805237668227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637086805237648240" xlink:to="us-gaap_AccountsReceivableNetCurrent_637086805237668227" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637086805237668227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637086805237648240" xlink:to="us-gaap_OtherAssetsCurrent_637086805237668227" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637086805237668227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637086805237648240" xlink:to="us-gaap_InventoryNet_637086805237668227" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637086805237668227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637086805237668227" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637086805237668227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637086805237668227" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637086805237668227" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637086805237668227" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637086805237758170" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_637086805237758170" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637086805237758170" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637086805237758170" xlink:to="us-gaap_LiabilitiesNoncurrent_637086805237758170" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637086805237758170" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637086805237758170" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637086805237758170" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637086805237758170" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637086805237758170" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637086805237758170" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637086805237758170" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637086805237758170" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637086805237758170" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637086805237768168" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637086805237758170" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637086805237768168" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637086805237768168" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637086805237758170" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637086805237768168" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637086805237768168" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637086805237758170" xlink:to="us-gaap_LiabilitiesCurrent_637086805237768168" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637086805237768168" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637086805237768168" xlink:to="us-gaap_AccountsPayableTradeCurrent_637086805237768168" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637086805237768168" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637086805237768168" xlink:to="us-gaap_AccountsPayableOtherCurrent_637086805237768168" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637086805237768168" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637086805237768168" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637086805237768168" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637086805237768168" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637086805237768168" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637086805237768168" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637086805237768168" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_637086805237768168" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637086805237768168" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637086805237768168" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637086805237768168" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_637086805237768168" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637086805237768168" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637086805237768168" xlink:to="us-gaap_OtherNonoperatingExpense_637086805237768168" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637086805237768168" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637086805237768168" xlink:to="us-gaap_OtherNonoperatingIncome_637086805237768168" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="us-gaap_NetIncomeLoss_637086805237778162" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="us-gaap_ShareBasedCompensation_637086805237778162" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="us-gaap_Depreciation_637086805237778162" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637086805237778162" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637086805237778162" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637086805237778162" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637086805237778162" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="us-gaap_AmortizationOfFinancingCosts_637086805237778162" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_637086805237778162" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637086805237778162" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637086805237778162" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637086805237778162" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="us-gaap_IncreaseDecreaseInInventories_637086805237778162" order="13" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637086805237778162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637086805237778162" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637086805237788158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805237778162" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637086805237788158" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637086805237788158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637086805237788158" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637086805237788158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637086805237788158" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637086805237788158" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_637086805237788158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637086805237788158" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_637086805237788158" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637086805237788158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637086805237788158" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637086805237788158" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637086805237788158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637086805237788158" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_637086805237788158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637086805237788158" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_637086805237788158" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637086805237788158" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637086805237788158" order="4" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637086805237828152" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637086805237828152" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637086805237828152" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637086805237828152" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637086805237828152" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637086805237828152" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" xlink:type="extended" xlink:title="40402 - Disclosure - OPERATING LEASES - Lessee, Operating Lease, Liability, Maturity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637086805237828152" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637086805237828152" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637086805237828152" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637086805237828152" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637086805237828152" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637086805237828152" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637086805237828152" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637086805237828152" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637086805237828152" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637086805237828152" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637086805237828152" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637086805237828152" order="6" use="optional" weight="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>plx-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.0.81 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/6/2019 11:42:04 PM-->
<!--Modified on: 11/6/2019 11:42:04 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureRevenuesStatementsOfOperationsDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesStatementsOfOperationsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637086805238177930" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637086805238177930" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637086805238217892" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637086805238217892" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="plx_GrantsAndReimbursementsReceivedOrReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637086805238237881" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637086805238237881" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" xlink:label="plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" xlink:label="plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637086805238247872" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637086805238247872" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_Notes2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637086805238257866" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637086805238257866" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637086805238257866" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637086805238257866" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637086805238267862" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_637086805238267862" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637086805238267862" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637086805238267862" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaintainOfMinimumCashBalance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LeasePracticalExpedientsPackage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637086805238307837" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637086805238307837" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_FairValueAssumptionsTerm" xlink:label="plx_FairValueAssumptionsTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_FairValueAssumptionsTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_FairValueAssumptionsRiskFreeInterestRates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_FairValueAssumptionsExpectedVolatilityRates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="plx_FairValueAssumptionsExpectedDividendRates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_FairValueAssumptionsExpectedDividendRates" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="40403 - Disclosure - OPERATING LEASES - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_DisclosureOfLeasesOperatingTable" xlink:label="plx_DisclosureOfLeasesOperatingTable" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="plx_CommitmentsAndContingenciesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_DisclosureOfLeasesOperatingTable" xlink:to="plx_CommitmentsAndContingenciesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="plx_CommitmentsAndContingenciesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="plx_CommitmentsAndContingenciesAxis" xlink:to="plx_CommitmentsAndContingenciesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="plx_CommitmentsAndContingenciesDomain_637086805238327824" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="plx_CommitmentsAndContingenciesAxis" xlink:to="plx_CommitmentsAndContingenciesDomain_637086805238327824" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="plx_VehicleLeaseAndMaintenanceAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_VehicleLeaseAndMaintenanceAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="us-gaap_LeaseAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_DisclosureOfLeasesOperatingTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_DisclosureOfLeasesOperatingTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesStatementsOfOperationsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - REVENUES - Statements of operations (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637086805238357805" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637086805238357805" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637086805238357805" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637086805238357805" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637086805238357805" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637086805238357805" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637086805238377793" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637086805238377793" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_AlfataligliceraseToFiocruzMember" xlink:label="plx_AlfataligliceraseToFiocruzMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="plx_AlfataligliceraseToFiocruzMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ProceedsFromReimbursementOfExpenses" xlink:label="plx_ProceedsFromReimbursementOfExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromReimbursementOfExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromSaleOfProducts" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>plx-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.0.81 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/6/2019 11:42:04 PM-->
<!--Modified on: 11/6/2019 11:42:04 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="plx_DocumentAndEntityInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">OPERATING LEASE RIGHT OF USE ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES NET OF CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities net of capital deficiency</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License And Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">REVENUES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES (1)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES, NET</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss for the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE-BASIC AND DILUTED</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling General And Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:to="plx_GrantsAndReimbursementsReceivedOrReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable_lbl" xml:lang="en-US">Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable_lbl" xml:lang="en-US">Grants And Reimbursements Received Or Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable_lbl" xml:lang="en-US">Grants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock award</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock award (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Convertible notes conversions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Convertible notes conversions (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" xlink:label="plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" xlink:to="plx_StockIssuedDuringPeriodValueConvertibleNoteExchange_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueConvertibleNoteExchange_lbl" xml:lang="en-US">The value of outstanding notes exchanged with the company for shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueConvertibleNoteExchange_lbl" xml:lang="en-US">Stock Issued During Period Value Convertible Note Exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueConvertibleNoteExchange_lbl" xml:lang="en-US">Convertible notes exchange</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" xlink:label="plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" xlink:to="plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange_lbl" xml:lang="en-US">The numbers of shares issued in exchange for outstanding notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange_lbl" xml:lang="en-US">Stock Issued During Period Shares Convertible Note Exchange</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange_lbl" xml:lang="en-US">Convertible notes exchange (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial expenses (income), net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Net loss in connection with conversions of convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:to="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_lbl" xml:lang="en-US">Issuance of shares for interest payment regarding conversion of convertible notes,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_lbl" xml:lang="en-US">Issuance Of Shares For Interest Payment Regarding Conversion Of Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_lbl" xml:lang="en-US">Issuance of shares for interest payment in connection with conversions of convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (decrease) in contracts liability (including non-current portion)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in accounts receivable and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase in other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Increase in restricted deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayments of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Net payment for convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash used in financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase in liabilities for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Convertible notes conversions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US">OPERATING LEASES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">OPERATING LEASES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xlink:label="plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xlink:to="plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy pertaining to recently adopted standards that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted standards [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted standards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Newly issued accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_Notes2021Member" xlink:to="plx_Notes2021Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_Notes2021Member_lbl" xml:lang="en-US">Notes2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_Notes2021Member_lbl" xml:lang="en-US">Notes 2021 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of liability component based on income approach</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturity analysis of operating leases</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:to="plx_SupplementaryIncomeStatementInformationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for supplemental income statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock_lbl" xml:lang="en-US">Supplementary Income Statement Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's disaggregation of revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's contracts liability</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" xlink:label="plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" xlink:to="plx_RevenueRemainingPerformanceObligationAmountTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueRemainingPerformanceObligationAmountTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of revenue remaining performance obligation amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueRemainingPerformanceObligationAmountTableTextBlock_lbl" xml:lang="en-US">Revenue Remaining Performance Obligation Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_RevenueRemainingPerformanceObligationAmountTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's unsatisfied performance obligation</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi U S Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex U S Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">B [R]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">2021 Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaintainOfMinimumCashBalance" xlink:to="plx_MaintainOfMinimumCashBalance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required to be maintained under long term debt agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Maintain of Minimum Cash Balance</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non-Creditable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientsPackage" xlink:to="us-gaap_LeasePracticalExpedientsPackage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xml:lang="en-US">Lease, Practical Expedients, Package [true false]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory Write-down</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price (USD)</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_FairValueAssumptionsTerm" xlink:label="plx_FairValueAssumptionsTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FairValueAssumptionsTerm" xlink:to="plx_FairValueAssumptionsTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FairValueAssumptionsTerm_lbl" xml:lang="en-US">Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FairValueAssumptionsTerm_lbl" xml:lang="en-US">Fair Value Assumptions Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_FairValueAssumptionsTerm_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FairValueAssumptionsRiskFreeInterestRates" xlink:to="plx_FairValueAssumptionsRiskFreeInterestRates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates_lbl" xml:lang="en-US">Risk-free interest rate assumption used in valuing an instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates_lbl" xml:lang="en-US">Fair Value Assumptions Risk Free Interest Rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates_lbl" xml:lang="en-US">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FairValueAssumptionsExpectedVolatilityRates" xlink:to="plx_FairValueAssumptionsExpectedVolatilityRates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates_lbl" xml:lang="en-US">Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates_lbl" xml:lang="en-US">Fair Value Assumptions Expected Volatility Rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="plx_FairValueAssumptionsExpectedDividendRates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FairValueAssumptionsExpectedDividendRates" xlink:to="plx_FairValueAssumptionsExpectedDividendRates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FairValueAssumptionsExpectedDividendRates_lbl" xml:lang="en-US">Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FairValueAssumptionsExpectedDividendRates_lbl" xml:lang="en-US">Fair Value Assumptions Expected Dividend Rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_FairValueAssumptionsExpectedDividendRates_lbl" xml:lang="en-US">Yield</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNoteMember" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_DisclosureOfLeasesOperatingTable" xlink:label="plx_DisclosureOfLeasesOperatingTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DisclosureOfLeasesOperatingTable" xlink:to="plx_DisclosureOfLeasesOperatingTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DisclosureOfLeasesOperatingTable_lbl" xml:lang="en-US">Disclosure of Leases, Operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DisclosureOfLeasesOperatingTable_lbl" xml:lang="en-US">Disclosure of Leases Operating [Table]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_DisclosureOfLeasesOperatingLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_lbl" xml:lang="en-US">Disclosure of Leases Operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_lbl" xml:lang="en-US">Disclosure of Leases Operating [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2019 (excluding the six months ended September 30, 2019)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">After 2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted cash flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="plx_CommitmentsAndContingenciesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesAxis" xlink:to="plx_CommitmentsAndContingenciesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommitmentsAndContingenciesAxis_lbl" xml:lang="en-US">Commitments And Contingencies Axis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommitmentsAndContingenciesAxis_lbl" xml:lang="en-US">Commitments And Contingencies [Axis]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="plx_CommitmentsAndContingenciesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesDomain" xlink:to="plx_CommitmentsAndContingenciesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommitmentsAndContingenciesDomain_lbl" xml:lang="en-US">Commitments And Contingencies [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommitmentsAndContingenciesDomain_lbl" xml:lang="en-US">Commitments And Contingencies [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CommitmentsAndContingenciesDomain_lbl" xml:lang="en-US">Commitments And Contingencies [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="plx_VehicleLeaseAndMaintenanceAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:to="plx_VehicleLeaseAndMaintenanceAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_VehicleLeaseAndMaintenanceAgreementsMember_lbl" xml:lang="en-US">Vehicle Lease and Maintenance Agreements Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_VehicleLeaseAndMaintenanceAgreementsMember_lbl" xml:lang="en-US">Vehicle Lease And Maintenance Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_VehicleLeaseAndMaintenanceAgreementsMember_lbl" xml:lang="en-US">Vehicle Lease [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xml:lang="en-US">Lease Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xml:lang="en-US">Lease Agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" xml:lang="en-US">Percentage of Change in Operating Lease Monthly Rental Payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" xml:lang="en-US">Percentage of Change in Operating Lease Monthly Rental Payments</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Contracts liability at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Contracts liability at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_lbl" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_lbl" xml:lang="en-US">Additions during the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Revenue recognized during the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Unsatisfied performance obligation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="plx_EmployeeStockIncentivePlan2006Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">It represent the employee stock incentive plan for the particular period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">Employee Stock Incentive Plan2006 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">2006 Employee Stock Incentive Plan Member</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award grant date fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ProceedsFromReimbursementOfExpenses" xlink:label="plx_ProceedsFromReimbursementOfExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromReimbursementOfExpenses" xlink:to="plx_ProceedsFromReimbursementOfExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromReimbursementOfExpenses_lbl" xml:lang="en-US">The cash inflow from reimbursement of expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromReimbursementOfExpenses_lbl" xml:lang="en-US">Proceeds From Reimbursement Of Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromReimbursementOfExpenses_lbl" xml:lang="en-US">Total proceeds from reimbursement of expenses</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfProducts" xlink:to="plx_ProceedsFromSaleOfProducts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">The amount of proceeds from sale of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">Proceeds From Sale Of products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">Total proceeds from sales</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Represents information pertaining to Chiesi.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_AlfataligliceraseToFiocruzMember" xlink:label="plx_AlfataligliceraseToFiocruzMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AlfataligliceraseToFiocruzMember" xlink:to="plx_AlfataligliceraseToFiocruzMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AlfataligliceraseToFiocruzMember_lbl" xml:lang="en-US">Represents information pertaining to alfataliglicerase to Fiocruz.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AlfataligliceraseToFiocruzMember_lbl" xml:lang="en-US">Alfataliglicerase To Fiocruz [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AlfataligliceraseToFiocruzMember_lbl" xml:lang="en-US">Alfataliglicerase to Fiocruz [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>plx-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.0.81 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/6/2019 11:42:04 PM-->
<!--Modified on: 11/6/2019 11:42:04 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureOperatingLeases" roleURI="http://www.protalix.com/role/DisclosureOperatingLeases" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureOperatingLeasesTables" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureInventoriesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureOperatingLeasesLeaseCostDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesLeaseCostDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureRevenuesStatementsOfOperationsDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesStatementsOfOperationsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureRevenuesContractWithCustomerAssetAndLiabilityDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesContractWithCustomerAssetAndLiabilityDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureRevenuesUnsatisfiedPerformanceObligationsDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesUnsatisfiedPerformanceObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20190930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="loc_plx_DocumentAndEntityInformationAbstract_187665" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637086805238567664" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_DocumentType_637086805238567664" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637086805238597647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_DocumentPeriodEndDate_637086805238597647" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637086805238597647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_EntityRegistrantName_637086805238597647" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637086805238597647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_TradingSymbol_637086805238597647" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637086805238597647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_EntityCurrentReportingStatus_637086805238597647" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637086805238597647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_EntityInteractiveDataCurrent_637086805238597647" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637086805238597647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_EntityFilerCategory_637086805238597647" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637086805238597647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_EntitySmallBusiness_637086805238597647" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637086805238597647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_EntityEmergingGrowthCompany_637086805238597647" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637086805238597647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_EntityShellCompany_637086805238597647" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637086805238597647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_EntityCommonStockSharesOutstanding_637086805238597647" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637086805238597647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_EntityCentralIndexKey_637086805238597647" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637086805238597647" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_CurrentFiscalYearEndDate_637086805238597647" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637086805238607639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_DocumentFiscalYearFocus_637086805238607639" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637086805238607639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_DocumentFiscalPeriodFocus_637086805238607639" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637086805238607639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_plx_DocumentAndEntityInformationAbstract_187665" xlink:to="dei_AmendmentFlag_637086805238607639" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637086805238607639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_637086805238607639" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637086805238607639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637086805238607639" xlink:to="us-gaap_AssetsCurrentAbstract_637086805238607639" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637086805238607639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637086805238607639" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637086805238607639" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637086805238677595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637086805238607639" xlink:to="us-gaap_AccountsReceivableNetCurrent_637086805238677595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637086805238677595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637086805238607639" xlink:to="us-gaap_OtherAssetsCurrent_637086805238677595" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637086805238677595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637086805238607639" xlink:to="us-gaap_InventoryNet_637086805238677595" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637086805238677595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637086805238607639" xlink:to="us-gaap_AssetsCurrent_637086805238677595" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637086805238677595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637086805238607639" xlink:to="us-gaap_AssetsNoncurrentAbstract_637086805238677595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637086805238677595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637086805238677595" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637086805238677595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637086805238677595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637086805238677595" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637086805238677595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637086805238677595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637086805238677595" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637086805238677595" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637086805238677595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637086805238607639" xlink:to="us-gaap_Assets_637086805238677595" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637086805238677595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637086805238677595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637086805238677595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637086805238677595" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637086805238677595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637086805238677595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637086805238677595" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637086805238677595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637086805238677595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637086805238677595" xlink:to="us-gaap_AccountsPayableTradeCurrent_637086805238677595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637086805238687587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637086805238677595" xlink:to="us-gaap_AccountsPayableOtherCurrent_637086805238687587" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637086805238687587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637086805238677595" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637086805238687587" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637086805238687587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637086805238677595" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637086805238687587" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637086805238687587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637086805238677595" xlink:to="us-gaap_LiabilitiesCurrent_637086805238687587" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637086805238687587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637086805238677595" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637086805238687587" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637086805238687587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637086805238687587" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637086805238687587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637086805238687587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637086805238687587" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637086805238687587" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637086805238687587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637086805238687587" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637086805238687587" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637086805238687587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637086805238687587" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637086805238687587" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637086805238687587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637086805238687587" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637086805238687587" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637086805238687587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637086805238677595" xlink:to="us-gaap_LiabilitiesNoncurrent_637086805238687587" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637086805238687587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637086805238677595" xlink:to="us-gaap_Liabilities_637086805238687587" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637086805238697581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637086805238677595" xlink:to="us-gaap_CommitmentsAndContingencies_637086805238697581" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637086805238697581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637086805238677595" xlink:to="us-gaap_StockholdersEquity_637086805238697581" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637086805238697581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637086805238677595" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637086805238697581" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_271" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637086805238697581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_271" xlink:to="us-gaap_StatementTable_637086805238697581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637086805238697581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238697581" xlink:to="srt_ProductOrServiceAxis_637086805238697581" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637086805238697581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637086805238697581" xlink:to="srt_ProductsAndServicesDomain_637086805238697581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637086805238697581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637086805238697581" xlink:to="us-gaap_ProductMember_637086805238697581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637086805238697581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637086805238697581" xlink:to="us-gaap_LicenseAndServiceMember_637086805238697581" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637086805238697581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238697581" xlink:to="us-gaap_StatementLineItems_637086805238697581" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637086805238697581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238697581" xlink:to="us-gaap_Revenues_637086805238697581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637086805238697581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238697581" xlink:to="us-gaap_CostOfRevenue_637086805238697581" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637086805238697581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238697581" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637086805238697581" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637086805238697581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238697581" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637086805238697581" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238697581" xlink:to="us-gaap_OperatingIncomeLoss_637086805238707575" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238697581" xlink:to="us-gaap_OtherNonoperatingExpense_637086805238707575" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238697581" xlink:to="us-gaap_OtherNonoperatingIncome_637086805238707575" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238697581" xlink:to="us-gaap_NonoperatingIncomeExpense_637086805238707575" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238697581" xlink:to="us-gaap_NetIncomeLoss_637086805238707575" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238697581" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637086805238707575" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238697581" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637086805238707575" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="us-gaap_StatementTable_637086805238707575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238707575" xlink:to="us-gaap_IncomeStatementLocationAxis_637086805238707575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637086805238707575" xlink:to="us-gaap_IncomeStatementLocationDomain_637086805238707575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637086805238707575" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637086805238707575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637086805238707575" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637086805238707575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238707575" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637086805238707575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637086805238707575" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637086805238707575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:label="plx_GrantsAndReimbursementsReceivedOrReceivable_637086805238707575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637086805238707575" xlink:to="plx_GrantsAndReimbursementsReceivedOrReceivable_637086805238707575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_637086805238717570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238717570" xlink:to="us-gaap_StatementEquityComponentsAxis_637086805238717570" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637086805238717570" xlink:to="us-gaap_EquityComponentDomain_637086805238717570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637086805238717570" xlink:to="us-gaap_CommonStockMember_637086805238717570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637086805238717570" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637086805238717570" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637086805238717570" xlink:to="us-gaap_RetainedEarningsMember_637086805238717570" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238717570" xlink:to="us-gaap_StatementLineItems_637086805238717570" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238717570" xlink:to="us-gaap_StockholdersEquity_637086805238717570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238717570" xlink:to="us-gaap_SharesOutstanding_637086805238717570" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238717570" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637086805238717570" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238717570" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637086805238717570" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238717570" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_637086805238717570" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238717570" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637086805238717570" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238717570" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637086805238717570" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_StockIssuedDuringPeriodValueConvertibleNoteExchange" xlink:label="plx_StockIssuedDuringPeriodValueConvertibleNoteExchange_637086805238717570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238717570" xlink:to="plx_StockIssuedDuringPeriodValueConvertibleNoteExchange_637086805238717570" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange" xlink:label="plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238717570" xlink:to="plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange_637086805238727563" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238717570" xlink:to="us-gaap_NetIncomeLoss_637086805238727563" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238717570" xlink:to="us-gaap_StockholdersEquity_637086805238727563" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238717570" xlink:to="us-gaap_SharesOutstanding_637086805238727563" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637086805238727563" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_637086805238727563" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" xlink:to="us-gaap_NetIncomeLoss_637086805238727563" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" xlink:to="us-gaap_ShareBasedCompensation_637086805238727563" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" xlink:to="us-gaap_Depreciation_637086805238727563" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637086805238727563" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637086805238727563" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637086805238727563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637086805238727563" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637086805238737558" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" xlink:to="us-gaap_AmortizationOfFinancingCosts_637086805238737558" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes" xlink:label="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" xlink:to="plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes_637086805238737558" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637086805238737558" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637086805238737558" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637086805238737558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637086805238737558" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637086805238737558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637086805238737558" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637086805238737558" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637086805238737558" xlink:to="us-gaap_IncreaseDecreaseInInventories_637086805238737558" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637086805238737558" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637086805238737558" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637086805238737558" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637086805238737558" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637086805238727563" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637086805238737558" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637086805238737558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637086805238737558" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637086805238737558" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_637086805238737558" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637086805238737558" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_637086805238737558" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637086805238747550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637086805238737558" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637086805238747550" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637086805238747550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637086805238737558" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637086805238747550" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637086805238747550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637086805238747550" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_637086805238747550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637086805238747550" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_637086805238747550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637086805238747550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637086805238747550" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637086805238747550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637086805238747550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637086805238747550" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637086805238747550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637086805238747550" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637086805238747550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637086805238747550" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6370868052387475501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6370868052387475501" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637086805238747550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637086805238747550" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637086805238747550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637086805238747550" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637086805238747550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_637086805238747550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637086805238747550" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_637086805238747550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637086805238757543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637086805238757543" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637086805238757543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637086805238757543" xlink:to="us-gaap_InterestPaidNet_637086805238757543" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637086805238757543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637086805238757543" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_637086805238757543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_637086805238757543" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637086805238757543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637086805238757543" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeases" xlink:type="extended" xlink:title="10401 - Disclosure - OPERATING LEASES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaap_LeasesOperatingAbstract_413802" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_637086805238757543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413802" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_637086805238757543" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10501 - Disclosure - REVENUES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_637086805238767539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_637086805238767539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="10601 - Disclosure - STOCK TRANSACTIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637086805238767539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637086805238767539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10701 - Disclosure - SUBSEQUENT EVENTS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_349978" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637086805238767539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_349978" xlink:to="us-gaap_SubsequentEventsTextBlock_637086805238767539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_637086805238767539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_637086805238767539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637086805238767539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637086805238767539" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637086805238767539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637086805238767539" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock" xlink:label="plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock_637086805238767539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock_637086805238767539" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637086805238767539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637086805238767539" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637086805238777532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637086805238777532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637086805238777532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_637086805238777532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637086805238777532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238777532" xlink:to="us-gaap_DebtInstrumentAxis_637086805238777532" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637086805238777532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637086805238777532" xlink:to="us-gaap_DebtInstrumentNameDomain_637086805238777532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member_637086805238777532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637086805238777532" xlink:to="plx_Notes2021Member_637086805238777532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637086805238777532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238777532" xlink:to="us-gaap_StatementLineItems_637086805238777532" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637086805238777532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238777532" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637086805238777532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesTables" xlink:type="extended" xlink:title="30403 - Disclosure - OPERATING LEASES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaap_LeasesOperatingAbstract_413805" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_637086805238777532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413805" xlink:to="us-gaap_LeaseCostTableTextBlock_637086805238777532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637086805238777532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413805" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637086805238777532" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30503 - Disclosure - REVENUES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411881" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SupplementaryIncomeStatementInformationTableTextBlock" xlink:label="plx_SupplementaryIncomeStatementInformationTableTextBlock_637086805238777532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411881" xlink:to="plx_SupplementaryIncomeStatementInformationTableTextBlock_637086805238777532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_637086805238777532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411881" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_637086805238777532" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_RevenueRemainingPerformanceObligationAmountTableTextBlock" xlink:label="plx_RevenueRemainingPerformanceObligationAmountTableTextBlock_637086805238777532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411881" xlink:to="plx_RevenueRemainingPerformanceObligationAmountTableTextBlock_637086805238777532" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_637086805238787525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637086805238787525" xlink:to="us-gaap_TypeOfArrangementAxis_637086805238787525" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637086805238787525" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637086805238787525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637086805238787525" xlink:to="plx_AmendedPfizerAgreementMember_637086805238787525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637086805238787525" xlink:to="plx_ChiesiUSAgreementMember_637086805238787525" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637086805238787525" xlink:to="plx_ChiesiExUSAgreementMember_637086805238787525" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637086805238787525" xlink:to="dei_LegalEntityAxis_637086805238787525" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637086805238787525" xlink:to="dei_EntityDomain_637086805238787525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637086805238787525" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_637086805238787525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637086805238787525" xlink:to="srt_StatementGeographicalAxis_637086805238787525" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637086805238787525" xlink:to="srt_SegmentGeographicalDomain_637086805238787525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637086805238787525" xlink:to="country_BR_637086805238787525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637086805238787525" xlink:to="srt_RangeAxis_637086805238787525" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637086805238787525" xlink:to="srt_RangeMember_637086805238787525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637086805238787525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637086805238787525" xlink:to="srt_MinimumMember_637086805238787525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637086805238797519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637086805238787525" xlink:to="srt_MaximumMember_637086805238797519" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637086805238797519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637086805238787525" xlink:to="us-gaap_DebtInstrumentAxis_637086805238797519" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637086805238797519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637086805238797519" xlink:to="us-gaap_DebtInstrumentNameDomain_637086805238797519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637086805238797519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637086805238797519" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637086805238797519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_637086805238797519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637086805238787525" xlink:to="plx_SignificantAccountingPoliciesLineItems_637086805238797519" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637086805238797519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637086805238797519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637086805238797519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637086805238797519" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637086805238797519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637086805238797519" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637086805238797519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637086805238797519" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637086805238797519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637086805238797519" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637086805238797519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637086805238797519" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance_637086805238797519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="plx_MaintainOfMinimumCashBalance_637086805238797519" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637086805238807512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637086805238807512" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637086805238807512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637086805238807512" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637086805238807512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637086805238807512" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637086805238807512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637086805238807512" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637086805238807512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637086805238807512" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_637086805238807512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="plx_PaymentOnNetSalesPercentage_637086805238807512" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage_637086805238807512" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="us-gaap_LeasePracticalExpedientsPackage_637086805238807512" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637086805238817507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637086805238817507" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637086805238817507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637086805238797519" xlink:to="us-gaap_OperatingLeaseLiability_637086805238817507" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637086805238817507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637086805238817507" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637086805238817507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637086805238817507" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637086805238817507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637086805238817507" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637086805238817507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_637086805238817507" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - INVENTORIES - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_353300" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_637086805238817507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_353300" xlink:to="us-gaap_InventoryWriteDown_637086805238817507" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637086805238817507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_StatementTable_637086805238817507" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238817507" xlink:to="us-gaap_DebtInstrumentAxis_637086805238827501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637086805238827501" xlink:to="us-gaap_DebtInstrumentNameDomain_637086805238827501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637086805238827501" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637086805238827501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238817507" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637086805238827501" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637086805238827501" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637086805238827501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637086805238827501" xlink:to="us-gaap_FairValueInputsLevel3Member_637086805238827501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238817507" xlink:to="us-gaap_StatementLineItems_637086805238827501" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238827501" xlink:to="us-gaap_SharePrice_637086805238827501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_FairValueAssumptionsTerm" xlink:label="plx_FairValueAssumptionsTerm_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238827501" xlink:to="plx_FairValueAssumptionsTerm_637086805238827501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_FairValueAssumptionsRiskFreeInterestRates" xlink:label="plx_FairValueAssumptionsRiskFreeInterestRates_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238827501" xlink:to="plx_FairValueAssumptionsRiskFreeInterestRates_637086805238827501" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_FairValueAssumptionsExpectedVolatilityRates" xlink:label="plx_FairValueAssumptionsExpectedVolatilityRates_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238827501" xlink:to="plx_FairValueAssumptionsExpectedVolatilityRates_637086805238827501" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_FairValueAssumptionsExpectedDividendRates" xlink:label="plx_FairValueAssumptionsExpectedDividendRates_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238827501" xlink:to="plx_FairValueAssumptionsExpectedDividendRates_637086805238827501" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_StatementTable_637086805238827501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238827501" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637086805238827501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637086805238827501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637086805238827501" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637086805238827501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637086805238827501" xlink:to="us-gaap_FairValueInputsLevel3Member_637086805238837495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238827501" xlink:to="us-gaap_DebtInstrumentAxis_637086805238837495" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637086805238837495" xlink:to="us-gaap_DebtInstrumentNameDomain_637086805238837495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_SevenPointFivePercentageConvertibleNoteMember" xlink:label="plx_SevenPointFivePercentageConvertibleNoteMember_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637086805238837495" xlink:to="plx_SevenPointFivePercentageConvertibleNoteMember_637086805238837495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238827501" xlink:to="us-gaap_StatementLineItems_637086805238837495" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238837495" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_637086805238837495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238837495" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637086805238837495" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238837495" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637086805238837495" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesLeaseCostDetails" xlink:type="extended" xlink:title="40401 - Disclosure - OPERATING LEASES - Lease, Cost (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaap_LeasesOperatingAbstract_413817" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413817" xlink:to="us-gaap_OperatingLeaseCost_637086805238837495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413817" xlink:to="us-gaap_OperatingLeasePayments_637086805238837495" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413817" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637086805238837495" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413817" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637086805238837495" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413817" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637086805238837495" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails" xlink:type="extended" xlink:title="40402 - Disclosure - OPERATING LEASES - Lessee, Operating Lease, Liability, Maturity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaap_LeasesOperatingAbstract_413830" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637086805238837495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413830" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637086805238837495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413830" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637086805238847487" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413830" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637086805238847487" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413830" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637086805238847487" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413830" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637086805238847487" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413830" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637086805238847487" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413830" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637086805238847487" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413830" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637086805238847487" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413830" xlink:to="us-gaap_OperatingLeaseLiability_637086805238847487" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="40403 - Disclosure - OPERATING LEASES - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaap_LeasesOperatingAbstract_413854" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_DisclosureOfLeasesOperatingTable" xlink:label="plx_DisclosureOfLeasesOperatingTable_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_413854" xlink:to="plx_DisclosureOfLeasesOperatingTable_637086805238847487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_CommitmentsAndContingenciesAxis" xlink:label="plx_CommitmentsAndContingenciesAxis_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingTable_637086805238847487" xlink:to="plx_CommitmentsAndContingenciesAxis_637086805238847487" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_CommitmentsAndContingenciesDomain" xlink:label="plx_CommitmentsAndContingenciesDomain_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesAxis_637086805238847487" xlink:to="plx_CommitmentsAndContingenciesDomain_637086805238847487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_VehicleLeaseAndMaintenanceAgreementsMember" xlink:label="plx_VehicleLeaseAndMaintenanceAgreementsMember_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain_637086805238847487" xlink:to="plx_VehicleLeaseAndMaintenanceAgreementsMember_637086805238847487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesDomain_637086805238847487" xlink:to="us-gaap_LeaseAgreementsMember_637086805238847487" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637086805238847487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingTable_637086805238847487" xlink:to="srt_RangeAxis_637086805238847487" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637086805238847487" xlink:to="srt_RangeMember_637086805238857482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637086805238857482" xlink:to="srt_MinimumMember_637086805238857482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637086805238857482" xlink:to="srt_MaximumMember_637086805238857482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingTable_637086805238847487" xlink:to="plx_DisclosureOfLeasesOperatingLineItems_637086805238857482" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_637086805238857482" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637086805238857482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_637086805238857482" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637086805238857482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_637086805238857482" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637086805238857482" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_637086805238857482" xlink:to="us-gaap_SecurityDeposit_637086805238857482" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_637086805238857482" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_637086805238857482" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesStatementsOfOperationsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - REVENUES - Statements of operations (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_637086805238857482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238857482" xlink:to="srt_ProductOrServiceAxis_637086805238857482" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637086805238857482" xlink:to="srt_ProductsAndServicesDomain_637086805238857482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637086805238857482" xlink:to="us-gaap_ProductMember_637086805238857482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637086805238857482" xlink:to="us-gaap_LicenseAndServiceMember_637086805238857482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637086805238857482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238857482" xlink:to="srt_StatementGeographicalAxis_637086805238857482" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637086805238867478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637086805238857482" xlink:to="srt_SegmentGeographicalDomain_637086805238867478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_637086805238867478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637086805238867478" xlink:to="plx_PfizerMember_637086805238867478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="country_BR_637086805238867478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637086805238867478" xlink:to="country_BR_637086805238867478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637086805238867478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637086805238857482" xlink:to="us-gaap_StatementLineItems_637086805238867478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637086805238867478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637086805238867478" xlink:to="us-gaap_Revenues_637086805238867478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesContractWithCustomerAssetAndLiabilityDetails" xlink:type="extended" xlink:title="40502 - Disclosure - REVENUES - Contract With Customer Asset And Liability (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637086805238867478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_637086805238867478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_637086805238867478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_637086805238867478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637086805238867478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637086805238867478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_6370868052388674781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_6370868052388674781" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesUnsatisfiedPerformanceObligationsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - REVENUES - Unsatisfied Performance Obligations (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_637086805238867478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_637086805238867478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637086805238867478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637086805238867478" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637086805238867478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637086805238867478" xlink:to="srt_TitleOfIndividualAxis_637086805238867478" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637086805238867478" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637086805238877469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637086805238877469" xlink:to="srt_ChiefFinancialOfficerMember_637086805238877469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637086805238867478" xlink:to="us-gaap_PlanNameAxis_637086805238877469" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637086805238877469" xlink:to="us-gaap_PlanNameDomain_637086805238877469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637086805238877469" xlink:to="plx_EmployeeStockIncentivePlan2006Member_637086805238877469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637086805238867478" xlink:to="us-gaap_AwardTypeAxis_637086805238877469" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637086805238877469" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637086805238877469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637086805238877469" xlink:to="us-gaap_EmployeeStockOptionMember_637086805238877469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637086805238867478" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637086805238877469" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637086805238877469" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637086805238877469" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637086805238877469" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637086805238877469" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637086805238877469" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637086805238877469" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637086805238877469" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637086805238877469" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637086805238877469" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637086805238877469" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637086805238877469" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637086805238877469" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637086805238877469" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637086805238877469" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637086805238877469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637086805238877469" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637086805238877469" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637086805238877469" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637086805238887462" order="9" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637086805238887462" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637086805238887462" xlink:to="us-gaap_SubsequentEventTypeAxis_637086805238887462" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637086805238887462" xlink:to="us-gaap_SubsequentEventTypeDomain_637086805238887462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637086805238887462" xlink:to="us-gaap_SubsequentEventMember_637086805238887462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637086805238887462" xlink:to="us-gaap_TypeOfArrangementAxis_637086805238887462" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637086805238887462" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637086805238887462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637086805238887462" xlink:to="plx_ChiesiMember_637086805238887462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637086805238887462" xlink:to="srt_ProductOrServiceAxis_637086805238887462" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637086805238887462" xlink:to="srt_ProductsAndServicesDomain_637086805238887462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_AlfataligliceraseToFiocruzMember" xlink:label="plx_AlfataligliceraseToFiocruzMember_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637086805238887462" xlink:to="plx_AlfataligliceraseToFiocruzMember_637086805238887462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637086805238887462" xlink:to="us-gaap_SubsequentEventLineItems_637086805238887462" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ProceedsFromReimbursementOfExpenses" xlink:label="plx_ProceedsFromReimbursementOfExpenses_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637086805238887462" xlink:to="plx_ProceedsFromReimbursementOfExpenses_637086805238887462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20190930.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts_637086805238887462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637086805238887462" xlink:to="plx_ProceedsFromSaleOfProducts_637086805238887462" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm1919495d1_10qimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm1919495d1_10qimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" *G!7<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX\^$GA[XF-"=:TVWOC!]S>H.VO'PN$PJJ_[3\)[^.Q>-E#_9_B.8_P"'N?A
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M>E<9\3_CQX6^#T"/X@U6"R>4?+$6!=OH*5_>L!V"SJRY[>W-/S7EGPT_:]\
M_%'6?L.EZW#]I<XCBF(0R?05ZBG(SZTP%)P*0O@=#0S]>Y]*XWXC?&[P_P#"
M_5M-L=9OEM+C4W"0*6 WDG  ]>:3W [$S8['\J#-MZ@UQGC'XZ^&_ GB'3-*
MU+4%MK[5,&WAR,R!C@5V$3[ESS\W3TI] )<TGF#ZUY_\3_VEO"'P=U@6/B#5
M5LKDQB0*W<'_ /763H'[:?PX\1WL=O!XCLXY96VJ)&"@_K2NAV9ZN&S2U!97
ML5[ LL4B21R ,K*<A@:F#@CK38D .:6F>8%!R1P>:7S!MSD8]: '4P2@MCG/
MTIQ8;:XJ/XZ^')OB,?"OV\)K<8W&V!!)&W=_+F@/,[4'(I:9%(''':E:0+U/
MM0 ZBD5PPX-!<*.O09H 6FF3!Z'\JHR^*=.@UB/3WO+=;Z5#(D!<;V48R0/3
MD5SGB+XZ^'/"WQ"M/#=Y?+'JUZ!Y4!(RV1GB@-CL@<TM0P,RN0Y')RM2[@#0
M M%-696 PP.>GO2JX8<'- "T444 %%%% !1110 4444 %%%% !1110 4444
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M6";+F;P^A4HH!8^6">E:/4SCH>7ZE^VUX\^)WBC4+?X;>%XM1L--E:.:YF?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK?\ Y[P_]]BB[T%YA86B6%M'#$-L<2A%'H!4]5UU"W!_X^(/^^Q2_P!I6_\
MSWA_[[%# GHJ#^TK?_GO#_WV*/[2M_\ GO#_ -]B@">BH/[2M_\ GO#_ -]B
MC^TK?_GO#_WV* )Z*@_M*W_Y[P_]]BC^TK?_ )[P_P#?8H GHJ#^TK?_ )[P
M_P#?8H_M*W_Y[P_]]B@">BH/[2M_^>\/_?8H_M*W_P">\/\ WV* )Z*@_M*W
M_P">\/\ WV*/[2M_^>\/_?8H GHJ#^TK?_GO#_WV*/[2M_\ GO#_ -]B@">B
MH/[2M_\ GO#_ -]BC^TK?_GO#_WV* )Z*@_M*W_Y[P_]]BC^TK?_ )[P_P#?
M8H GHJ#^TK?_ )[P_P#?8H_M*W_Y[P_]]B@">BH/[2M_^>\/_?8H_M*W_P">
M\/\ WV* )Z*@_M*W_P">\/\ WV*/[2M_^>\/_?8H GHJ#^TK?_GO#_WV*/[2
MM_\ GO#_ -]B@">BH/[2M_\ GO#_ -]BC^TK?_GO#_WV* )Z*@_M*W_Y[P_]
M]BC^TK?_ )[P_P#?8H GHJ#^TK?_ )[P_P#?8H_M*W_Y[P_]]B@">BH/[2M_
M^>\/_?8H_M*W_P">\/\ WV* )Z*@_M*W_P">\/\ WV*/[2M_^>\/_?8H GHJ
M#^TK?_GO#_WV*<E]#*V%EC8^BL": ):*** "BBB@!&Y6F'I4AY%-?A*'L'4Y
M7Q_XRTWPCX9O+G5+^TT^WVL!+<3!$SCIS7ENC:]9>);7[5I]Q#=VKG"2Q.'5
MOH17-_\ !5'*_L\$<[7ND! .."0*Y+]A]]_[/>CY+$Y;KVZ5]-A,O7]G/&)]
M;'R6/SARS:.!MIRM_D>MGAJJZ_HUOXET6ZT^\3S;6]A:"9,D;T8$,,CGH35K
M[QS2.XB7+,%^IKE]3NO;4\\^!'[*_@G]FVUU&'PAI"Z6FJ2^=<8E=][>OS$U
MZ)N.UN?F;'S@8(J/[5%_SUC_ .^J7[5%_P ]8_\ OJG+E4?9IZ%.3E+G>YYO
M=?LC> KKXWI\1#HB#Q7&FQ;SSI"1^[\O."V.GM7&_%[_ ()J_"GXV>/SXEUG
M0S_:LC*T\D$K1"XQ_> .#7O/VJ+_ )[1_P#?5'VJ+_GK'_WU7/.G'E4>P_:R
MYN;N>0^ OV#/A=\,?B#9^)]#\,PZ=JUE;_9TEAGE7*]\C=R3@5M?#G]D[P/\
M*?B5JWB[0](6S\0:T7-W=B5V:7<^\\$D=?:O1/M47_/6/_OJE^U0_P#/6/\
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M:<_RKN(=?^ &E[2"':9D?\(-IO\ S[+_ -]&@^!],'_+LO\ WT:V2?.7*_\
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MP@NG?\^R_P#?5+_P@^F?\^R?]]UKK\P^7)_X#3MWT_[XI/EZ!KT,8>!M-/\
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M._Y]E_[ZK8HH]F%S'_X073O^?9?^^J/^$%T[_GV7_OJMBBCV87,=O VG ?\
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M(I5(,5R!C# G'\NU>R^.O!(O[60,H0[,GOG->IA[3I<R>K.6I#ED?GIXRO\
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MR<"O4/V!?V6;W2?A)JL=U J7$\[-M8#C+9KW3]D/2/#[?L\:-/!Y,\JV(R2
M>PKMOV?KNVFAU&.W9/\ 7LQ0#IR>* /%=>^!DNC2>6\32''.T<"N*\6^ CI\
M)CD3,1.3&:^X#IMMJ#-YENA;UQ7&>-O@/IOB^VG#9CED4A=M 'XC_P#!8O3(
M[>Z\(06R?9H)+A%?"\<D5[!X$\!_\(U\-M!^S_O8#9*6/X5L?\%EOV4=7GN?
M",%I:2S6UG<J7DQ[BO2_"OP[?2?AEHT,R;=MB@Y'M0!\Y_$+22)W_=./^ G%
M<KI-FXD6(*[#G=M&<'M7U=J/PS@U9 )45E(]*Y^S^#]CX>U9VCA+&7G'T_\
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M)QZ2"OI>(;8P/3B@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#%]KA^U6[R0[$"ALDJQ[GVJY_P $Z_CM_P +(\2V>G[D2[%H;Q B_+R2./\
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M>1=(97C'4!P3^@KZ\A!6)0>N.: '4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 (>E5;BK3_=JM(A)'%*WOQ9,MFO(^9_^"J,H7]G
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M[G6)+2W B(&QL[5/;L:]Q_9*\;V=AX.T+1'WF\O=0FECD_O ))Q^N?PK@/\
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M?++>PMTR2)CWKR'Q%XC_ .$9^$^G7*3'?J%L),=-IW$5SG[6WQ-QJFN:</\
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M_P"./#_BBYU2\TN<P31EDCFC)(&1ZT ??OCOP_%XB_8]T+6'D-HMM'\PSCU
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M"']I5_C3\,+"XU6X47=A=!,GC<,U]'>(?C=;Z9\*\"8+E H=&P2<<<B@"_\
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MC6K>$13XQL# 5\;?MX?L*3?L$>%/!<,%\;Q9;Y)%;>2QYR,YK]&+778_C/\
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ML&9"6SS^)H ]O_X*/>"=7^-WQ:\">,/ TO\ 9^B*L,D\8/,N,%MWK7/>-?\
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MY3T>X0#M[BOW\L&W647&"$&?FSSBON.&8M4&?(9_4YJT?0FHHHKZ4\ ****
M"BBB@ HHHH **** "BBB@ KYX_:-_:3\4_"'X]:)IVC7RP6D\<>^-DR#N;![
M^U?0]?'/[;J[OVE- //RQP9'U>OH^&,-2J8GV%97C9Z/Y'RO&>*JT,NC4H-I
M\RV^9^EF@2>?IEO(Q+.\2EB>^114?AGY=,@7^["G\J*^ ]3]'IRYHW-*BBB@
ML**** "BBB@ HHHH **** "BBB@ HHHH *1P"ISTQS2TC' H ^6/VC;3P9X$
M^*;ZWKZQVYVC$L\X5?R)IUQ^V=\,M3\-?V3;^(M'5MN%\N5#Y?TQ7R5_P4Q_
M9L\2_M.?M0?9-1\6-H_A2U"F6**38Q7/-?/O[<7[&'PS^!GP&M[KP)XKU2^\
M6W\JPV\8N0Q)(] /6@#[)\9?$GPEJ>JB&Z^*'V>UED^:/[2%7'IS7:_ /3/A
MOX$\0S7?AGQ5I>K75YR_^E1N5.._/%?DIX#_ .")WQ\_:%\("ZU;Q5/HJF'S
M8FD?:>1D=:?\.O\ @EU\:OV6[>]U%?&%]?2V3'Y1+GS* /WEM+3^UQYL=]#<
MO(,D"0%0*\*_X*$? 37OB5\*;)-&DWSV\ZR,(SNP ?:OQ4\:?MT_M3?##7)+
M?3[359K:([00K?-BO>OV-/\ @MO\6_!$%W-XV\/7=]:P*?/$D;'R_K0!]9>+
M]4UOX>VMA+?Z/?74PLELSLC8_-C&<#ZUZKHAO?#_ .S8+V[@N(DN P:&13N/
M?H>>]?)GA[_@XX\#>)_%9LM5T.VYE"AI(^%KW[Q#_P %8_@_XIT/3A=:G:[)
M02UN& 5.E ')P?&#1_A3X?6X59(/.W&53$<OD'CI7SG\*_'L5A^TH?%,=K;F
MVDN]YA:(,'&>XQ7UU_PV)^S]\8]1M=(>/3W?[JJL@^:NSB^!?P&MXO.-Y8V?
MFKO!,ZC;F@#U/XE_M<)X1^#.D7NFV$,@U%1&(!&%3.!T[=Z^<7_90N/CE:Z[
MXHUS>GV:%YH8B_"9]JUOB?\ %OP%J-K:^&+'4K/[%IC;HIC.",_Y%>B^!OCI
MX*\)_#/4DO-?MKE[B HL:2#+4 ?GQH?[(NFQ0WWB-64QK*R$$[2C!LY_2M_]
MNC0[?Q7_ ,$XKKS-SG36=DR>?E ->^:)\*-7^+/@/45\/V!^P27!F7C[X+?_
M %Z\P_;F^&UYX0_9 U#P5,N/$.K;C:0?Q$$8X'UH X[P?X]M/AA_P1ENC%IL
M4]Q?P[$G:+/\/K70_P#!#[5]+\9? _\ L[6]7:.QDRLT ;[K<\?2O%OB/XQO
MO#O_  2W;PM=6LHU#31M>V1/G (ZX_"NM_X-_P#PN/&^E:II]Q#=VXL;8S8=
M<9Q0!]!^,?A7/^RI\5-0\4>#62ZL+YRC+]XY/_UC756GAK6/B#HPUJ[U*2WR
M0SVZ/TSW(KSS]ISXR)X0\%>*;@S>5#I,Y50QSN( YJ+X6Z/XO^.GP+L]?\(Z
MIMEN -Z$?*0* /A__@N?K$FN:_X/TZ"\FF:*Y1%$A. <@"OI_P#9JT/Q1#\'
M?#]MKTUE+;06:^1AE9^G''6OCS_@L-\.?&?P[\6>$)O%S1JD\HV2*N.>U=A\
M$-7\=W6N>&)=.DO]7L;>W021)G:!CF@#[J^'/Q9TOX5WEY#J((GU%"B2*F,]
ML5RGC7X^6_P6TB*Y\.:7%+>WUV/.:6') YYP1[U!XQ\;:=IVC:<VIVT4%[<D
M,J/UA/3'Z?K7>_"7X/'XV:899M,-Y' =T<B+0!X)^TI\?H?$_B"!'FM4OKB)
M-Z#:-I.,@"OIW]F/Q/\ #*\\!6_AF]N$&K-:^=+"KC:6.>M?/'Q"_P""2?C/
MXD?'NW\2JMU:Z/#<#,0!Y X%>N:_^R-H/[-GB!M9NM1F^UO JLA/<"@#5U?P
M#X0^&6AZG'X6OH[&YU%_X,>]<9^S_+XB^"OQ.^VOJSZJ;MR7Q)NV+VP*X_XV
M?!;QIKG@&Y\4>'XKJ6&'/RQY-<U^Q[-XMLH6U3Q';3Q['< S9^7!(H ^E?VD
M?CCK/CC2KJ/3C=&-5Q<2LA)5<<BO2O\ @EOKOAOX5_"O6]0MYYKE9)2]QLRS
M!N^*X#X:^,(=8^$/C4W5M#.KPOLD5>5XJ_\ \$3_ !-I&N^%?&%E(!=F.X?$
M+CK[4 ?3O[1OQ>T_Q9\"/[6M6,,,5PN7D^7'7KFL7XX>*X_$/PC\%_8KL7/[
MN!W <%CP,XKSC]L;XJM??#ZY\(?\(Y+IVGRW,8-PH(&,UB:M;I\,;/1HUEFN
M;.WTY98][=]N<"@#HOB+>B73EA68+*[=&."O KYY_:)U._\ "O@,6TCPR%GW
M#YAGH:EUG]HZ3Q;XTD9](N8H(2$,I)"DBN4^)?Q"\)^/-52UN-2,=YVC)&.E
M 'RM\+M.C\6ZGXRL[;64T/4)I-QF>0(",C/)KZ;_ &$OVX;WX&:Q#X+N+YM6
M+MY8N9&W(<\<-TKXM^('P\M/%'C3Q3HPUMM)N3-NB>,X+KD5ZC^SO^RCXRD\
M!;-%@N=4OHY-T5V5);'K0!])?M26L_CKXPVXGCC5M20R!^ 0*^9?VE?&EWX1
MN;31+F?S84NPFYNJ *1UKZ9TGX*^+)=$MH==:1O$45OMCW#YD KPOX\_LB:U
M\0_A]!K%Q<LES]O,3O[A6_PH \4_9^N]%^'?B7Q#JWVUO[1FGQ;;9,MN; &!
M]:]1^+QGUWP5;7VK337,\ARZKG<1]!7SY^SS\"=4MOV@-1L)YY+M+24#D9"G
M/!/TK[&\=>&[.*#3].CU&RGUZ-AY-KQB7IQB@#"^#'Q4\,^(?@GXAT73C=Z=
M]C_UT,Q9=_/H:S_@=X#M_B#\3_#MH8$@+W"^00.2-W7/>N>\2^)+OX%:EXFU
M7QUX2ETR&ZB,B"*,JCG.:Y_]BS]LRQ_:L_:3TC3=%L7T2#0R DO3=CF@#ZZ_
M:@EUSX6_M$Z9H\<336T5NC,ZK\JCW->2_L(>-W\/_P#!1/6;Q(#)/+;2<CG'
MS"O5/VC/B[K,/QK>W:V@U2$6:QM+U8=:\I_9"TVZ\)?M$:EXY2Q+Q;6A</T3
MG/\ 2@#ZR\6WMGXD^)[76L>7;P+< N'/S=?2N"_X*T^-_!=E^PGXDMM(G\RY
M6%N,Y.=OI6+\9I[OXBZJVKV&H6D)F/F-$).F*^1OVX?C1IMM^S3XHT2]OENM
M4.=I5LXXZ4 ?,7P26#4/V?+LVSA+G>"V3C\Z^YO@YX(F?X(^'[J[F\H_95\L
M@X).!7YM? [XGPZ1\*;R$P/-<74@CPO10#P?UK]-?@OX?EU[X >'7^UK(4LE
M*1A^0=O2@#SK]KO25AT/07BDW7#W,8W@Y_B%>N7GANXLS$GGK,!;Q,O&>HKP
M#]L-K_0-,T(2M)'B=<+C_:KW#1?&'D:/:R$[Y&BC7YOI0 GBO2&T;PJ]Q&NZ
M2''*^M9TGVKQ3X.C:3>SB(MCTZUM>(]?SX2N5D7 8+N'H:S]'O)+*V7:/W<D
M.<>HQ0!Z5^RH7B^'\:3HOS7!'S5]J^$=*@U7X?K;[=NT#&T5\4_!#Q%;7?AR
MWCB^0I<;2/<U]]?!325E\(V\9&Z1E!% &!X,\ +!XJTZ7YAMO+<Y(_Z:+7V?
M#Q$O?BO"-#\/LFIVO[M?DN8S_P"1!7O*<** %HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH 1NE1A@:D?[M50<))]::74F6S?8J>(7
M7^QKOL A.<X'2O(Y4*2$%64^A.:W_P!J#XV6'P%^%MSJM_:RW44O[K:AQ][C
M^M><_"?XDVWQ9\&0:[:026\-XQ(1SDCI7K8*A6]A*J_AN>)C<7AWB_8+XTK_
M ".EHHHK4@**** "BBB@ HHHH **** "BBB@ KX:_P"#@9L?L06'_8RVW_HB
MXK[EKX5_X.#?^3(+#_L9;;_T1<5YF;66%J7^T>CDT;XOE9^+&N3>7X=D(/16
M_E73?%C4/M>JZ/WQI\6,=^*Y'6O^1<F^E;GQ-8I<:05X;^SX<?*6[MV'-?E2
MAS4'R'Z:ZL75C?8XGQ-*@UNS;_;Q7U7^R)LD\2")P(]T!R>N:^7];\$ZM<ZJ
MDCVYLX1,B*UU^XB&>_/^-?7/[,/P0U_PY\3M'M[R[T6^TW4U(,EAJ"22 8/;
M'M7TW#6 JSH.1XO$F,IJ<8H[[Q.MOI/BR]2$I()[/EAV*Y-=Y^Q-XO@U&]UK
MPW<G>NL0%EC9L 8R#_,5SO[67@'1?V=H+;5KK5#;1:G:2HAN,%P?F'3CCWKS
M_P#9G\9I;_%[1+^"6)X;<LS%&QYZG;FOG\7;#9I3C+5-K0[<-4A6P3[I'O7[
M)WCW7?@E\1X/!<>Q8;[6);>^5USO5=[+C_OD5P_[9-EXA&H^/+Z2RMY-&N;\
M1?:G(W1<J-JGZU[7KOP_@O/VC/ NOV$C1V.MWGVF1P,A3Y;CK[DU\V?ME_';
M4-*O/B3H3ZD7\.Z?JJM+"80968R+T->U#*H87+JD(1NF[GA5\1SXRF^P_P#9
M9\1&]\.S:"DCHK:9',L6?E8[I0?Z5\?_  C^*.F_#OQ=\0_ 4\$D9U&X9)90
MI(B*/U'YU]'_ ++^I?\ %S?"\EOYOE:CI@!1AR<NW6OF[Q%X&T6W_P""CWB_
M3O$$\NEZ?+/=$L./^6@-=.47G@''8>9M0Q?M>YZ#IUS81^$M?TS>;U-.N-/N
M8R5P5A)AWX'IRPJ]^T,+37?"]A;Z8\*_9]/DN3'*P7,!R.,^ZM7,^ ;O3[SX
MU:_IUE++/IDD*VB/CYI,8$7_ (]MKIOVC/!-W\)M-7^T?LXN[OPRD;+<<;5,
MUQC;T]:Z</%2A?L8XF'LYJ2ZG*P3#Q3\(/#\>WY])EDM)&]E*;23[\X^E>H?
M$BRDU?5O#</V1&W622[B/F/E%<_R->:_L^:2NL?#WQ#._P#J;&\LIFC)Z(PE
MS^H6O=_'NAR1>+_"E_ Z*J)+ RD\%7#$?I6D$JE+GDMF95+QJI)F)H>NW^E?
M#WQDD1>V>VM/,A^4],LWZ9K]4_\ @E=XE?Q)^QUH$ER UPX/FL#R2 .#7Y?>
M$]&G\?\ BCQ.D;JENVBS;D[,</&,?BM?H;_P2,\5Q7/[)FD<_P#+>:.0#^%A
MM K+"8>*KNKWZ'5B*_-"S/JG7?#\>IEF;&YA@#/ KB?%>N^$?AUJ]I8Z[K&D
MZ7?W[+%;QW$RHTA/3 )ZFN[COO\ 1692GXU^;'_!63]AGQ[\<_VB_"GC?PGJ
M7FV&E-%-/!YYQ$Z/R<9]!7K1@^:R/'/OKQ%X2M/LWRB(C'!()#>XKYU_:+^%
M&FV^CWU_]DB%U*AC5@IR,\_TKW[P)X@CU/P#IX6ZM[R>WM(XY@ASB0*,UY[^
MT3>6]C\.M3FGP9?*!3V.X#^M1BXI1L:0=I(_,O5KVXT#QAJ*\D+;2H >[;#B
MO/M-OYT\3QAUE;_1)4BV*2&)'.,=:])^(.O&SU:\<QP^:5GEYZX7</Z5P-EK
MRV_B>Q60(GV/39KSCVR:^0J45SGNN4G!6.+\1Z'=:3XJFU)E$B7-F1"2W]XC
M'\JI_#CP9>1WU_I<CC-Y&S[HSO9?W@)'%;/Q$N_+\4>%;'S0T=U )9!GHJJ=
MOZFJWPIN,ZYK]UYCK)IUGYCO_=9F4D?F:[Z=H4]#G49-V9]4_P#!-K5UGUWQ
M6\;R,L1BMAO4CE ,U]$>-/#T%U\/?$]U)R_FKC\C7RI_P2L\2_VKIOB9LJ?]
M+9L^N37U/XWU7ROA]XAC]9%_D:]G*W=GDXR%F?-TSK"EG(655@=6D+'C '->
M.?M,_$R*]M-1BTN2XB2ZNT$FP\-M"L,?4BO4O&UN]UX6\N,[7:-B?^^#7S1\
M3S]CT^!I6RJ7"Y([813S7A9M7E3:MU/8RN*G>+Z'U'^Q[\3-./A"7P%>:GC5
M?$<$]Q"'<," J J<=^E5?$'QPU+3_A7J_@+[-#Y/EFY:11AOOJ/_ &:O)O@S
MI9\$_M!?##56EM;FVUN.5 0^#!N* Y^N/TKUGQG\';R^_:,U7P]&KJTZ$AQ]
MT1;U8\_05Y6?Y?+$X:A^?S.K!U53Q$GNST+]E*]T/X/_  VL;K7+2>6\UP3P
MV8#X<##D-C.<9'6O@7X^_'_1/BI^V1'J%SH"21070MKQ&DXN K8 //!Q]*^V
MM<T__A9'QNTW1="D1[;PYII1U5L^5L)WM_P+!_.OSE\5?"[Q)#^T]>SW.BW\
M5O=:IM@FEC*PRC?][..U>O*/)@'2@NAC:'UKVDF?I!\&CH5^VKMI&C0Z)8Q:
M)<%+6/HC>9#D_4UY-XHE)M=4"Y$K)'AMQ7;]WO7KO[.OAJ2W\)^-)Y?+Q8:7
MY.8SD-N9>?\ QVN#\ ?#FZ^*7BY]-MD?R?-1[F8C@1J1FOG<?E\ZT*5*JN9/
M>_H>ID]>&'JSJ1U9V'P-T-? 7PMN=>U0QK<:S,+>S5P2[_*JDKFOG+QMJF_Q
MYXHD)SOAN .>G*5[[^T5\1+6^\1>&M#TQ=ECH5_]G4KT<[4R:^9_&,IDU[Q*
MQ.T?9Y_F_%*QKT:5+ TJ5%6L]CKP-O:2DWN=%^PQK]_I_BK4[6UU">VMVT\^
M;$F=K_.G6L7]KK59U\4VD,$\R R9=1)A6.>I]ZV_^">VBR>,/B1J%K:&V>?^
MS@H::<*H&].PK,_;8T.;2?BBMG*YEDMF&\I@HI] 17=AZ-:&"E==S#$5:/\
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M5XT\!Z]BWU*_N5C;)9I6;>!^-9WBSQU>_$2YQJ86)Y'Y+#H?J: /?/$/QO\
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M[LBO^5>E1',8]QF@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!I:V,L;CEE?<'H ^8_BY^Q?K_QG^!]_I;VTFGWWV<[)$3YDD]0:_-S3/\
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MG<9<LPKH#^WAX+\1%8+I=.D5TV-EUK\'OBCX ^).A:A=73:RD=SDY02*!BO
MT^._Q#L?'QTVZUJ\ [F)^#^- '[6?M<>%/!5SK%WXPTY= >U@!D>(NNZOEGX
M??\ !3#2?#_B5K%M$M+G3E8A(PH*@#K7YU?$#]I/6+?Q(-(UOQ5J4%C/PZ^:
M<'ZUZ[\-OA[>>(_AL][X)LV\27F R[078?E0!]JZIX6^&G[<FHS:K_PAUG:S
M63!BJ1J&D(/:OIWX"_\ !)_X ?%+PK9:GKN@6]MJD(VD/MS@5^27A?\ :\\;
M?LUV?V2?3FT[497Q)&8\%3GWKK_@9_P5B^(GCGX_V?AZ^EGM;"? W(=H/Y4
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MM36U]K5_:06>K1VME&RK<2HV&[=2*Y.]_P"%4:P-7\3>(8+>\UZVD;Y)P?\
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M@4 ?8=M?23ZRN3_RUC_I7J*?<'TKR+1;N+5[RVN[>1)+69XRDBG(;I7KD?\
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MX4WON90.<?6OBSX'>)_%>I?M,ZG9^+/-N]%L6=KORSD2-GT]J^M_^"6'PE\
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MPC\!O#FAZ_(;F[@\D+.Q^]TK[)CXC7Z4 .HHHH **** "BBB@ HHHH ****
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M?AMK "V'S= ,Y_"O3/AIX5B\9:I\.+&ZD\FQ\L&[DQD11><Y9ORKS+783+9
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MC5&YSAAUKY1+!O#UR!G=N3(/KQ7Q?&[E*O&9]!PNXJDTC*\7G'A^R'I>.?\
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M_P 4OA[)%J^D"VU"(>9)B+!*?3Z5];Z&VM7O_!,N?6[&ZS+ #'):-UR  >*
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MYU^I^=8J=;_6-1;]WD?Z'K[_ 'J2@?=_&BO$/I0HHHH **** "BBB@ HHHH
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M6E8^;E#6$CO?V;_BE-XB\ ^+;J?3-'/D:>N_R[()NY7C.*\XU;Q5I&IQ1/\
MV) ID(&$D*C/T!KN_P!FS33IOP!^(5SCC[.BC_OI:\HL[,R6T);@O*I^@XKP
M,SJ+EA"W0]C"0NY3['2ZGJ>G?\)U$&TM5 ;C]\Y[#L3BNF\>^*<>)='M(;&W
M#"W53D_Q8RW\JXW7;$7'BJ/:?O;5SZ5M:Q']L^)%NZ?<B# Y^E<6'K;I'0XJ
M4D=[^QS=7&O_ +7OP[R4CB7Q#!E5X_Y:BOZ0[)LVD8Q]U0*_G-_8/L=_[6W@
MB0C"C6H\<?\ 385_1G:?\>Z?[H_D*^WX;;="5^Y\9G$%&L24445]$>0%%%%
M!1110 4444 %%%% !1110 5FVWQY\,?"WQY;V>L:G':WEPFV*)ESG<>.WM6D
M:^._VV_^3E?#O_7.'_T.O7R/*88[&3PU5^[R\Q\_Q!FM7+<''$T_BNE]Y^EF
ME7PO!E6W(5#*=N.**B\,KC1[7_KBG\A17Q:O=I]V??K9&C1113&%%%% !111
M0 4444 %%%% !1110 4444 %(WW:6D/2@#X5^/7[(5I\3?VV]'\7I?2PS:=(
MI,9/!P<XJ?\ X+D:V_@W]BO4+F(D>7MQCMP:]1^)&K_9/C;8Q9"M-, ".O6O
M*O\ @NO MW^Q+J*R<12!22_T- '\ZGC_ .,USXVTY5N+EY(R57:3TKW3_@E+
M^S9!^U!^VAX;L]0L_M6B6DR/."/E^7!YKY_\5^!;*TT(S0D9X(%?J1_P:]^&
MK.YF\:ZO<11M=:8I:)V'W?EH _:/3-+LO!&@V>F6:1PVEK!Y:!1C8H QBOF+
M_@HC:WWQ,_9]UC3_  \%EO\ Y&9B,L,,,XKU:Q^)9\8>#+F<MLV,T(?L#7EO
MQ@O;K2-"LQI>6:\E"73=5V^M 'XX_P#!6Z2[TU/AS97SEKW3]+5) ><-N;-?
M+]C<_8_ -VZY?+8^G%?<_P#P67^']FOQ0T9+F>(S-9;D7=R>IZ5\+^2=/\*7
MMNL4A#ONR5X% '*>$_ 4OBO51-;N?M(&(U'<UZ!\$-?\5_"WXJV]AJ=JRPWT
M@Q\WW1ZUA_!G5-3T_P 36TMGI[SF*3.-G'ZUZG\2GOYOB7HNK7R""6Y*1"'T
M[4 ?7VBL+NPAD+ EU&[;7T#^QU^T_#\&/$DEA(=D<^,DGL:^>?!%BL.B6A)/
MSJ/Y"O,/C#\09/#7QVTS3?M1@AO(< [L<\4 ?I!_P5+_ &KQ>_LY#0;63=_;
M<(:-QSD$9/Z5^%_Q.BLM,:[+OG8V=I/)-?IS^T5H-QJ7[.?A_4993=1Z=:$F
M0G/)4J/YU^7_ (7\$O\ &CXV/HA9ML]PR$@\<F@#T/\ X)T_M$_\(]^U-X6F
MNH%BLK')=D3:3R.IK[F_:N^+?@GXE>)]6U.S@A_M.[=F+X []J_/3Q'\)$^&
M?QE71-'O]M^J'OC9BN,\6_&?Q2^N-:V[3W/]FW#13E>2P!(H ^G->^$WC#X>
MZ9_PD3Q0IX-UN;R9;AG^X6X.3]#7EWP&\&:3K_[5U]HB74$^FP ,EQNSLW9S
MS^%?3GQM\0R>-?\ @CMI\4Q>WFGU 1DL2K)DJ,U^6/B?4O$W[+OQ:_T&\N,W
MEN-A+$^9]/SH ^XM)\!Z%X0^*GBJ6UU&*5+<DM<1G/.[I7F/[5D4.K^'H;R[
MC#"9E2*1>1MSCD5R_P"QKI?B&3PCX@U*Z674+[6,MY<A+!<G/0UW?A;Q?;^(
M=93PKJNCRRW,Y,7ES)Q&?44 <?\ #W]F74?$6EK=Z-LDM4CWDGD?2O=?V$_C
MIJ7[#'Q"EU[$MMYD;PRH3PQ/3BM_]G;X$^+_  ]X@FTS2+1Y-&.6VYR5KU.[
M_P""7/Q _:'T^YNO[/,"6N9<_=#CTH ^0/%/[2'BCXL_M ^/_$-D9X]*U(2R
M3L_S DCM7T=_P3(_;8U#X&_LU^,])T>TMKTWAD>57P69L4>(OV0K+]G[]B3Q
M[JFILEIX@LI&B\HL"Y!DV_R-?#_[&OQEL/AA8Z[_ &E<3%KV1A'%S\V: .T_
M:/\ C-X@\2RWEW?QB*)Y"R*.<'FJOPKEA\'_  -N_&$\0U&\O)C!'%(,^6=V
M,XKHO&G@>#XD?#>+4;J7[#;S,2KL<5P5_JVG:-\*9O#\.II)Y<IDW;N<YR*
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M (K\J.3[?/I4YC5N[",X%?D/\,_V1;[XI^./$4VO7;Z>Z74C ,2 >: /2?\
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MT\C(Y()_&N,_8A@@?_@H'\1-0D#8TV!W)*GG@\ _A58*4DE&VQKBFG%W>I]
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MFKX,W>IE3I;>)-,6&(#AI/ML?/YU^X^GMNL83ZH#^E $U%%% !1110 4444
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M]AJI)"ZW(DF>.,T?L*^%AH/[+_CW4-+A @U,_95<KD$C(//M7H7[=?@>QF^
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M;7)R?)7)]>**^4FK2:/ME+F7-W-&BBBI&%%%% !1110 4444 %%%% !1110
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MO4/'/C ZO\,M;9X80DZ%E51P@[8K"\&?$S3/^&/+?2BT<=S)<CS&4_,HY]:
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M_I[K!<6DF_&>&(YKSO\ 9^LYK+P/9V[P[3'#G'<5+XITR;5;:>SCG,?F,>*
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M[6TU"2TC9=A"'[Y- 'ZF?!+PB_A/]BV\T[6=3DU&>:!WDE:7>%XZ9K\IOC/
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MX]0L91<6DH)! KO_ -DCPQ:#XN2WRQ+%,UJ2[ <MR#7?).+2Y3GG:=FCSO\
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MK+Q/IES:QHT)\L*I'!)[T ?,7CGX9>)O&7Q5/F%6TYI3L<-D"NVT;X!7'@.
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MF'P%H.8K3PE83.A)1A"IR3S0!UG[-OQ%^(FF? S_ (0:U\,W,=Q<QF.-G4@
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MB^&BL<<&_P#=X&1UKT+P;J20>#+:UM(PL5N@7 '05LRV*7DUORKO(N,9Z<4
M>7:!\*[BVW+%"FUN Q'W15G5?A2;"*(W$854SG'\=>AV.D7-E%-E\?O, 9J#
M4+::^P\TF4B[&@#SRP\#VEI ^V%MQ^X/05I:)X.L;%=YM<LY^<[>E=/<6GG3
MJZ!0%&=O3BND\'_#75O&UU'':0MY$HRS;<8H XVV\&:;)(IL(&:=V ^5<8KV
MSX-_LY3:J\;ZBC+"<,%*UZ!\+/V<;#P7:+)=JLMQG(!YYKU6VLA;VJ;<1;<
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M3G<!]VN8T[PE':2M%- Z2 \Y% '*Z1HIF2%_+'6M.7X=O=R2.OR&3  %:EW
M-&N1#DD'H0.E7(;N9(."=XYSCM0!FC1_[%FA9,[(T <>]32GS9/-V_NVX-:U
MG9?VA;EY6RQXJ]>Z5#:1Q[B,;>: .+NO#\DTAD1?W'\1IV@:''=7DD8Z8X%=
M3/;1WP%O!PS]ZF@T3^Q8L.FYT&"1W- & VD0:=;N&&21M%9O]F21IF92L0!
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MRTRZ-]*]^^ ?A+P[K6H_9+_2DRS9R5''Z5?^.GP5\'W^HPVLL*?9P_S(.XH
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MMJO[+A\%> [B\M+==3U*),I"?XJ\4_91^*6KWWQ@\2:?X@LVTS[& (8R,?Q
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M^*))UE?5-,\Q!A2 ?\: /G+4_!T#PI)N$2CAESS52QT@ R&$9C7@DU]*7/\
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M W<5^B-I_P $5_@;8$F+1;X9ZYO9>?\ QZNB\-_\$I_A'X5O8;BTTN^CDA&
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M;@]/I7,#X9VW_/WJ'_@2_P#C1_PK2V_Y^]0_\"7_ ,:ATF'M(G4O&%'%&/\
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M-9VH_LL>&M3;,C:B3W_TE_\ &AX235FQ?6UV/S]M/ "?#?\ M2SBW*D[23J
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M<-3YI[.:/L'3UV@T4S1IOM5E%-P&EC#$ \<T5\]:UX]CZJ]]2Y1113 ****
M"BBB@ HHHH **** "BBB@ HHHH *#110 W!'0?K28/\ =_6GT4 ,Q_L_K1CV
MI]% #,?[/ZT8_P!G]:?10 T+[?K1M]OUIU% #=OM^M&WV_6G44 ,Q_L_K2%<
MG[OZU)10 P1;?N\&C#^H_*GT4 ,P_J/RHP_J/RI]% #"C'N/RH",.X_*GT4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOA_\6->U>UU-7T?79?M$EJ4P4D[G^=>E",@]>]5O^$@L/^?VT_[_ "_XT?\
M"06'_/[:?]_E_P :<GS;DI6V+E%4_P#A(+#_ )_;3_O\O^-'_"06'_/[:?\
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M_P"?VT_[_+_C0!<HJG_PD%A_S^VG_?Y?\:/^$@L/^?VT_P"_R_XT 7**I_\
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M_A(+#_G]M/\ O\O^- %RBJ?_  D%A_S^VG_?Y?\ &C_A(+#_ )_;3_O\O^-
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M& 1SUQ6=X-_8-GT#X%^-?"-WXDEO+CQ9>R7OVQHO]4[;<';GV]:^B?[4MO\
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M]1_WV:W_ /EKWSCIGBLG6_&5AH6M:=875T([K5)#':(!_K&",QS[8!H K?\
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MX5GHG_/J/^^S728HQ0!S?_"L]$_Y]1_WV:/^%9Z)_P ^H_[[-=)BC% '-_\
M"L]$_P"?4?\ ?9H_X5GHG_/J/^^S728HQ0!S?_"L]$_Y]1_WV:/^%9Z)_P ^
MH_[[-=)BC% '-_\ "L]$_P"?4?\ ?9H_X5GHG_/J/^^S728HQ0!S?_"L]$_Y
M]1_WV:/^%9Z)_P ^H_[[-=)BC% '-_\ "L]$_P"?4?\ ?9H_X5GHG_/J/^^S
M728HQ0!S?_"L]$_Y]1_WV:/^%9Z)_P ^H_[[-=)BC% '-_\ "L]$_P"?4?\
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MC% '.Q?#71E?Y;49_P!XFM/1/#EMX>MVCMH]JNV2,U?Q1CG- "T444 %%%%
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M!J3_ (0ZQ_YX'\ZQ_ 'QDT+XGZ_K.F:3/+-=Z#<-:7*^7@!MJD'K[UU"+E&
MW;HAM8MW]ZB%.$ES"G4G!\I0_P"$-L?^>#4?\(=8?\\&J]&Q7!9B0>N$SUX]
M:P_B1\1]*^$7@;4-?UJX:/3]-1GD95W%@!D]Q4Q4&BFYIV+W_"'6'_/!J/\
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M,$?*#]<T*KH=F-S( &/;/-5RP#FF9W_"'6'_ #P:C_A#K#_G@U:'E[U/)4(
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 C?=II& *<_W:;]XU,MM
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MJ/M$?]]/^^JY3_A3^E^MW_W\H_X4_I?K=_\ ?R@#J_M$?]]/^^J/M$?]]/\
MOJN4_P"%/Z7ZW?\ W\H_X4_I?K=_]_* .K^T1_WT_P"^J/M$?]]/^^JY3_A3
M^E^MW_W\H_X4_I?K=_\ ?R@#J_M$?]]/^^J/M$?]]/\ OJN4_P"%/Z7ZW?\
MW\H_X4_I?K=_]_* .K^T1_WT_P"^J/M$?]]/^^JY3_A3^E^MW_W\H_X4_I?K
M=_\ ?R@#J_M$?]]/^^J/M$?]]/\ OJN4_P"%/Z7ZW?\ W\H_X4_I?K=_]_*
M.K^T1_WT_P"^J/M$?]]/^^JY3_A3^E^MW_W\H_X4_I?K=_\ ?R@#J_M$?]]/
M^^J/M$?]]/\ OJN4_P"%/Z7ZW?\ W\H_X4_I?K=_]_* .K^T1_WT_P"^J/M$
M?]]/^^JY3_A3^E^MW_W\H_X4_I?K=_\ ?R@#J_M$?]]/^^J/M$?]]/\ OJN4
M_P"%/Z7ZW?\ W\H_X4_I?K=_]_* .K^T1_WT_P"^J/M$?]]/^^JY3_A3^E^M
MW_W\H_X4_I?K=_\ ?R@#J_M$?]]/^^J/M$?]]/\ OJN4_P"%/Z7ZW?\ W\H_
MX4_I?K=_]_* .K^T1_WT_P"^J/M$?]]/^^JY3_A3^E^MW_W\H_X4_I?K=_\
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MTG6'O[M+:ZL84^:+=SG.X],5N^*/BSJFA>)?B?+;*B2:):0RVY"?-U3\Z/\
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M>:?<S%94VY[BOV$'3H1['K5I7CS+8QG",)<LGJ(7VNO!;J,9XZ5YG\3OVN/
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M+OQK^+/PG\4^*;#6=,L+;PS)=K#&+<E[A8F;J=WMZ5U%U^U[XQ^-;>"/#7A
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M17N_PX\-7?A7P?:6EY()[N&,!ROW,^U= G2G5*V*>YY'H7P:OYOB_P".-1U
M;=.\06Z6\93J08E1B/UKDM)^'7Q)\(^"Y/"%E!87&E_/%%?.Y\Q(F/3&/ZU]
M$'I0GW:'N'0\-\!_LWW_ ,._B-X3GMW633M$TA[6>3O))E/YX->X0?ZL<8]O
M2G/]VD3I3)ZCJ***!A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]HFKJHO=+AV,(NO)YKT2BGR^[R"]H?-GC+X._$#X+_';Q+XG^'UKIVMZ=XL
M-Q:WAVF!P0=PX/H:P]:_9E^(_B^V\$W^N7]O?ZG8^)!J]VF\[;.$,I6,<<X
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MZE\ _"5E:V4DT]M=V32*.L87&:]HT.(PZ1;*P*L(P"#V-(9;HHHH ,48HHH
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M>>.?:O8_V;?C=#^T1\+K+Q'#;G3WG8Q7%LW2*16PR@^Q!%>5_LH> ]6\-/\
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M_G%8@M=8/_+U'1]CUG_GY3\J -O'^<48_P XK$^QZS_S\I^5'V/6?^?E/RH
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M%% !1110 4444 %%%% !1110 4TG(I7^Z:CVG9WI2O;0.MCYB_X*I#'[//\
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MX>LO#<=A=+8AQ/:2>6O.U?FSD>E?HC*!.WSC>DGRO$5R OO3/[/BDM=GDPO
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MR2&>(7,9W 8Z8'Z5^@\>D6D429MD55=&C4(@$;?@/K3VTF%RZ206NSSB[8A
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M%9QD63^1  RDN#C'&.ON:U?B'\-=4\,?$S7K%[2]NVM/AVM@;A(W*2S>3'D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4LFE7)LKPQPDBW()&<_458_X;K^'L^M:?;#4YIEU(JL5RL1$"YX )Z9KP_\
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M&;=U^:2<]@JCO7PK\%] FTVV\<6VN^.[;PMJ#ZI=2WEC=V8\^Y7<<%6*'.5
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M+O\ [Z_^M1_PL>\_Z EW_P!]?_6H ZVBN2_X6/>?] 2[_P"^O_K4?\+'O/\
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MH ZVBN2_X6/>?] 2[_[Z_P#K4?\ "Q[S_H"7?_?7_P!:@#K:*Y+_ (6/>?\
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MJQO^$HG_ .?":C_A*)_^?":G>RLA792\6?!CPKXYU-;S5M"T^^ND  EDC^;
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MH 1ONTC#@4K'"TQR2E'F&[L?,W_!4?5+K2/V=9I+6>6W<3H"T;;206&:X_\
M8LU"2^^ 6E--.\\I9MSNV23Q7HO_  4:^'.J_%#]G^YM-)A,L\,R2N%&2%!!
M-?&?P>_;(U'X.^#(- ?1Q(]D[*S8/7BOO,JP,<5E#C3:4^9==;:GYCG6-J8#
M.U6J)NGRM>5]#[@QGI@_C005(!P,^XKY*;_@H[?1MDZ(#Z=:^A/V9_'FH_M
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M+_[<6H?"WXBZKH)T13_9TA0-@_-SBN? X66)GRT7H>GF./A@X7K+4^C"<?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5]:TNUUS3Y+6[MXYX)AAD<9!%%%<4:D^:Z>IM744N2VG8YX_!WPML(_L#2P
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4"3MA0O'04445C!MJ[.RR6B5C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm1919495d1_10qimg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm1919495d1_10qimg002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" .:!6P# 2(  A$! Q$!_\0
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M^D6RA@FPJP[CMR,XY'\J_6C_ ()!?M=3_M8_LFZ9>ZQ>"\\2Z.QL;^3(W2$
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MQ>4L /7&X_6O3_V%?^"XWQ)^'7Q1TWPW\1;J36=#OKM;62::!4GM23MR> <
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M'0+C3? 43*UT8=/$<1DS\GSY!/;M63GR45B.YO%<U9GZ4_\ !'C_ (*!:O\
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M4U\2?M\?\$2+_P#8H^&?_"?^%/%\^KVFCW,<KI)9B"6!BPY#!VKZ8_X(._\
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MKI,;1QI_$"\G^%>C_L?_ /!9*Z_9H_9V\/>%+3X17]S:Z3;>6UR)&C\_+$Y
M"'/7UKSL'SU<-SG9548V1H_\$S?^"P?C?0/C1!\,OC#YQ>2X-I#/<_-/;OCC
M>QY.3QU[U^@G[>G[9FF_L<?L^WOBZ9DGNI8PNG0'I,[8Q7X8_M,?$#6_C_\
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M^-W[8G[".I:;KGB_4?%ATYR)&FU2[>YMI1UV$%FQ^5?J=_P3,_X*&Z;^W?\
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MC/\ Y2J6'_8P7/\ [/7IUO\ D:KU1YM/_D42_P +/T/_ .#BY<_LA>'^=O\
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MS_\ [(7P3N_^"CG[<45GK!N/*UR[EU#49$.#Y&\;MI_A.6&*_H=^+?P8\/\
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M'_@EKJ5W9S136\OA$JK!N/\ 4$'FOS:_X-U06_; U]<E3_9IR@[_ #5^SJ_
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MYPA'4X_2OKC_ (*9?\%9-$_:[^"=U\//AIX:U9K=]E]J$\D/EF**/YONC/&
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MP_\ @J#8ZCH5K<RV>L^(9-0163<((5=V&0/N\ 5K!*.*=2)$GRX;V<3],O\
M@N]^R1JW[0W[-.G^(=#M7NM6\)2&4PJN3+%@[L#\J^.?^"5/_!6OPK^R)\-;
MWP5X]T2:2UMKIKFWECB#30.Q)92I].._:OV[;1TN['[/.JS1F(Q,C#AA[U\U
M_%K_ ((_? [XR:\=6U'PC;VVH,23-:D1EL]=W!S6/)RU6H[/5^I<97I)/=;'
MYS?$[_@K]\3/VB?VH;/2?@S;,FEW#I:V-H;?S/.&<%GQC&./SK[Z_;M\8?&O
MX,?L6:?KG@=[6;Q;I,*RZO'!;GYEQEBJ@]L&O3OV</\ @GA\*?V5[@7'A#PI
M8V-^.MVP#2GUP<<5[)=Z?]N@\J>&-XI%*LC<A1Z'US6F*=Z?+3T(PVD^:>I^
M/7['/_!=:UT[3-6T3X\V-QJ<TDNV.:*'S91V(93V_&OF+_@I=^T+\*OVG?BM
MIY^$?@J'29@IBNGC012WLKY"DH!UY7OVK]DOBS_P2 ^!7Q@UY]2U#P;;VEY.
M29);%A"V?7D&M#X)_P#!*;X)?L_ZT-3T+P?:/J<?*7-WB5PPZ'H.E.G&"UL*
M3DMF5?\ @DS\&]9^"/[$/@S1M=C,%_\ 9VG>(]8P[LP!_ BOI8KFH+*U-HJI
MM 55ZKP/3&*L4ZOO.Z%36FI^<'_!?C]BW6OCM\+]*\::!92WM[X3+_:K>(%V
M,+9^;C\*^9?^"5'_  67T?\ 9(^&<G@+Q_8W+Z=I[O-:W4#[I8LDYC9"/?U[
M5^V5UIL=]"\4B!XI%(96Y5P>Q%?-?Q?_ ."1OP0^-6MMJ.K^#;&'4)7+2W%F
M!$SDG.>AK'"KV;<(Z1>Z-,0E5LY:N.WD?D__ ,%+?^"@M[_P4O\ B5X>\.>!
M]'O1I%NS+;0.I::YD<KRP X''O7ZK?\ !+7]DJY_9$_8]TS0-0'EZS=JUY=\
M?<=E''Z5UO[/_P#P3?\ A)^S-J7VSPIX2L+;4%89O)U$LQ ]#@8_*O;OLSNC
MAE&"H  /6JC^[PDZ4-+W,VG4KQJ2U2/YV_V?;F.;_@K%H;[OW<OBJ,)GJQ\X
M5_1/IX @0#^Z 17BFD?\$X/@OH?Q$A\66W@+1HO$<-U]M6_5/WOFY!W9^H%>
MXP0>4.,X[#TK527L(0[)$-.5:4WW'2#:A/H,U^2/_!S0AFM_A^0V/ED/3J?W
ME?K@PRI^E>8_'/\ 9"^'G[3<=JOCSPII7B46)S;B[3/EC\_<URU(<TDGL=4)
M.*;6Y\L?\&]J%?V$;0$/$QOI_D8YQ^]?)_&OO#[,DR<\@']:X_X*_ /PG^SQ
MX430O!NAV6@Z0CLZ6MJNV.,L2QP/<D_G7911E/UKKK2YY<QRT(N"L07%FI4Y
M_/TK^>C_ (*3P*?^"IWB4QQ^=MUK:"1U/F'%?T/2INKQ'QY_P3F^#7Q-^(4O
MBO7O &@:GK]Q-]HDO+B(M+OSG.<BL*2Y:ZJO=&T_X+IK9GJ'@*W">"]*"[OE
MM4 R>ORBOQY_X+\_L4ZWX5^,,?Q4T.S>XTK5PJW<D:$_9YU/!;V.1^5?LO9Z
M0FG:?%:P*(8HD"($/$>.F!4/B?P?IWC'29M.U6RM[ZQN5Q+#,@97SUI8B[J>
MTCN%#W*?)T>Y^5W[%_\ P< >$_!?P,L]"\=:;J']O:+"+>-[4;X[D*.!GC!_
M.OCSXW_$/Q?_ ,%?OVS+=?#^F3"WFG6&**(F5;*W!^8N<#G&3[9K]=O'W_!%
M3X >/M;DO;KP=;Q.[;]D1"IN^F/ZUZ[^S[^Q[\/OV8]/-KX,\,Z?HX? >2%
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M_9CQIM;P9J)(.#;/T^AK^>+]D.1X?^"GNDIR&_X2&3</3]YQ7] WPQ\5:?\
M&/X4Z3J5N4NK#5K5'96^8,"/F!(KS[PY_P $V_@EX4\=+XGT[X>:#::X)C<"
M[2(B3S#_ !=:VIP=.NIK9)F7M&\.Z?70]JL8<V\1Q_",GOTJT;<%,5';6@A5
M0N551@*#P*L43U)IJT;,^+/^"XT^_P#81US#(=LZKG/3FOEK_@V;C62/X@'<
M ADMPN#G?\IS7ZD_%CX+>'/CGX4ET'Q5I5MJ^D3ONDMIQE7KG?@%^R)\//V7
MHKU/ ?A/3/#2W[;K@6B[?.(Z$_A481<EY/=E8I<\5#H5?VS/@"G[1_[-_B;P
MHH N=1LVC@)[/CBOPQ_9&_:$\1?\$H?VM[M?$VDW"VAE:WO[*4F)I(PW#(<'
M/?M7]$9@+*W^UBO*/V@/V'?AK^U! R^,O#%AJ+D8$^P"=?HV/Z5"A[.HYT]&
M]_,M\M2DJ=75(_-_]O7_ (+Q>%OB]\ ;OPS\/].U8WFO1-:W4US%L$",,%4Q
MG<>3SQ3_ /@W^_8AUW3/&5[\6?$EA):6<Z&'33+D2N[ ACM(X&"*^S/A[_P1
MC^ OP[\21:K!X/@O;J!M\1O&$FQAWX KZ>T70+7P]80V=G;0VMM;KMC2-=JK
M^%=-)JG=PT;,:G-*/LW\/8^"?^"VW_!.>^_:I^'UOXM\*1"3Q/X=0B6)%YNH
M@2Q&.YP37Y\?L4?\%5?B7_P3R^U^$-3TFYU32;*0[M.O$*21-Z*YSQ^%?T"/
M;;CR/4$_WJ\O^+'[$/PK^.EQYWBOP3HFKR_Q/-#R_P!2*Y8<\7R)^[V-Y)27
M,U[W<_%?]N'_ (+.>/OVV_#R>$M+THZ%I5VP$UE:.9KFZ)Z*2 .,X[5]=_\
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M5>P?6Z7<^D0^6HWY)KYM_P"'EGAG_H5O''_@CNO_ (W1_P /+?#/_0K>./\
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MI=SZ0^Z:<IR*^;/^'EOAG_H5O''_ (([K_XW2_\ #R[PU_T*WCG_ ,$=W_\
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M]"MXY_\ !'=__&Z7U:KV*^MTNY]((<&E#\U\V_\ #RWPR?\ F5O''_@CNO\
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M\^*^;?\ AY9X9_Z%7QQ_X(KK_P"-TO\ P\M\,_\ 0K>.?_!'=?\ QNDL-5[
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M$>M/^?>#_OVM7\'T%&#Z"CVE0/84^Q0_X1ZT_P"?>#_OVM'_  CUI_S[P?\
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M*@>PI]BA_P (]:?\^\'_ '[6C_A'K3_GW@_[]K5_!]!1@^@H]I4#V%/L4/\
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M@^@HP?04>TJ!["GV*'_"/6G_ #[P?]^UH_X1ZT_Y]X/^_:U?P?048/H*/:5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%-D.,4 .HIF_ Z_K2>9[U+=@NB2BF
M;_<4;_<50:#Z*9O]Q1O]Q0&@^BF;_<4;_<4!H/HIF_W%&_W% :#Z*9O]Q1O]
MQ0&@^BF;_<4;_<4!H/HIF_W%&_W% :#Z*9O]Q1O]Q0&@^BF;_<4;_<4!H/HI
MF_W%&_W% :#Z*9O]Q1O]Q0&@^BF;_<4;_<4!H/HIF_W%&_W% :#Z*9O]Q1O]
MQ0&@^BF;_<4;_<4!H/HIF_W%&_W% :#Z*9O]Q1O]Q0&@^BF;_<4;_<4!H/HI
MF_W%&_W% :#Z*9O]Q1O]Q0&@^BF;_<4;_<4!H/HIF_W%&_W% :#Z*9O]Q1O]
MQ0&@^BF;_<4;_<4!H/HIF_W%&_W% :#Z*9O]Q1O]Q0&@^BF;_<4;_<4!H/HI
MF_W%&_W% :#Z*9O]Q1O]Q0&@^BF;_<4;_<4!H/HIF_W%&_W% :#Z*9O]Q1O]
MQ0&@^BF;_<4;_<4!H/HIF_W%&_W% :#Z*9O]Q1O]Q0&@^BF;_<4;_<4!H/HI
MF_W%&_W% :#Z*9O]Q1O]Q0&@^BHV;_: _&A6Q_%^M*X:$E%0ERPZD8]#UHCD
M,B Y('\Z+BN345'Y@]?SI?.&.OZT]>P70^BH]W^W^HHW?[?ZBC4=UW)**CW?
M[?ZBC=_M_J*-0NNY)14>[_;_ %%&[_;_ %%&H77<DHJ/=_M_J*-W^W^HHU"Z
M[DE%1[O]O]11N_V_U%&H77<DHJ/=_M_J*-W^W^HHU"Z[DE%1[O\ ;_44;O\
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M2?\ HEUU_P"!D7_Q=>W>2/;\S1Y(]OS-'M(B^K5.YXC_ ,-,?$G_ *)==?\
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M_P#1+KK_ ,#(O_BZ]N\D>WYFCR1[?F:.>(?5JG<\1_X:8^)/_1+KK_P,B_\
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M_P"B777_ (&1?_%U[=Y(]OS-'DCV_,T<\0^K5.YXC_PTQ\2?^B777_@9%_\
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M-,?$G_HEUU_X&1?_ !=>W>2/;\S1Y(]OS-'/$/JU3N>(G]I;XE'_ )I?=?\
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MOJOZT;5]5_6CZQ2[!]2J]SY[_P"&K?BI_P!$CO/_  ,B_P#BZ/\ AJWXJ?\
M1([S_P #(O\ XNOH3:OJOZT;5]5_6CZQ2[!]2J]SY[_X:M^*G_1([S_P,B_^
M+H_X:M^*G_1([S_P,B_^+KZ$VKZK^M&U?5?UH^L4NP?4JO<^>_\ AJWXJ?\
M1([S_P #(O\ XNC_ (:M^*G_ $2.\_\  R+_ .+KZ$VKZK^M&U?5?UH^L4NP
M?4JO<^>_^&K?BI_T2.\_\#(O_BZ/^&K?BI_T2.\_\#(O_BZ^A-J^J_K1M7U7
M]:/K%+L'U*KW/GO_ (:M^*G_ $2.\_\  R+_ .+H_P"&K?BI_P!$CO/_  ,B
M_P#BZ^A-J^J_K1M7U7]:/K%+L'U*KW/GO_AJWXJ?]$CO/_ R+_XNC_AJWXJ?
M]$CO/_ R+_XNOH3:OJOZT;5]5_6CZQ2[!]2J]SY[_P"&K?BI_P!$CO/_  ,B
M_P#BZ/\ AJWXJ?\ 1([S_P #(O\ XNOH3:OJOZT;5]5_6CZQ2[!]2J]SY[_X
M:M^*G_1([S_P,B_^+H_X:M^*G_1([S_P,B_^+KZ$VKZK^M&U?5?UH^L4NP?4
MJO<^>_\ AJWXJ?\ 1([S_P #(O\ XNC_ (:M^*G_ $2.\_\  R+_ .+KZ$VK
MZK^M&U?5?UH^L4NP?4JO<^>_^&K?BI_T2.\_\#(O_BZ/^&K?BI_T2.\_\#(O
M_BZ^A-J^J_K1M7U7]:/K%+L'U*KW/GO_ (:M^*G_ $2.\_\  R+_ .+H_P"&
MK?BI_P!$CO/_  ,B_P#BZ^A-J^J_K1M7U7]:/K%+L'U*KW/GO_AJWXJ?]$CO
M/_ R+_XNC_AJWXJ?]$CO/_ R+_XNOH3:OJOZT;5]5_6CZQ2[!]2J]SY[_P"&
MK?BI_P!$CO/_  ,B_P#BZ/\ AJWXJ?\ 1([S_P #(O\ XNOH3:OJOZT;5]5_
M6CZQ2[!]2J]SY[_X:M^*G_1([S_P,B_^+H_X:M^*G_1([S_P,B_^+KZ$VKZK
M^M&U?5?UH^L4NP?4JO<^>_\ AJWXJ?\ 1([S_P #(O\ XNC_ (:M^*G_ $2.
M\_\  R+_ .+KZ$VKZK^M&U?5?UH^L4NP?4JO<^>_^&K?BI_T2.\_\#(O_BZ/
M^&K?BI_T2.\_\#(O_BZ^A-J^J_K1M7U7]:/K%+L'U*KW/GO_ (:M^*G_ $2.
M\_\  R+_ .+H_P"&K?BI_P!$CO/_  ,B_P#BZ^A-J^J_K1M7U7]:/K%+L'U*
MKW/GO_AJWXJ?]$CO/_ R+_XNC_AJWXJ?]$CO/_ R+_XNOH3:OJOZT;5]5_6C
MZQ2[!]2J]SY[_P"&K?BI_P!$CO/_  ,B_P#BZ/\ AJWXJ?\ 1([S_P #(O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#7B'1M4G:ZMKAPF VW$@)Z]#^5+^Q!J<'Q@_X*'?%+QOX<"2>%GABLDNHO\
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M%6,[0@(X)]>112BZGP+N_N%6J1I0YY[:+[SMZ*C>0G=LVN%..&Z?6B65HW4
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M\'_#7QFL(+;Q#IUOJD=G<I=1AAC$B9"L/ID_G71Z?:1V,$5O;1A([=-D<1/
M ITJI-*FX[R!P/2GLF7W'GM@UI]KV?S^86NY5.EK#C1112 ._P"-?/'P6_Y/
MW^)/_7K!_P"BXJ^A^_XU\\?!;_D_?XD_]>L'_HN*NS"[2/.QOQ1/IL]!]*='
M33T'TIT=<,=V>CT0ZBBBJ **** "BBB@ KY\_;@_Y'#X5?\ 8?\ _C=?0=?/
MG[<'_(X?"K_L/_\ QNM*7Q(Y,=_ E\OS/:S_ *C\110?]1^(HJ)?&=*^"(5#
M( T3!L;"/G^E35#*VV,_/L..,C()]ZKJ.73_ !+]3XWC^-OB6/P9^T!=#4'E
MF\,ZAMTO@9A :48]^@JAH&A?%_Q[^SE#\1#\0+O3KJ.P&H6>FQQQ[%7&?GRI
M)_.JA\)ZF/ /[2\+Z?J27%[J3M!LMS^_&^7F/CD?XU[9\,M-N4_8#TVVDMKH
M7)\.B.2!H2+A9-GW=N*]252$<,U+R_4^?K^T^L2Y.]3\XGAG[4'B;4_V@?\
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M'=2,:%40E\JN!C;FO0/@MX]\1_#?]K76O!'BC5)=2MK^R6]TZ:8 >9A2K*,
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MW)NW=_\ I*/U*U'QO8>,/A]?:EH&OZ:8I+1C;7T4ZRQ1'&=V02#]*\\_9_\
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M P,=J8]K%)C='&VWD94<5)126FPVDU9D4MG%.FUXHW7T9013H[>.)<*B*.N
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M>2YG<DO*[EB3[DU7)S2!0O3C\:6O06FQX,VY[@QW'F@G-%%!D%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5]:>#_\ E$_XO_Z_9?\ V:ODNOK3
MP?\ \HG_ !?_ -?LO_LU9/\ C4_4];*]Y^A^?LO^M--ITO\ K33:^WZH\:I_
M$844451D%%%% !1110 4444 %%%% !1110 4444 %%%%( 4[3D<?2AOG7!Y'
MH:** >NY+:7TME<QRQ22QR1D%61BK+CT(Z5]7_LF?\%5_&?P+-OINNL_B'0
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ML?LX?$36KKX1>)=%&A>(9Y+RXT[4(F=;21@22I9#QN]#WK[25,D;]K[<[?E
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MIL]!]*='33T'TIT=<,=V>CT0ZBBBJ **** "BBB@ KY\_;@_Y'#X5?\ 8?\
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M_P G[_$G_KU@_P#1<5=F%VD>=C?BB?39Z#Z4Z.FGH/I3HZX8[L]'HAU%%%4
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MGCO2XHEU[4&,1NBN63Y37@'P$_X*1>-_A#XSN[W4KD^)([B.222VOI"T;#T
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M3W$'AOPYJ,\DR19S,0[#;P,UPT\S:E%RV<.;\O\ ,[L1D<+55!^\JBC^$O\
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M'Z5].^!?$>@_\% OV3O&,NI^'M*TO6?"D :VFMXQD'#;.<#H :H^+=%.I_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7=UYS7Z1_P#!'G]L[^V;)_AOKMT4F@RVEM(?O+UQD^^:^/S_ "Q2C[6EO?\
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MQ\,?^/\ ^-'_ !?/_GCX8_\ '_\ &O;O^$\T/_H-:/\ ^!D?^-'_  GFA_\
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M /C1_P 7S_YX^&/_ !__ !KV[_A/-#_Z#6C_ /@9'_C1_P )YH?_ $&M'_\
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M^-'_  GFA_\ 0:T?_P #(_\ &CGCV#ZK5_Y^/\#Q'_B^?_/'PQ_X_P#XT?\
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M-K[?JCQJG\1A1115&04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXT?6E_SZ7X_YA]6E_P _G^'^1\Z_:?VB/^?;PE^;_P"-'VG]HC_GV\)?F_\
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M_P!XM_\ !M/_ /%U]1T4>Z'+$^7/^'3'PY_Y_O%O_@VG_P#BZ/\ ATQ\.?\
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M_P#\77U'11[H<L3Y<_X=,?#G_G^\6_\ @VG_ /BZ/^'3'PY_Y_O%O_@VG_\
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MPU_S]:O_ .!\O^->L$;I.ORCYE(Z,*%.X9]>17PKQU9.S/TAX2@H<ZN>3_\
M#'WAK_GZU?\ \#Y?\:/^&/O#7_/UJ_\ X'R_XUZS13^NUNX+!T+7U/)O^&/O
M#7_/UJ__ ('R_P"-'_#'WAK_ )^M7_\  ^7_ !KUFBCZ[6']3H>9Y-_PQ]X:
M_P"?K5__  /E_P :/^&/O#7_ #]:O_X'R_XUZS11]=K!]3H>9Y-_PQ]X:_Y^
MM7_\#Y?\:/\ AC[PU_S]:O\ ^!\O^->LT4?7:P?4Z'F>3?\ #'WAK_GZU?\
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M_P# ^7_&C_AC[PU_S]:O_P"!\O\ C7K-%'UVL'U.AYGDW_#'WAK_ )^M7_\
M ^7_ !H_X8^\-?\ /UJ__@?+_C7K-%'UVL'U.AYGDQ_8^\-8.;K5S@9_X_I3
M_P"S5RR_#"S^$W[17A6VTNYU0Q7T+NZR3LRGA_5O:OH%QN0@]"*\B^)K;?VG
M? H' ^SRC'_ 9*NE5G5E[QS8C#4(>\KW/<(ON8/YT^%=N>]-3[@^E2+TKB>K
M.^%U&PM%%%!04444 %%%% !7R#_P5 _Y*I^S_P#]C:W\HJ^OJ^0?^"H'_)5/
MV?\ _L;6_E%0!]31_<3_ 'C_ .@T41G]VG^\?_0:* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "D=L(S#[J]">]+2@&618Y,!<@$>_I0!X]^W7^TY;_L
MD?LP>)/&#RI#>QVYAL=S8WW# [ /Q_G7\U_C_P 6W7CWQMJFKWTK2W=[<O.[
M'N6K]*/^#B[]J]?%OQ&T?X76%PIL-"0W>H1HW)F<X56'JNP_]]5^8&]F1<XW
M=6/KZ4 )1110 4,-PZ _4444 '!8' W+T/<?2NO^$'QX\6? KQ=%X@\+:U>:
M3J5LPP\$A0N/]K!YKD*=C&&4@$=0>]%F]A<T4N6:N?J!\ /^"P'@?]I;0[3P
MI\=M+MXYF41QZU !O#'ABP(X[=Z[CXN?L$S1^'/^$F^&^H0^*_"LH,R+;\S1
M+UR0":_(60F4=@W]W'RM]37M7[*?[>?Q%_9'\1I=^'-;F-KN'F:?,Y>WE4=5
M//0UT4,5.D^5GE8S)<'B4Y*-I,^B=0TZ;2;Y[2ZAFANH^#&R<CZU !@88J&[
M#-?1_P */VR/@7_P4-TZ+3_%L<7@3Q[(@1;H,L<%S+VY..]<I^T!^Q1XL^!<
MBWSVRZKX?<;H;VV4LFP]"6Z5[U''1JKE9^?9ED&*PKY]X^6IXUG#8/7]*6EV
M$*Q!)0'\J:#FNI:['AM-.S%HHHQ0"3:N@HHHH%>X4444 %%%% !1110 4444
M %%%% TF]$%%% &30)Z:,*,9H<;" >"W3WJ&[N4MH2[_ '5.#CL:B=6-*+E4
M=O4RKXJEA:?M<4TH^;) VX\4R:]CMX=S-^(Y7\ZP-3\:R,P2U39V!/>N[^#?
M[&GQ+_:'U")]'T2ZEMW(W7<T;1P*#Z>OYU\GB>)DI\E-<WIJ?$8KBZG6GR95
MAI5:G1I.R]=;:G(WOBM8HAY2 DG!9CA1^-9\&JZCXBE\BTCEF=F 40J6!-?H
MQ\ ?^"*>DZ1:+=>-=4FU.XSEK94Q&OMU-?5/PJ_8^\"_".V2+1_#MA 5Z2/$
M"U>74JYE7=XSM$]?"<"\9YWKF=58>F^BM>WR3/R'\!_L'_%KXH*CVOAJ[ABE
M&5DNLQH1]<&O;_A]_P $3?'?B+8WB#5+'28^"1$OFG^E?JG:Z'!9)\D*+@8
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MP<=/6B7NNP#J* AV[OO'^)0PX^AI_E!5XYSU&X$C\J &448V\<_C10 4444
M%%%%  >:YSXG?$2P^#WPYUKQ/J<HBT[0;5Y9'8XW$#YOY#%='7Y[_P#!P;^T
M^_PU_9ML/ >GRE+[Q=,[3.K?/Y,8 (/LV_\ 2@#\>/VD?C+>_'_XU^(/%>H2
M-+<:K=O)D]ADX%<-0KB10P_B&2/[I]** "BBB@ HHHH **** "E7&[GIWI*
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MHW05?\+^$-4\<Z^FEZ18W&H7T[;5AMXR[)]<9J9SA#XS6&'G/X#.A(DE9?\
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M:SX7^(VI_LN6XN%@UCQ9_:=LZ@[5T]FD=D)[#YH_RKWK]O7XK:Q\.?C3\/\
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MXGM_B+-%':0PSV)6WM9AQYA<C:1G'?M1U^:^[D3?_DW^0'EW[17PD\9>/O\
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MIUC=Z4R[1;RP Q@>PQ6YGECG[PP:%^4 <MCINYK/G4W8NII)2Z(\]\&_LP^
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M25L@8BRQYZ\_K6C\:/#_ (Y_8A^,?P\U6U^(.OZWIWB75%MM4M+N9Y%D+%>
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M6,O[D_T'4;NH^<?U,+Q'X:OT\-ZIKGQ'^.]QX?\ %RO,L%G8ZA)]GM\@[%4
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M(/\ Q_\ I"/K_P#9A^&H^$GP@T'1H=1OM55;=91<7;%GP0,CDGU]:\(_;O\
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M T>.=)HY/LD1=)!S&P0 K^E;==%?^++U9SX;^##T7Y!11161N%%%% !1110
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M03^M3^#_  9\7/B5\5=)U+Q%;V?A+P]I/[R:WM5RUXPR>?T_*OI@Q;F).<]
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M?^2Z?J7ALMC1?,O/_P FM_D?$_\ P4N^%]QJGQC\(2:+.+?4/%9DT2]C7K+
MQ3+'_/>OK_X8^#8/A]X#TC1X1MBTZ!(=_K@5YCX)_9 BTSXSOXQUO6[[6KBW
M)^PV\\BM'!DYR!C/85[4B>6B+U523@]ZO$U[TE'L+"8?EJN3'4445P'HA111
M0 4444 %%%% !1110 4444 (\>Y&/?;G_P >%?GQ_P '%_Q6_P"$4_94T/0H
M& N=9U1;AESUB5) ?U85^A#+T/;&TU^-'_!RI\3QK/QY\(>%8I.-$TMGE0'O
M+L<9_"@#\SBGDJ@3_5[,FBG-)GTZ8Q3: "BBB@ HHHH **** "BBB@ HHHH
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M9(XJS4:M\U25[]VVS]^2LK(****!A1110 4444 %%%% !1110 4444 %%%%
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M.Q[V BU&["BBBN$[0HHHH **** "BBB@ HHHH 0]*\A^)_\ R<_X%_ZX2_\
MH,E>O'I7D/Q/_P"3G_ O_7"7_P!!DKJP?QOT.+&_"CW)/N#Z5(.E1I]P?2I!
MTKEZL[5\*%HHHH **** "BBB@ KY!_X*@?\ )5/V?_\ L;6_E%7U]7R#_P %
M0/\ DJG[/_\ V-K?RBH ^IH_N)_O'_T&BB/[B?[Q_P#0:* &OTI@3S$ YY..
M*D8;A2!-JX!^OO1#2:?K^@;I)][GRA\'=*AO?^"E'CZZ,,:R16$21LQW8QZ4
MGPWT:VE_X*9>,Y7B3<NEQR+($7(;+\^Q]Z]X\-?L^Z%X4^+&H^,+195U34XQ
M'+EB1QWZTW1OV>]%T'XPZIXVMVN%UG5;9;:5BY*@#/(&?>O2CC+0DO\ IU**
M_P 6EOUU/"GE\^:ZZU5+_MW6_P#PQ\W76O6G@?\ ;V^)6HW$"265GX<2YN82
M#^_"^<>@]<&H_A1X^\>?$_X?3ZUX=OO"/@[PI.LCK"J)YK+SG<"I.>*^C!^S
M'X:;XKZMXO>.>74=;M%LKM))"T<D8W<;2<?QGM7$V/\ P3N\"Z;J#R02:O%:
MO*939I>2+!GKC:&QC\*ZWC:;4?*"7S5[G.\OKMSLMZDVO\+Y;?DSYP_9CF,G
M[$/QA5[P7GE7MV#,J@*[&)>W&!SZ5]!_L\:#;6G[!-O;K BK)X?N9'7:N&;;
M(<DUU7A']B_PAX(\#^)O#VGQSPZ;XJ=GO(PYQRH4@<\<#K78>'/@UI'ACX6K
MX0MQ/_8ZVC680R'<%8$'G.>]8XG%1G.<EL[&F%P$X4Z<)[INY\&S%S_P3Q\$
MW3JRI8>*/,D)^ZB_:W7'TYS7T#^WWX]TA_V0[N)=0LI);_[,(4CF#M*-RG'M
MTKU+1_V4?"FF?!QO \ENUWH99G$<AY5BY?.?7)KB8_\ @F_X"DT::QNSJ5]!
M(/D$UP[>4=X8%<MQC&*OZS2;NW]J_P""_P @^I5XM66O*X_)M_YGEW[5\V[X
M&_!@K"S!M1LE).!M'DMVKJ_VC/BU=6G[1'A[PCX;TS16\5?9/.74]3"D6\?R
MXV=1GIVKV#QY^S!X=^(?A[P[IM_]I,'AF>*>TVR$8,:E0#S[U6^,W[)/A7XV
MZQ9:AJ,<]K?V2^6MU:2&&=DX^4NI#=O6LO;P;LWI=O\ (OZE4NM-H\J^^Y\F
M_&5O%-E^U'\(6\7>)M+U2Z.L@""UCC7R06C^\54<'W]*]&_97N[71OVU_BK#
MKLL<&JS/"ULUWA%:+YONL?QKTJQ_X)^^!;;4=*O9EOKN_P!)N%N(;J>=GF)4
M@J"Q.>/KWK>^,/['WA'XT:C#?:C'=6VH0JJ?:K6=H9' Y&2I!-=%;%TG#E@<
M]#+:L9\\D9EY\2/!6J_%OQ%HFD6<<OB2'2Y7FOH(E,;KL?Y68=>_6O /@1/!
M=_L&_$&&)MTJ2WPEB+#>W+= .<5]0_!O]E_PS\$K&XBTN*>26\4I///(7EE4
M]BQ)/ZUC?#C]BOPA\+O%>LZGIHO-NNK(+JTEF:2W;>""0A) Z]A7)SPY9+FZ
M+\T=SHU%*,HQ^%M_>G?\6<9\"?B#I&F?L"13-J-IB'1)XA&9%W*VUUVXZYKY
MM9TU+_@G3X/"*7BE\3-NS@=;ES7U):_\$W_ %M=S-_Q-?LTY<M:+>2+!EB2<
M(&VCKZ5O3?L3>$+CX7:?X29;D:5IE]]O@59",.&+ =>F3735Q5"]7E=^:5U^
M)RT\%7M2BU91C;?T,C]KNSCT[]BKQ!'%%Y<::5&JMM 6/YH^WK7@GQ.TZ#4O
M#7[-5K<6JRHWDB0R,,,-B\XSR*^S/B)\)M,^)WPYOO#&I^:^F:A"(955B"0"
M#G]*Y76OV2?#&N6_@Z*47&SP25_L\;R<;0 ,\^U84L;&%7GZ<R?RU'7RJ;P[
M5/XN227J[6_(\N_X*964$'PK\*O!&/\ 1-;MEC*J 5'/ ]JYOX:W=MHG_!0[
M77UUU22]TFW;3GFX5.9,A2>!VZ5]'?&CX"Z+\<?#UE8:WYTD.FW*7</EN8\,
MO3.#R*\!_:SOO"<WQ:M-%\;:'J-AIL5JOV3Q%9NR/GD;2R'=CI^=:X.KS484
M^JO^-B<PPTHUZLX_"U3M_P!N\]_S15^/VM:%J7[?7PWALVM7O421IWMR&+#W
M(KZ^@?S(%/4$<&O@WX&_#3P]XK_;'\/7O@>'4)]-\/V[M=ZG?%V$Q(/R@MGT
M_6OO*#'DKA64>A^M8XY15HHZLK<W5YWL/HHHKS6K'L+=A1112&%%%% !1110
M 4444 8GQ.U1= ^&7B.\<A5@TJYEW>FV)L5_+7\0_$9\7>.=4U-B2U]=2SL3
MU)9R?ZU_3+^V5J[:#^RAX_NP<>5H\HSG'4A?ZU_,+<?\?,Q'0OQ[4 1T444
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M5TO?JT8=U4?_ (#%O]#&4^;V_I#\SYG\??\ !$+Q!HG@N^/A_P ::1KNN:/
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M++CICD5Y9XD_X)97GQ/_ &L_&/A+0/$.G$:9!-JZO Q*H,C]WT[;L?A7O_\
MP2H\ ^,/A?\ MW?$3PWXOUB/4_$*^'V,K)*665CM.!_M ''X5%_P2GT+5?"G
M_!0CXP66MVUQ:7.K6&H+:K=$[Y/](&W9GVK2"O43_N?_ ")BY<M&Q\2_LQ_L
M':S^T[\;_$7@FPO8+:_\/Q2RO,<XD$;8;]36S^S/_P $XO$/[07Q*\5:6=8T
MS1=,\(SO!>ZA=/A$VL02!CVK[7_X)7_LT^,/A]^VW\5];UO0[JQTZ2VOEBGF
M)!ES*&RO'M6'^QW^RIH/CVT^,OQ UR#4O$(TO49_+\/6\F'O,2-P>OIZ5%.2
ME)1?6G*7XQ_S-:L>6+_Z^1_*1\Z_M.?\$C]3^"7P8F\?>'O%.F^+O#$3B.ZN
M8&)*]2<#'08]:]@_;-\.:?:?\$9?A+>1V-I'<W"HI<0*DF#MR2PYKZ-^*-_'
MJW_!)/QN=/\  #^ K1-Y729#N=/E/S'Y1_*O /VU5)_X(K?!U3_RT5/P^[64
MJWN-]Y4G]_,:4(<U6$O\?_MI^9HX%%'2CO73!7E)^2.:GJJ5/O9?>PZUW7P!
ML/MOB]V(SY,?Y5PP&6_6O3/V<8,W]Y/ZC%>9F-7EPK/@?%'$NCPYBJGDX_A_
MP3]FO^"&7A;^S_@UX@U/;SJ&HK\V/[BLM?>4:9 ]J^1?^"-.BKI/['5M/C#W
M5[.WY2/7US;/F'Z@5KET.7#(V\-\+]6X<PL>Z;^]L=']X_6OR^_X.1-1ATIO
M@W=SLX@MKR^E<)W4?9\U^G\;<OZ9K\P/^#CS2XM1D^#-M<Q>?;RWE]'(/8_9
MZ[%L?<P^$^@/ G_!8/X&Z-X(TNVN/$DBR6]K&CJ(00"%'?=7'_M ?\%S_AKX
M<\&2CP8;[Q!K$^Z."%( ,$CCH3ZUV?@#_@D)\#M>\%:9<W7@ZQEN)K:-Y)'@
M4ER5').*]!^&O_!,KX-_"_5%O-*\&:7!<I@J_D*.G3/%!1\F?\$<OV6/%_B+
MXO\ B3XY>.X);2_\0.WV.%EPX5N!^G%<Y^VH-O\ P6L^'>>^,?\ ?IJ_4K3;
M"UTZW2UMXXTBA&$1%PJU^6W[;G_*:_X<?0?^BFH _33Q!\3=!\(M%!J6K65C
M(4!*S2A3C%?.7[:/_!3OX<?L_?#C4A8ZU9ZQK<\316MK:R;Y&<@\XKB_^"P/
M[#%Y^T?\*O\ A)O#LUS;^(M!AWHL+E?M  Z''M_*OE#_ ((W?LT?"'XXZK<Q
M>-+%I_B%X?N&$MM>,#RK$$@'GKB@#US_ ((??L\>(+O4?&'QA\2V<MG>^*+O
MS+02+AS&=[-^?RUR'[']HGBG_@MY\1;S4\9T^:ZFMU;EA^\&*_4_P_X8L_#6
MBPV-E;Q00V_RHL2X5 /:ORB_:J-Y_P $_P#_ (*UZ;\2I;>0^%O%\[?;)1]Q
M5D<&0>G'% 'ZX6H\N%5SD@5+FL#X=>.-.\>>$;#5-.NXKRUO8A(DJ'(;-;K#
M)H 4G:*^-O\ @MUX=L=>_82\0RW93[1I\L4EL[^ID3./P)K['EF6,?,:_,C_
M (+G_M#KX^B\-_!WPK-_:>NZ]<HEXD)SY2L^%!QZ'!H ^CO^"-&K7.M?L ^#
MI;IR\H26/GLHF<+^@%?-?_!P6<>+?A-_V$T_]&&ON?\ 8H^#B? 7]F7PKX8"
M;)M.LHUN..LI&7_\>)KX:_X.!AGQ=\)O^PFG_HPT ?HY\*!CX=:-_P!><1_\
M<%>(_P#!3W]I-?V9?V3O$>KQ3I%J5U']FL\G#.[!ON_3'ZU[7\+6Q\/=)9C@
M"RB_] %?E;_P5K\9:G^VE^V3X=^"7AF[D2+3B?MSH<JA<KDD#^[@_G0![?\
M\$,?@5!X ^!=YXYU:2%-9\:RFZ=I&&]5ZXZ_[5;?_!<#X"6GQN_9<DU73I(3
MJ_A(-?0NCCS%3 +X.>P6O+?"_P#P1@^+'AO0H-.L?B_?VEK;#RXX8U8J@'I\
MXJ;6O^",?Q9U[2Y[*^^+VH7MM<(8Y(GC;:ZGJ#\] 'T#_P $?_VIH_VC?V4]
M+6XE']JZ"GV&X0M\ZD=,_G7T5\;5"_!?Q6!_T!KO_P!$O7Y-?\$X+[5_^"<W
M[?6K?"GQ7?/)I&L1G[)(W"RS8.P_BV!7ZQ_&B02_!'Q0PZ-HETWYPO0!^?'_
M  ;N_P#'A\6O^Q@;_P! 2OTU_P"6E?F7_P &[W_(/^+/_8P-_P"@)7Z:?\M*
M ./_ &@>?@MXJ_[!4_\ Z":^"O\ @W4X^#?C/U_M8?\ M2OO7X_?\D7\4_\
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M104%%%% !1110 4444 ?)G_!;4?\:^/%7UC_ /0UK^>LGI[ 5_0K_P %M?\
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MUQ@YK\J/^"FW[*VN_L9?'"U^._PVADBTG[2LFK06X(Z\MT[9!K]7[?B+'3
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M+L-GW=L0#?G7;(5A3G(SQD#B@ @CV1>7N^5<8QV]J_,C_@X'<+XO^$N&W?\
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M3KE;-0EQ))&#N..?QKQ3]C7QA;>"OCWI-Q<OY<,V8V9CP"00*[#]L?\ 9_\
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M]:B^-'P9NO@IXD_LV_N$EN$56;9TP1Q7V9X=\+6'QFN_"?Q"(3;IMB6NE/\
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MVMM.+FVCD'210PYSUJJ?P@./2O(?B?\ \G/^!?\ KA+_ .@R5Z\>E>0_$_\
MY.?\"_\ 7"7_ -!DK;!?&SBQOPH]R3[@^E2#I4:?<'TJ0=*Y^K.U?"A:***
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MX/\ [3'CKP+JWQ!^%?C:[74M>\-Z:]WI^J ?-)&.C$>G(YKSC7?VKO'FD_\
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MUM\5OA9I&N6=K=V4%Y "L%RA22/'!!!&>HK2+LK =:>E>0_$_P#Y.?\  O\
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MXWU.SO+?^TKJ2WTS3XTS<:EAR@*CTX/ITKXSUKXM:[\%_A7XU_9Y@>5=8O\
MQ+'IFE(O5M/G>(R'UQB27\JZ#]N7X/WWPR^,O[/_ (:LM3@\.:/IEB($O)XO
M.@CN2).6W \[CZ5F6?3?@'_@IEIVK^-],TCQ;X/U_P %C5I,6%UJ,:E)2P..
M4+ >F#7(_$O6YQ_P5Q\);+AQ:_\ ".2,$5\1OS%AB.G2O-/VH/V;=?U?2_#B
M>/OC+IAM(]5@FL?L\*>;*X/ &Q<A2,UTGQ(TB:#_ (*9^$K>"4W5PO@J1(Y0
M<$[4B 8@^M'2_E/_ -)T_$F5[Z?W?_2M?P/7/BK_ ,%+=+\(?$._\->&/#>K
M^,[[1\K?-8IN2%@<$9R.<UU7P7_;P\+_ !J\#ZYJ4$-YINJ^&HWDU#2;E-MQ
M%MSGCT]Z\-_X)$7VCZ+H_P 1M/U:>U@\5Q^([HWANV"7#QF60K@MU7'OZ5Q>
MM75EK/\ P49^+5UX7:)M#3PHT6HW-N/W(N.>.."3\U95-)6CV?X4[_F7&W(N
M;NOQJ6_(]0\.?\%>+#QQX6BU;P_X(\0ZY:PJKW\EK#E( <YP2>3P?6O5IOV[
M_"]S^RQJ?Q3L-\NEZ5$[SV[C]]&Z#<48#IVKR7_@D9XH\'V7[$5F@N]+@:%Y
MA?K(R(R-@;MV>2*^=O"W[[]B_P#:1U"Q'_%.3W]R+#(S&R^6,E0>*=6[CI_S
M[B_OE%?J1"RFT_\ GY)?^2R_R/I/4_\ @KWHVGZ'9Z\G@OQ%<>%)55KG5UB_
M<VZGJW7.!].U7?%G_!630M&MHM6T_P *^(-2\(%5$FMK#^Y4L,Y'(.!D#IVK
MF_&WAJST?_@CK>6ZVL<2IX7=V7:,-E7.?K5A_#-I8_\ !'5XH+&+RQX:>X>,
M*!\X#$'T["KQ#]G&3CTM^-@HZ[GN7Q5_;9\&_";X/Z1XMN[MKB+Q#'&VF6D*
M,T]XS ?*H Z]>O'%>>^ O^"G&G:CXUT_1_%OA+7?!2ZU*(;"[OT!@D)&1DH6
M()QWKXL^,6EZUK-G^S&%UH:+I\UB EY-$)8(KC$I7.01P*]5_:?_ &=-?UC0
M/#T'CWXS:1]D?58I;)8+:/SIG#9788TR ?J*(\LVV^[7W,UJ*S/IG]I#_@H;
MH'[-WQDTOPCJ.GZA?WFJ6#W5HEFF][E@4 _/=FL7X0_\%)=.^(/Q3MO!>O\
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MO]F,Z>DWESZO="-5 ^\@'S?S%?6DF1<%^T9YK\VO^"XOQ._M'Q+X:\/Q,?\
M08WFD7/]_;C_ -!KAS2;IX=V/SCQ2S#ZMPSBZL7O:*\[N*?ZGRO^SQIVW3KJ
M[QS)+M)]17IF[?SVS@5ROP<T<Z=X%L^@\X"0UU)&V5L?=Z@5^E<.8?V64THO
M1Z/[]3\TX3PKP^1TH6]YV?R>HM%%%>Y/6I*7H?43LY704444B0HHHH ****
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M&UOY15]?5\@_\%0/^2J?L_\ _8VM_**@#ZFC^XG^\?\ T&BB/[B?[Q_]!HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:4I#%CR3TR.XKYR_:'\9>,OV;?A?_P )G%\>;;5_%-HZ27NDO,KB<?Q!5#Y
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M[2D7[1?P#TR\F=3JNG(MI> =3(!@M]"0:]_4_,O7FO6H5%4IJ:/U_)<RHX_
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M'X@ZM?>'-:\1^$/B%/\ VG%+IUJTGV:Y#,=A*J?^>C?E7#_"_P"*&H_M,?\
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M:]$;ASSGG\JY;X-?"?3O@QX$M=#TXY2/G/N>I_&NIQMIO67-Z?@4M%8****
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M_P 15>7#6/I.&:3EB;GI0I%/\Z6CI7PT)6CRGZ1+WGS!1113 **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** $/2O(?B?\ \G/^!?\ KA+_ .@R5Z\>E>0_$_\ Y.?\"_\
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M6\?RVX'4DEAG\*.96<NB5_EW] /L9 $&T<*.%!_A%#2*KXSO[953Q7R5?_\
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MM+V>IU]%-\U?6E#9KTC]*%HHS10 4444 %%%% !1110 4444 %%%% !1110
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MLU_-TZ_>?N'\*/BOI/Q;\(VNJZ5=07,%Q&)/D.?+]C74QS+)G#9XY]J_$?\
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M_H,E=6#^-^AQ8WX4>Y)]P?2I!TJ-/N#Z5(.E<O5G:OA0M%%% !1110 4444
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MRW,]Q=R2$LT\S9)JO_'N[TID)[T )1110 4444 %%%% !1110 4444 %%%%
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M/^&[?BU_T1'6_P#O^G_QR@#ZVV>S?]\FC9[-_P!\FODG_ANWXM?]$1UO_O\
MI_\ '*/^&[?BU_T1'6_^_P"G_P <H ^MMGLW_?)HV>S?]\FODG_ANWXM?]$1
MUO\ [_I_\<H_X;M^+7_1$=;_ ._Z?_'* /K;9[-_WR:-GLW_ 'R:^2?^&[?B
MU_T1'6_^_P"G_P <H_X;M^+7_1$=;_[_ *?_ !R@#ZVV>S?]\FC9[-_WR:^2
M?^&[?BU_T1'6_P#O^G_QRC_ANWXM?]$1UO\ [_I_\<H ^MMGLW_?)HV>S?\
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MA_:&'['L'EG_ ":/+/\ DUX__P +W\9?]"-=_P#?0_\ BJ/^%[^,O^A&N_\
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M-=_]]#_XJC_A>_C+_H1KO_OH?_%4?V?B>X?VAA^Q[!Y9_P FCRS_ )->/_\
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M^M "T4F#ZT8/K0 M%)@^M&#ZT +128/K1@^M "T4F#ZT8/K0 M%)@^M&#ZT
M+7&?M!_!W3?C[\']<\)ZK$LEKK-L\&6&?*8J0K_@3FNRP?6FRQ^9&03P1@T
M?RQ_M._ K4_V</C7K7A75XS;W&FW;Q@LO#*/F0CV8$"N>^'?PJ\0?&'Q FF^
M'=)O=9U"=@JP01G"D^_ K]Z?^"CG_!)?PQ^VIXWTGQ==ZG_8$FFQ%=3E2($W
M$"Y8D]/FQGGKT]*\;TOXI_"_]B?P]'X;^$NAVU[K,:E9]7GB5Y2>1D,<D4 >
M%_LP?\$7M"^&?A^W\7_&[7(;&W4"7^QHI#Y[]\,!_C7M/C[]L_3_  %X3'A3
MX5Z%;>%]"C7R5N(4"3S@=R1SS]:\4^(?Q5UWXH:Q)?ZSJ-Q=W,S$NKL<)SP
M*YQ3M.>_;/;Z4 7=5\0W7B34I;N\O)KFZE.6:0YYJD<@\XS[4)\F??UH P*
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M>1_*G_VA\</^?C0O^_7_ -:O:HF$8/S-DU)N;^\] 'B/]H?'#_GXT+_OU_\
M6H_M#XX?\_&A?]^O_K5[=N;^\]&YO[ST >(_VA\</^?C0O\ OU_]:C^T/CA_
MS\:%_P!^O_K5[=N;^\]&YO[ST >(_P!H?'#_ )^-"_[]?_6H_M#XX?\ /QH7
M_?K_ .M7MVYO[ST;F_O/0!XC_:'QP_Y^-"_[]?\ UJ/[0^.'_/QH7_?K_P"M
M7MVYO[ST;F_O/0!XC_:'QP_Y^-"_[]?_ %J/[0^.'_/QH7_?K_ZU>W;F_O/1
MN;^\] 'B/]H?'#_GXT+_ +]?_6H_M#XX?\_&A?\ ?K_ZU>W;F_O/1N;^\] '
MB/\ :'QP_P"?C0O^_7_UJ/[0^.'_ #\:%_WZ_P#K5[=N;^\]&YO[ST >(_VA
M\</^?C0O^_7_ -:C^T/CA_S\:%_WZ_\ K5[=N;^\]&YO[ST >(_VA\</^?C0
MO^_7_P!:C^T/CA_S\:%_WZ_^M7MVYO[ST;F_O/0!XC_:'QP_Y^-"_P"_7_UJ
M/[0^.'_/QH7_ 'Z_^M7MVYO[ST;F_O/0!XC_ &A\</\ GXT+_OU_]:C^T/CA
M_P _&A?]^O\ ZU>W;F_O/1N;^\] 'B/]H?'#_GXT+_OU_P#6H_M#XX?\_&A?
M]^O_ *U>W;F_O/1N;^\] 'B/]H?'#_GXT+_OU_\ 6H_M#XX?\_&A?]^O_K5[
M=N;^\]&YO[ST >(_VA\</^?C0O\ OU_]:C^T/CA_S\:%_P!^O_K5[=N;^\]&
MYO[ST >(_P!H?'#_ )^-"_[]?_6H_M#XX?\ /QH7_?K_ .M7MVYO[ST;F_O/
M0!XC_:'QP_Y^-"_[]?\ UJ/[0^.'_/QH7_?K_P"M7MVYO[ST;F_O/0!XC_:'
MQP_Y^-"_[]?_ %J/[0^.'_/QH7_?K_ZU>W;F_O/1N;^\] 'B/]H?'#_GXT+_
M +]?_6H_M#XX?\_&A?\ ?K_ZU>W;F_O/1N;^\] 'B/\ :'QP_P"?C0O^_7_U
MJ/[0^.'_ #\:%_WZ_P#K5[=N;^\]&YO[ST >(_VA\</^?C0O^_7_ -:G)??&
MYV^:XT+ Y_U.?Z5[9N;^\](S/CAFH \I\%V_Q&\2ZM<6?BZ/2;C1KVV>WG6%
M<,0P(Z8]Z_.[]L#X W/P"^+NI6&QAIMPWG6DH&-P/.!]/Z5^LFW=_&X->0_M
MI?LYV_[0/PMN%B0-K.D(9;1\9+CJ1^IH _*-F+MDD'@=**M:WHT_AS6+FQN$
MV2VLAC;Z@\_K56@ HHHH **** "BBB@ HHHH *1E^3CJ3R*6BA: >O?L8^,/
M"OAKXH^3XOLX)M*NT**TBAPCG&T\_C7T=X+_ &;?"/@#XPP>*M.^(UI::+:S
MB[CM4DP<YSM(SC'%?"1;802 <'//:IVU.>6)H_M3>5(.F[I1+WE9DN*::?4^
MU/#W[07A[Q7_ ,% 8M:COX;;2[.U>)[F8X60D,.#3_@3\2_#^F?&3XMW$^K6
M4,.J0N+8N^%F.SJ*^(U&^+@[0.P/- ?<O);<O<'M[T2]Y.+ZIKY,IZRY_-/[
MMCZR_8F\?:+X<\'_ !.34-2M+:2^%P+99GV^:2N!M_&C]CSXBZ-H7P ^),&H
M:K!;3W;2>1$\F&DX ^4?6ODR.X9U/'F#^ J?NT*^\'KCOM/ ^M3.*E>_6/+\
MOZ84_<CR+;FYOGI_D?=O[*6@Z=XT_8"UC3=5O5LK.\N98VF/\!\XD'\P*S;>
M;PS^Q_\ LQ>)=+B\06>OZOX@&$,#;B!S_C7A'A#]JM?"W[+]_P"!/L7G&ZD:
M0.O;,F?ZUX_+,\J8)=I QQO;.T9Z5I.SOYV_ 45:2DNE_P 3ZQ^(WQ'T6]_8
M)\'Z3%J5I+J,,T+20!_FBPO.15_]L'XD:'K>G_#".PU2SN_L14S;&SY.=G7T
MZ5\=^;MP>44\ 9X)IQ9DZY&>F3UJ(74U/JG?YVM^0WJN7Y?C<^MOVS/B!HOB
M']I+P+?V&IV5Q:016T;RHV5B97).?3J*[;QY^TAX>\#_ +97AW6%U"WN].;3
M5M9YXCN\MOFZ>O6OA1@[Q%2IQG.">::\GGC)&1C')Y2IA344DN[E\V#U^ZQ^
MB^I^(([#Q1?>(9OB7:Q:%)%)-!;6PS.?E)VD;A_.O+OV6_CCH7C33?'W@W6=
M6^R1:Y,[VUS(H^;.""QSQ^M?'[WDPM A>1H?X<MTJ"&0QMN0^6?[RG!-7/WM
MPA[NQ]\_LZ>&O!G[-7A+QGIK^+]/O-1U6SE(VOD%<?*,^O2O@[56674)G7#*
M\C[6'< U$TSS[I6D8L.C;N6'>FL  -J%5;E:35VGV&I-)I=1M+115-W=Q)65
M@HHHI %%%% !1110 5]S_L=_\F(ZW_U_M_[-7PQ7W/\ L=_\F(ZW_P!?[?\
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M_G_]:N_\P_[='F'_ &Z . ^U?$+_ )Z6/Y__ %J/M7Q"_P">EC^?_P!:N_\
M,/\ MT>8?]N@#@/M7Q"_YZ6/Y_\ UJ/M7Q"_YZ6/Y_\ UJ[_ ,P_[='F'_;H
M X#[5\0O^>EC^?\ ]:C[5\0O^>EC^?\ ]:N_\P_[='F'_;H X#[5\0O^>EC^
M?_UJ/M7Q"_YZ6/Y__6KO_,/^W1YA_P!N@#@/M7Q"_P">EC^?_P!:C[5\0O\
MGI8_G_\ 6KO_ ##_ +='F'_;H \_-]\0XQGS+'\?_P!51:5X^\6Z7\1M.TG5
M?L;0Z@I92GH,^WM7HCR-L/WNG>N!\<-N^.OA;+8_<O\ R:@#U:BD7I2T %%%
M% !1110 4444 %>!_MI?\CE\+O\ L.G_ -DKWRO _P!M+_D<OA=_V'3_ .R4
M >QP_<B^A_K2TD'W(OH?ZTM !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\;O"_@&^6;^UO%L<DMJR@X"H&S^JUZ;MVL!]X)&H)[AL"@ HHHH #P.A/('
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MB31TZHN/M,>.?KT%?FU>Z<^DW<EM*C1R0,49&ZJ1VH BHHHH **** "BBB@
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MJ@;.I-?%?BGXEZ]XYB@&IZC=ZE]EQY1FEYB Z$5MQ_M(>,X_#ZZ:OB&_^Q*
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MM,****H84444 %%%% !7W/\ L=_\F(ZW_P!?[?\ LU?#%?<_['?_ "8CK?\
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M#(.,AE[=Z\\_;E_:FLOVU_AMHOPZ^'>G:CJ>IZY?6SWTK6QCCL8$E5F)SU.
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M7U3PI\*$M;Z;2H&DE\PVL2AN!GV]Z3V ^?+>QE+1RFVEP_?!P*]"^)WP<LO
M7@#0=4AD=Y-1BRX))P2!5V[_ &B+.\\(?V<FAV(;R=C2A ".G/2N^\?^$&^+
M/P@T Z9<VR_9 !(&?&.E5 #S_P 9?!6Q\-^#O#&H1.QEU>3]X"3@$[>*Z77/
MV?\ PGX#GLI-;OW1[V-?+4,< D]ZV/CI##HWP\\&6GGQ3-;72JYC;)'*UH?M
M$?""Z^(]QH\MC/"C1Q1[TE?'R@YR/?K6;W \>^//P?C^%U_:R6T_VC3[Y!)&
MP'3/2O/Z]O\ VKM?M+71]$T*.9)KBTA D9><$=J\0JD 4444P"BBB@ HHHH
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MNI_.NJFJ7M'%](*7S=M/Q.2I7K?5JDNKJ./R3?\ D>O_ +._[3>MZ?\ &]O
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MDB!*M_L^AX%7D.UCC]*B6_3R6ES"1G:4\WY![Y]:2G9:^7XV-$DG_7];$X?
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MQ\\1_&BZAG\17[WD<7W%4G:GX4 <6IW9.6;))R:6E9R[9+^9Z'VI* "BBB@
MHHHH **** "BBB@ K[G_ &._^3$=;_Z_V_\ 9J^&*^Y_V._^3$=;_P"O]O\
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M;?,HH]E\3?\ !4;X6Z#HMKJ%MJ,VLPS1>;*UDH9;8?[>,X(KL]>_;,\&:+\
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MH/QRMOA_)([:[>69OD3=T0 Y_E7EY_X*C_#AO%-UI$,M[=7UE?-IUQ'#%O\
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M[?\ LU '&'I10>E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTS]B3]BS3OV+/"VL:-INH7-_%J5Z]X3*V=NYF.,X_P!JO<** "BBB@ HHHH
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M;J^(RJ'D+GUKM?AC\(=(^%&F)%;VZ3W@.6F(YS762MYGS>O:@!D@RB*GRHG
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MKT444 %%%% !1110 4444 %>!_MI?\CE\+O^PZ?_ &2O?*\#_;2_Y'+X7?\
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MPW_X16"*35IM/EBA>49$))B^;O65-.>(IQ;T;7Y,56_U>JX[I2_-'Z&-(=I
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M_P EO\)_]<G_ )/7?CO]#7 >.O\ DM_A/_KD_P#)Z /5Z*** "BBB@ HHHH
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M[K?Y'PC\8OB0/V]?VN/AU!X*TV]N=&\(S?;KS4)D* \,=H_ BNP_8ETUM/\
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M.BDW88J>&!P5/4?A2@$D_*W'J* "B@9(S@X]<<4@.: %HI V?_KTM !1110
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M/[7M=3LI=-";VN!*/+4=<D]*XG3OVO?AKJOB1;"+Q?HKW"Y 'VI-K'T!SUH
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MA?4[:RUR6&WMI7.WEY,_RKK=&_9)\?W/[37ASXA:UJVGRM8YBN[=-H6&/85
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M:E=-A+*^)]/)./Y4 4**Z73?A#XBU!ODTF=_3*D5T6E?LM^+M5"YM5@!Z;J
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M'M6GVJU^^GI9?J./P4SQ_P 6:UXS^(?ASX$_#CQU+?Z=#J\S+JX#D2W C\H
M'_OMOSKN?^"FW[('A'X5_"[PGKOAJW;1[FPU:UBG$4AV7"LPZ^_!KV'XQ?\
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MR.>AH*\+[$D^^:6BG=[$\D=PHHHI;*Q76X4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4UX\G()5O4?X=*=10"TT0A!*]><<D #)]:4?<QQQT..A
M]:** $9=S'W;<1ZTJLRN3G.>O'6BB@!@CP!\Q^4Y4^E*L>R7(Z$893R&_.G4
M4 (44KMVC;Z4O.T#/"G*C^Z:**'KN PQ9YR=Y^\W][ZCI3&LA))N8DG.1CC'
MY5-12:3W$TFK/^NHP1$+]\[L_>P.GI0\0;I\O&.*?13Z6&M-B(VJX7&1L&!R
M>*5X-Z 9/RMN4YZ5)11Y M+6Z#53RY 5.!W7L:;<P>?"ZK\FX<8[5)2,,BA:
M/F0+31' _"WX Z5\,_&'B'6X%:?4O$<_FW,\OW@,DA![#/Z5U\7A:PAU>34%
MMHA?RIY;7&WYROI5XY<<TZA:*R%9"; 3[=, X&/I2@E2.> > 0#112LKW&-2
M/8S$$[F/7TH2(1@X[],\XIU%'*AW?ZB*@C'RC'OZ4QH-P')X_6I**;U=V**Y
M59"! ) ?08QZTTPJT83'RJ05_P!G';/6GT4;NX;)+L(RA\YYRY;\#VKAOC]^
MSYH'[1WA>UTCQ#'(]I9W:7D0C;!5U.1_*NZHI-)JS#OYE'1="AT&TA@@R(H$
M5$4\X"]*LM: D8.WG)P/O>U2T4Y>]>_7]!65K?+[AD<.S/)/7;_LY&.*<B[%
M/<D 9(]*6BC?48UEW$\X^@Q@^M B!Z\\8/O[TZBCI8+=1BPXB5<Y*=&[T\'#
M9XSW..M%%'6XK*U@HHHH& [_ $-<!XZ_Y+?X3_ZY/_)Z[\=_H:X#QU_R6_PG
M_P!<G_D] 'J]%%% !1110 4444 %%%% !7@?[:7_ ".7PN_[#I_]DKWRO!OV
MRL?\)K\+P3C_ (G;8^7/9* /8(/N1?0_UI:(H\1!07W[=W*CU^M.V?[_ /WP
M/\: &T4[9_O_ /? _P :-G^__P!\#_&@!M%.V?[_ /WP/\:-G^__ -\#_&@!
MM%.V?[__ 'P/\:-G^_\ ]\#_ !H ;13MG^__ -\#_&C9_O\ _? _QH ;13MG
M^_\ ]\#_ !HV?[__ 'P/\: &T4[9_O\ _? _QHV?[_\ WP/\: &T4[9_O_\
M? _QHV?[_P#WP/\ &@!M%.V?[_\ WP/\:-G^_P#]\#_&@!M%.V?[_P#WP/\
M&C9_O_\ ? _QH ;13MG^_P#]\#_&C9_O_P#? _QH ;13MG^__P!\#_&C9_O_
M /? _P : &T4[9_O_P#? _QHV?[_ /WP/\: &T4[9_O_ /? _P :-G^__P!\
M#_&@!M%.V?[_ /WP/\:-G^__ -\#_&@!M%.V?[__ 'P/\:-G^_\ ]\#_ !H
M;13MG^__ -\#_&C9_O\ _? _QH ;13MG^_\ ]\#_ !HV?[__ 'P/\: &T4[9
M_O\ _? _QHV?[_\ WP/\: &T4[9_O_\ ? _QHV?[_P#WP/\ &@!M%.V?[_\
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MM !11AO3]:,-Z?K0 448;T_6C#>GZT %%&&]/UHPWI^M !11AO3]:,-Z?K0
M448;T_6C#>GZT %%&&]/UHPWI^M !11AO3]:,-Z?K0 448;T_6C#>GZT %%&
M&]/UHPWI^M !11AO3]:,-Z?K0 #O]#7 >.O^2W^$_P#KD_\ )Z[\ YZ?K7 ^
M-LGXV^&PXVL$;;^34 >K44"B@ HHHH **** "BBB@ KRK]I_X$ZG\:H/#SZ3
MJ*Z9>:%>-=I*1G)(7C]*]5ILG- '@A^"7Q8=5W>.$)48!V'I_P!]4O\ PI3X
MK_\ 0[1_]\'_ .*KW?%&* /"/^%*?%?_ *':/_O@_P#Q5'_"E/BO_P!#M'_W
MP?\ XJO=\48H \(_X4I\5_\ H=H_^^#_ /%4?\*4^*__ $.T?_?!_P#BJ]WQ
M1B@#PC_A2GQ7_P"AVC_[X/\ \51_PI3XK_\ 0[1_]\'_ .*KW?%&* /"/^%*
M?%?_ *':/_O@_P#Q5'_"E/BO_P!#M'_WP?\ XJO=\48H \(_X4I\5_\ H=H_
M^^#_ /%4?\*4^*__ $.T?_?!_P#BJ]WQ1B@#PC_A2GQ7_P"AVC_[X/\ \51_
MPI3XK_\ 0[1_]\'_ .*KW?%&* /"/^%*?%?_ *':/_O@_P#Q5'_"E/BO_P!#
MM'_WP?\ XJO=\48H \(_X4I\5_\ H=H_^^#_ /%4?\*4^*__ $.T?_?!_P#B
MJ]WQ1B@#PC_A2GQ7_P"AVC_[X/\ \51_PI3XK_\ 0[1_]\'_ .*KW?%&* /"
M/^%*?%?_ *':/_O@_P#Q5'_"E/BO_P!#M'_WP?\ XJO=\48H \(_X4I\5_\
MH=H_^^#_ /%4?\*4^*__ $.T?_?!_P#BJ]WQ1B@#PC_A2GQ7_P"AVC_[X/\
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M /+/^%9^,_\ H/1?]\__ %Z/^%9^,_\ H/1?]\__ %Z]3Q1B@#RS_A6?C/\
MZ#T7_?/_ ->C_A6?C/\ Z#T7_?/_ ->O4\48H \L_P"%9^,_^@]%_P!\_P#U
MZ/\ A6?C/_H/1?\ ?/\ ]>O4\48H \L_X5GXS_Z#T7_?/_UZ/^%9^,_^@]%_
MWS_]>O4\48H \L_X5GXS_P"@]%_WS_\ 7H_X5GXS_P"@]%_WS_\ 7KU/%&*
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;SGOGWKTYQQ1(/EH <#FBD7[M+0 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6908079504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementaryIncomeStatementInformationTableTextBlock', window );">Schedule of Company's disaggregation of revenues</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes the Company&#x2019;s disaggregation of revenues:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Nine Months Ended September&nbsp;30,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">(U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Pfizer</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 4,701</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 4,649</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Brazil</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 7,385</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 2,573</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Total revenues from selling goods</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 12,086</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 7,222</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Revenues from license and R&amp;D services</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 24,848</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 16,665</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Company's contracts liability</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth data regarding the Company&#x2019;s contracts liability:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Nine Months Ended September&nbsp;30,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">(U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Contracts liability at the beginning of the period</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 42,895</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 25,015</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Additions during the period</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 22,151</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 34,929</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Revenue recognized during the period</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (24,848)</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (16,665)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Contracts liability at the end of the period</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 40,198</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 43,279</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueRemainingPerformanceObligationAmountTableTextBlock', window );">Schedule of Company's unsatisfied performance obligation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table represents the Company&#x2019;s unsatisfied performance obligation:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">(U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Unsatisfied performance obligation</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 50,584</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 76,969</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueRemainingPerformanceObligationAmountTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue remaining performance obligation amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueRemainingPerformanceObligationAmountTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryIncomeStatementInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental income statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryIncomeStatementInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6905392176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6759195504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 21,442<span></span>
</td>
<td class="nump">$ 37,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">8,716<span></span>
</td>
<td class="nump">4,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">2,756<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">7,525<span></span>
</td>
<td class="nump">8,569<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">40,439<span></span>
</td>
<td class="nump">52,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
<td class="nump">1,953<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="nump">5,573<span></span>
</td>
<td class="nump">6,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">OPERATING LEASE RIGHT OF USE ASSETS</a></td>
<td class="nump">5,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">53,729<span></span>
</td>
<td class="nump">61,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">7,755<span></span>
</td>
<td class="nump">5,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">12,730<span></span>
</td>
<td class="nump">10,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">11,612<span></span>
</td>
<td class="nump">9,868<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">33,319<span></span>
</td>
<td class="nump">25,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">50,163<span></span>
</td>
<td class="nump">47,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">28,586<span></span>
</td>
<td class="nump">33,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">2,606<span></span>
</td>
<td class="nump">2,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,532<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">5,372<span></span>
</td>
<td class="nump">5,292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">91,259<span></span>
</td>
<td class="nump">88,659<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">124,578<span></span>
</td>
<td class="nump">114,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
<td class="num">(70,849)<span></span>
</td>
<td class="num">(52,881)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
<td class="nump">$ 53,729<span></span>
</td>
<td class="nump">$ 61,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6746527744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">a.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>General</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Protalix BioTherapeutics,&nbsp;Inc. (collectively with its subsidiaries, the &#x201C;Company&#x201D;) and its wholly-owned subsidiaries, Protalix&nbsp;Ltd. and Protalix B.V. (the &#x201C;Subsidiaries&#x201D;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;"> protein expression system (&#x201C;ProCellEx&#x201D;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;"> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s product pipeline currently includes, among other candidates:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">pegunigalsidase alfa, or PRX&#8209;102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">alidornase alfa, or PRX&#8209;110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (3)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">OPRX&#8209;106, the Company&#x2019;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company, together with its commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201C;Chiesi&#x201D;), plans to file a biologics license application (&#x201C;BLA&#x201D;) for PRX-102 for the treatment of Fabry disease by April 2020 through the Accelerated Approval pathway of the U.S. Food and Drug Administration (&#x201C;FDA&#x201D;). This decision is the result of a series of meetings and correspondence between the Company and Chiesi, on the one hand, and the FDA, on the other hand. The Company and Chiesi have initiated preparations for the BLA submission based on clinical data generated in the one-year completed phase I/II clinical trials of PRX-102 and from the ongoing phase III BRIDGE clinical trial, as well as safety data from all on-going studies. The BLA will also include extensive data from the Company&#x2019;s completed nonclinical program, as well as information regarding production of PRX-102. </font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On October&nbsp;19, 2017, Protalix&nbsp;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201C;Chiesi Ex-US Agreement&#x201D;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&nbsp;23, 2018, Protalix&nbsp;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201C;Chiesi US Agreement&#x201D;) with respect to the commercialization of pegunigalsidase alfa in the United States.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively,&nbsp;the &#x201C;Chiesi Agreements&#x201D;), Chiesi made an upfront payment to Protalix&nbsp;Ltd. of $25.0&nbsp;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&nbsp;Ltd. is entitled to additional payments of up to $25.0&nbsp;million in pegunigalsidase alfa development costs, capped at $10.0&nbsp;million per&nbsp;year, and to receive additional payments of up to $320.0&nbsp;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&nbsp;Ltd. is entitled to payments of up to a maximum of $20.0&nbsp;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&nbsp;million per&nbsp;year, and to receive an additional up to a maximum of $760.0&nbsp;million, in the aggregate, in regulatory and commercial milestone payments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under the terms of both of the Chiesi Agreements, Protalix&nbsp;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. ("Pfizer") in accordance with the exclusive license and supply agreement entered into&nbsp;between Protalix&nbsp;Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October&nbsp;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201C;Brazil Agreement&#x201D;) with Funda&#xE7;&#xE3;o Oswaldo Cruz (&#x201C;Fiocruz&#x201D;), an arm of the Brazilian Ministry of Health (the &#x201C;Brazilian MoH&#x201D;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Going Concern</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;">Since the Company is engaged in research and development activities, it has not derived significant income from its activities and has incurred accumulated losses in the amount of $341.0 million through September 30, 2019 and cash outflows from operating activities. As of September 30, 2019, the Company has outstanding $57.9 million aggregate principal amount of its 7.50% convertible promissory notes due 2021 (the &#x201C;2021 Notes&#x201D;) which are secured with a perfected lien on all of the Company&#x2019;s assets. Under the terms of the indenture governing the 2021 Notes, the Company is required to maintain a minimum cash balance of at least $7.5 million. As of September 30, 2019, the Company had cash and cash equivalents of $21.4 million. Based on its current cash resources and commitments, the Company may not be able to meet its current planned development activities and the corresponding level of expenditures for the next 12 months from the date of approval of the financial statements as of September 30, 2019 absent a refinancing or restructuring. These factors raise substantial doubt as to the Company&#x2019;s ability to continue as a going concern.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;">The Company&#x2019;s management is in the process of evaluating refinancing and restructuring alternatives, including a restructuring of its outstanding convertible notes, and related transactions.&nbsp;&nbsp;However, there is no certainty about the Company&#x2019;s ability to obtain such funding.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;">The financial information has been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business.&nbsp;&nbsp;If the Company does not complete a refinancing or restructuring, it will need to curtail or cease operations.&nbsp;&nbsp;These financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">b.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Basis of presentation</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201C;GAAP&#x201D;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full&nbsp;year.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2018, filed by the Company with the U.S Securities and Exchange Commission (the &#x201C;Commission&#x201D;). The comparative balance sheet at December 31, 2018 has been derived from the audited financial statements at that date.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">c.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Net loss per share</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Basic and diluted loss per share (&#x201C;LPS&#x201D;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s common stock, par value $0.001 per share (the &#x201C;Common Stock&#x201D;), outstanding for each period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The calculation of diluted LPS does not include 73,310,911 and 78,269,464 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes for the nine&nbsp;months ended September 30, 2018 and 2019, respectively, and 73,280,977 and 78,547,287 shares of Common Stock for the three months ended September 30, 2018 and 2019, respectively, because the effect would be anti-dilutive.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock', window );">Recently adopted standards</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">d.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Recently adopted standards</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February&nbsp;2016, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued ASU No.&nbsp;2016&#8209;02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). The new standard requires a lessee to record assets and liabilities on its balance sheet for all leases with terms longer than 12&nbsp;months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the lessee&#x2019;s income statement. The Company adopted this standard as of January&nbsp;1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company elected the package of practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12&nbsp;months or less off of its balance sheet. The Company recognized those lease payments in its statements of operations on a straight-line basis over the lease period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of the adoption date, the Company recognized an operating lease asset and liability of $5.9&nbsp;million and $5.7 million, respectively, as of January&nbsp;1, 2019 on its balance sheet.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Newly issued accounting pronouncements</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Newly issued accounting pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In June&nbsp;2018, the FASB issued ASU 2018&#8209;07, &#x201C;Compensation&nbsp;&#x2013; Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting&#x201D; that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in ASU 2018&#8209;07. The guidance is effective for fiscal&nbsp;years beginning after December&nbsp;15, 2018, including interim reporting periods within that fiscal&nbsp;year. Early adoption is permitted, but no earlier than an entity&#x2019;s adoption date of Topic 606. The Company does not expect the adoption of ASU 2018&#8209;07 to have a material impact on its financial statements.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to recently adopted standards that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RecentlyAdoptedStandardsPolicyTextBlockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6633044272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">NOTE&nbsp;4&nbsp;&#x2013; OPERATING LEASES</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company is a party to a number of lease agreements for its facilities, the latest of which has been extended until the end of 2021. The Company has the option to extend certain of such agreements on two additional occasions for additional five-year periods each for a total of 10 additional&nbsp;years. During the extended lease period, the aggregate&nbsp;monthly rental payments will increase by 7.5%&nbsp;- 10% for each option. The Company expects to exercise these options in future periods. As of September 30, 2019, the Company provided bank guarantees of approximately $437,000 in the aggregate, to secure the fulfillment of its obligations under the lease agreements. As of December&nbsp;31, 2018, the future minimum lease payments required under the operating leases for such premises are approximately $758,000, &nbsp;$758,000 and $621,000, for fiscal&nbsp;years 2019 through 2021, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company entered into several three-year leases for vehicles which are regularly amended as new vehicles are leased. As of December&nbsp;31, 2018, the future minimum lease payments for the&nbsp;years ending December&nbsp;31, 2019, 2020 and 2021 are approximately $474,000, &nbsp;$333,000 and $82,000, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth data regarding the Company&#x2019;s operating leases for the nine and three&nbsp;months ended September 30, 2019:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Nine Months Ended </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Three Months Ended </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:28.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Operating lease costs</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 907</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 314</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 999</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 337</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Right of use assets obtained in exchange for new operating lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 282</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 55</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth data regarding the Company&#x2019;s operating leases as of September 30, 2019:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Weighted average remaining lease term (in years)</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.6
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Weighted average discount rate</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 12.55</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth a maturity analysis of the Company&#x2019;s operating lease liabilities as of September 30, 2019:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2019 (excluding the nine months ended September&nbsp;30,&nbsp;2019)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 300</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1,128</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2021</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 949</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2022</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 826</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2023</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 803</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">After 2023</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 6,656</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Total undiscounted cash flows</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 10,662</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Less: imputed interest</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 4,908</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Present value of&nbsp;&nbsp;operating lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 5,754</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6903827408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - Chiesi [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 18, 2019</div></th>
<th class="th"><div>Oct. 16, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromReimbursementOfExpenses', window );">Total proceeds from reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Alfataliglicerase to Fiocruz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromSaleOfProducts', window );">Total proceeds from sales</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from sale of products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=plx_AlfataligliceraseToFiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=plx_AlfataligliceraseToFiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6746787328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Lessee, Operating Lease, Liability, Payments, Due Year Two</a></td>
<td class="nump">$ 1,128,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Lessee, Operating Lease, Liability, Payments, Due Year Three</a></td>
<td class="nump">$ 949,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments', window );">Percentage of Change in Operating Lease Monthly Rental Payments</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments', window );">Percentage of Change in Operating Lease Monthly Rental Payments</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember', window );">Vehicle Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating Leases, Future Minimum Payments Due, Next Twelve Months</a></td>
<td class="nump">$ 474,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Lessee, Operating Lease, Liability, Payments, Due Year Two</a></td>
<td class="nump">333,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Lessee, Operating Lease, Liability, Payments, Due Year Three</a></td>
<td class="nump">82,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating Leases, Future Minimum Payments Due, Next Twelve Months</a></td>
<td class="nump">758,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Lessee, Operating Lease, Liability, Payments, Due Year Two</a></td>
<td class="nump">758,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Lessee, Operating Lease, Liability, Payments, Due Year Three</a></td>
<td class="nump">621,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="nump">$ 437,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DisclosureOfLeasesOperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Leases Operating</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DisclosureOfLeasesOperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Change in Operating Lease Monthly Rental Payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesAxis=plx_VehicleLeaseAndMaintenanceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6905365872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details) - 2021 Notes [Member] - Fair Value, Inputs, Level 3 [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (USD)</a></td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsTerm', window );">Expected term</a></td>
<td class="text">2 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsRiskFreeInterestRates', window );">Risk free rate</a></td>
<td class="nump">1.62%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsExpectedVolatilityRates', window );">Volatility</a></td>
<td class="nump">74.99%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_FairValueAssumptionsExpectedDividendRates', window );">Yield</a></td>
<td class="nump">10.53%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsExpectedDividendRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsExpectedDividendRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsExpectedVolatilityRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsExpectedVolatilityRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsRiskFreeInterestRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsRiskFreeInterestRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_FairValueAssumptionsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_FairValueAssumptionsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>24
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M!84<" !#JW)J1Y#E:",+&<BD XZZ@J(..,8 D:VI7!6;>C+J@+-.4]8!QQB
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M-L5C"YS83A!]8488![/D&'*#XA!MC!,1QT0^CD;#:#2/)G1,:!Y-@$T$T$3
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M>S\6%&IEIG=Z+MSI=X7BO;_8>/RZ%!]02P,$%     @ >C=G3P>ADRM*!
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M7C;UOT'T$*3L;L((=>&#+8:"QL?CFW"VTYA-AL=^_D%L^<;E3U!+ P04
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MH/;A^ [/=AJSR?"F3S^(S=^X^ E02P,$%     @ >S=G3YCEK$6S 0  T@,
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MG\TT9I/A=)]^$)F_<?D;4$L#!!0    ( 'LW9T^!)>?([ $  &8%   9
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MN,>S'<=L-+SIIA_$YF^<OP-02P,$%     @ >S=G3WZ,*J7# 0  -P0  !D
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M)\5H*?XSW(!;N,O$:E22:_]%U:B-% N+3470UWEEO5^G^20]+&'A@&0)2-:
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MCN2!I]6XI8E"?*T&^7HQ4<(/F(;Z9J)<SCU"MP$^2P$R2SHS#(,'"?$@(>)
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M;]NRH-!(/4W5G-LOW"XD&^?'"RTO:/$/4$L#!!0    ( 'LW9T]P0 KQWP$
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M    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;'54VXZ;,!#]%<0'Q,20L(T
M:;-5U4JM%&W5]MF!X:+UA=HF;/^^MB$L9=T7;(_/G'/&V).-0KZH%D 'KXQR
ME8>MUOT)(56VP(C:B1ZXV:F%9$2;I6R0ZB60RB4QBG 4'1$C'0^+S,4NLLC$
MH&G'X2(#-3!&Y)\S4#'FX3Z\!YZ[IM4V@(JL)PU\!_VCOTBS0@M+U3'@JA,\
MD%#GX>/^=$XMW@%^=C"JU3RPE5R%>+&++U4>1M804"BU92!FN,$34&J)C(W?
M,V>X2-K$]?S._LG5;FJY$@5/@O[J*MWFX4,85%"3@>IG,7Z&N9Y#&,S%?X4;
M4 .W3HQ&*:ARWZ <E!9L9C%6&'F=QHZ[<9SY[VG^!#PGX"4!)ZZ62<@Y_T@T
M*3(IQD!.9]\3^XOW)VS.IK1!=Q1NSYA7)GHK<+S/T,T2S9CSA,$KS!L"&?9%
M OLDSOA=.HZQGR#V>HP=0?(/0;SQ.&%2A^$.$^WP?VPF7I7$HY)L5'R8@U_D
MX!4Y> B.&Q$?)O6+'+TB1P_!PT;$A_G@%TF](NE[@B3:B/@PVW^"5C>5@6S<
M&U5!*0;N^L,JNK2!1^QN^AM\ZB'?B&PZKH*KT.:]N%M="Z'!6(EVYE1;T[:6
M!85:VVEJYG)ZO--"BW[N2VAICL5?4$L#!!0    ( 'LW9T^1!ST%H $  ( #
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;&U3VX[;(!#]%<0'! =G
MFVYD6VJVJEJIE:*MNGTF]CA&R\4%$F__O@-VK&SJ%Y@9SIPS,T Q6/?J.X!
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MX"Q4-Y%]-M;)<2!H/ST!:'Z'\K]02P,$%     @ >S=G3SGK.X\R @  " <
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MRL>"8M\;J__.;[PV<IN)81Q%K=S3.UZ5%LWH8E)IV/O05JUK^]'_'@8'!&-
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MYPFX&DN\PI?&"SOVUC=(50ST"-_!_ACVVE5D5FF9 &F8DDA#5^+'U:[./#X
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M4NIM*+C)9BWJ4-#4^@@D6,-/K)[Z&TU!ODL0K\#B+3V?Z$=8ED@)R ;ZM'U
M$^!8,PN!(,0?G$:9H.=BV5_TKI93W&P9=M)\0866R0",)#M+:DAKVIVSMRFI
M/: Q\Y(7G,VE#,/!9YA$Y^SXK1X"W218<32Y(GU)(800!VJ:IHN>8TO<QV(&
M'G#3_IP +0O,],%_2N<Y\%=/#1U$F,TBS'V@'.U7./?0_TH^252LJ#@YVHV\
M);_E]H%J#]2]2[S? T8PX&'F&6MS@T9#](%EP&:TVJ",<3WX<#8$.4EC/=6
MV4."#4S%GT',DX"MXZ$)NC-0_^3B8JOW7N[CA\#+(:, @4Y&4YU*";9R!?Q[
M@DE@7YX1:D/UI8<HP E2M "RQ9, 64X33X:6^>>.*?"UPDY/1#G%<FR\9KF/
M"AA"5.0^.09/L*CXQ33ST%50T_+#("*QLZ4+!L"U*7W%R @A0G+Q EX>.NZJ
M7TET;"$T@D?L0)&WQ-+#Q4]SPBX2'$U^#MB U0ZAW"CH8T1"KT2* A' ?'W:
M"FFK44>[YLPJ6,D0T;1B1';8D/G@:@,!S.^"A6\:!YW#QDHN\BA8@'L#3Y6
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M%DV[YZOXZZ?X&58T(>E!7Q#UHS9FF- RA9&W<<G&+#%=!5>!N%,LKXW<FMB
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M$K-!\=^7JX#3 4RI!KE=IL-Q(395/UAG_.J^2+5WBH:OTS3[\?\#4$L#!!0
M   ( 'LW9T\=R(,%1 (  -H*   -    >&PO<W1Y;&5S+GAM;-56;6O;,!#^
M*T(9HX51VVF3LM4V;(7"8"N%YL.^%<4^VP*]>+*<.?WUDRR_)![KUJP;RY?H
M[CG=<X]>G%-8Z2V#^P) HX8S446XT+I\YWE54@ GU9DL09A()A4GVK@J]ZI2
M 4DKF\29-_?]I<<)%3@.1<UON*Y0(FNA(WPQ0,CE7\L4(OQP\OIK+?75*^3&
MV9O9S'\XO9KB)VW@%"/'\3&-<+"\P-[ODY[Y/^<UL0GUXIG43W)/R9?/(W^"
M>D)\:8F];N?C,)-B/(!S[ !3F7! &\(B?$T872MJLS+"*=LZ>&Z!1#*ID#8G
M;Y0%%JD>73APGKT4'0^G0JJVMJO@?M?=]$F@]ZQ RM@@<(X=$(<ET1J4N#%.
M.[D%?PBASEYM2Z,P5V0;S!=X3&@'4V0M50IJ*!/@'HI#!IF5HVA>V%'+TK-!
MK24W1DI)+@5I-?09G6%H$V#LWGXQ7[(][B9#;HX]$A\CJZ(WS:H[<SPUOY6\
MR^:X=VG]@WA123=2?ZC-<D3KVZL#=PHRVK1^DPT"##LI2[9]SV@N.+C%_+)@
M<&#!."1]'51(11\-G[TJB0% 8;0!I6FRBWQ3I%Q!H_OKU&2':IX?H>:7WN<<
M!"C"=D6;N_\_[_(_5GQ^^>>2VW^5J> 7U&C[WQ&(7!R#R.4QB/S;=]+KVLY.
M;]OK; .*UC5EFHI.;D'3%)P>^[2(\*U]T["]_C(V.$.OR=H\-/?X36X*&:F9
MOK-+;(,1'NU/5GBP'&:M!HH(C_9G2&G-W[8%Q]=L_!U02P,$%     @ >S=G
M3S'+6P=5 P  UQ4   \   !X;"]W;W)K8F]O:RYX;6S%F%MOFS 4@/^*Q=,F
M+4L@26]J*E%".[04LD"RQ\D!I[$*=F0[[=9?/T.6UJSIT5Z\/($OF(\#/I_-
MY1,7#TO.']#/JF1RY*R5VEQTNS)?DPK+SWQ#F&Y9<5%AI8OBOBLW@N!"K@E1
M5=GU>KV3;H4I<ZXN]V--1=<L<$5R13G3E77%@I(G^=I>%Q'6'1Y)AI<CI^<@
MO%7\AI:*B#%6Y%;P[8:R^Y'C.FA%A51I?>^F9T49K>@S*9J27/.G+US09\X4
M+M-<\+)LKJH;FHOT'>1+S8((1?-61X67,ZQ91\Y)3P_X2"5=TI*J7R.G.2^)
MHY^B:SQ&$X?]<1?$"_$O8>2K%<W)F.?;BC"UBZ,@97UW)M=T(QW$<$5&SKX+
MPJQ (5.:!D5L-Y3N6S^+OG54[)Y+Z8B]PB)Q076#B JW!K<'&23Q.(S3<(ST
M69I,HK&?Z<*U/_'C($0&I = >D>!3#-]N MC [(/0/:/"/G#,R ' .3@F)!]
M W((0 Z/"3DP($\ R)-C0@X-R%, \M0N9!K=QM%-%/AQAOP@2.9Q%L6W:*IQ
M@RA,#<@S /+,+F04+\(X2V9MH', Z-PNT(T?S=#"G\Q#=!?ZZ7Q6)YG,S-<]
M*&'W[-(ETW#F-Z]QHN%:,7-!D5@VR2S4KW'>YH&<X5J61IHEP5>4S?PX]8,L
MTI/4)(-$X5HV13J_3L-O<_U-H3IF60L,DH-KV0Y@NF@IS(7TX%KV@Y$PT >]
M,BR)_&BR059P+6OA<.XXB EYP;4LAK^3R$% R FN92GLL\E!,,@-KF4YP'/$
M7$%YD"4\RY9HS9$Q49B6K1AZD"H\RZHPX3K(+PI:=\'EG^V1B0GN.BP;Y)VY
MW$'9FJ"2FIB03CS+.GD7<Q=8$Q.2BV=9+F]23@=-");D$PJX5*V=)B07S[)<
M#F)*231GLB'"Q(0\XUGVS %,<QZ9F)!G/,N>>4GC'936#'5WB?@*Z4$%5B8F
M9!OO?]FFHS]&I@3.%?I.U1H%6ZEX*R%![O$LN\? G#.IV^6*D@)-B6B&,_^#
M0.[I6W;/VY7W007U(07U+2OHS1K\,"*DGWZCG^[^1V)!5I21(M;#2UV?XS*?
M"E0?=ENAP;!>MZRV91GHNH1-.&Y^_=5C[/^I7OT&4$L#!!0    ( 'LW9T\/
M[$Q+> $  $44   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V,UN
M@D 4AN%;,5R PSGC;Z.NW+AM>P,3'('(7V:FJ=Y]*9MBHG.Z,)\;"(&<\R[(
M$\+FW58FE&WCB[+SDTM=-7Z;%"%T;TKYK+"U\=.VLTU_Y]2ZVH3^TN6J,]G9
MY%9QFBZ4&\](=IOQS,GAN$W<X4C)Y-.XW(9MHBZ5^F[=V1?6!J^&$TW[!?TC
MU\[^9WU[.I69W;?95VV;<*?B;T&B[@=Q/(CA03H>I.%!LWC0#!XTCP?-X4&+
M>- "'K2,!RWA0:MXT H>M(X'K>%!E HRIO@D"6N\UB1P37BO20";\&*30#;A
MS28!;<*K30+;A'>;!+@)+S<)=!/>;A+P)KS>+.C->+U9T)M?\*TM?6SC]69!
M;\;KS8+>C->;!;T9KS<+>C->;Q;T9KS>+.C->+U9T)OQ>FM!;XW76PMZ:[S>
M6M!;O^!?R4AO7QAGCQ_!E4WNGUUR,_QAS0AN'ZZ5?7[&,/7A_I'2H=]BU7!\
M^ILR3/V-4#=_#7<_4$L#!!0    ( 'LW9T_H]2X:D $  .84   3    6T-O
M;G1E;G1?5'EP97-=+GAM;,V8WV["(!2'7\7T=K$(W=R?J#?;;C>3[058>VJ)
M+1! IV\_6G7)EBYQ49/?32D<..>#DN^BD_>M)3_8-+7VTZ0*P3XPYO.*&NE3
M8TG'2&E<(T/LN@6S,E_*!3$Q&HU9;G0@'8:AS9',)D]4RE4=!H^[\3;U-)'6
MUBJ701G-UKKXE72X3Y@ZJKLYOE+67\4)R>!Y$[/X.#9-8M0G[(@*OQ>V_;CN
M=4W.J8+^A6;*4N54F'S5Q"6IMXYDX2NBT-2IKZ2CXBTXI1=[WKETX44V,3';
MU.S'A/1R'&%;4S] %SEGY1"O!?65Z@*[)S^IX.$VY,;1T+H8=4'U;"\BS6/4
MLW;B.;=([=4IJ#BJ>$Q]N0_[:=RR>^\[\.^@9UUSVJF?CT. <&0@'-<@'#<@
M'&,0CEL0CCL0CGL0#CY" 4$Q*D=1*D=Q*D>1*D>Q*D?1*D?Q*D<1*T<QJT Q
MJT QJT QJT QJT QJT QJT QJT QJT QJT Q:X9BU@S%K-D%S=JU:2.5_HOD
MPYCEH3[K?F_.O@!02P$"% ,4    " !Z-V=/'R// \     3 @  "P
M        @ $     7W)E;',O+G)E;'-02P$"% ,4    " !Z-V=/)^B'#H(
M  "Q    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( 'HW9T^F(Z#Y\    "L"   1              "  9D!  !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( 'HW9T^97)PC$ 8  )PG   3
M          "  ;@"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M>C=G3]:6&M&4 @  #0H  !@              ( !^0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( 'HW9T_(*__VR ,  % 1   8
M          "  <,+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " !Z-V=/^01B*98#  !&#P  &               @ '!#P  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ >C=G3[>LU1YB @  YP<
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M965T."YX;6Q02P$"% ,4    " ![-V=/#'%>&;(!  #2 P  &
M    @ &N(P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M>S=G3S$,2DNT 0  T@,  !D              ( !EB4  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " ![-V=/S!/WB[0!  #2 P  &0
M            @ &!)P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( 'LW9T_G>IA#M $  ,X#   9              "  6PI  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ >S=G3]T^ L2S 0
MT@,  !D              ( !5RL  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " ![-V=/F.6L1;,!  #2 P  &0              @ %!
M+0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( 'LW9T^!
M)>?([ $  &8%   9              "  2LO  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ >S=G3Y2A_B>W 0  T@,  !D
M     ( !3C$  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'LW9T_QCAR(] $  $T%   9              "
M >D]  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ >S=G
M3W! "O'? 0  = 0  !D              ( !%$   'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " ![-V=/-TZ&A>@!   H!0  &0
M        @ $J0@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( 'LW9T^1!ST%H $  ( #   9              "  4E$  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ >S=G3PI+)K<I @  DP8
M !D              ( !($8  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " ![-V=/.>L[CS("   (!P  &0              @ & 2
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( 'LW9T^P$D,+
MEP(   P*   9              "  >E*  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ >S=G3YMM^V2  @  1@@  !D
M ( !MTT  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " ![
M-V=/+DF/,2X"   .!@  &0              @ %N4   >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( 'LW9T\OQWB"LP$  -,#   9
M          "  =-2  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#
M%     @ >S=G3Q^PJ=!5 @  ^0<  !D              ( !O50  'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " ![-V=/FLIP0,T!  "6
M!   &0              @ %)5P  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;%!+ 0(4 Q0    ( 'LW9T_[!.7:<"D   3&   4              "  4U9
M  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( 'LW9T\=R(,%1 (
M -H*   -              "  >^"  !X;"]S='EL97,N>&UL4$L! A0#%
M  @ >S=G3S'+6P=5 P  UQ4   \              ( !7H4  'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( 'LW9T\/[$Q+> $  $44   :
M  "  >"(  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M 'LW9T_H]2X:D $  .84   3              "  9"*  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     I "D $0L  %&,      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6748522864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING LEASES - Lessee, Operating Lease, Liability, Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2019 (excluding the six months ended September 30, 2019)</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">1,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2023</a></td>
<td class="nump">6,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted cash flows</a></td>
<td class="nump">10,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">4,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 5,754<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6749720784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6631506016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">NOTE 7 &#x2013; SUBSEQUENT EVENTS</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On October 16, 2019, the Company received total proceeds of approximately $2.6 million from expense reimbursements in relation to its collaboration with Chiesi and on October 18, 2019, the Company received total proceeds of approximately $3.2 million from sales of alfataliglicerase to Fiocruz.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In accordance with ASC 855 &#x201C;Subsequent Events&#x201D; the Company evaluated subsequent events through the date the condensed consolidated financial statements were issued. The Company concluded that no other subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6749605328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">NOTE&nbsp;3&nbsp;&#x2013; FAIR VALUE MEASUREMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value. The fair value of the convertible notes derivative is based on Level 3 measurement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 35.45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The fair value of the $57.9&nbsp;million aggregate principal amount of the Company&#x2019;s outstanding 2021 Notes as of September 30, 2019 is approximately $57.7&nbsp;million based on a Level 3 measurement.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company prepared a valuation of the fair value of the Company&#x2019;s outstanding 2021 Notes&nbsp;(a Level 3 valuation) as of September 30, 2019. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2021&nbsp;Notes</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Stock price (USD)</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 0.21</font></p>
				</td>
				<td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Expected term</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 2.13</font></p>
				</td>
				<td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Risk free rate</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1.62</font></p>
				</td>
				<td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Volatility</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 74.99</font></p>
				</td>
				<td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Yield</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 10.53</font></p>
				</td>
				<td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6746541552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of operating leases</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth data regarding the Company&#x2019;s operating leases for the nine and three&nbsp;months ended September 30, 2019:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Nine Months Ended </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Three Months Ended </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:28.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Operating lease costs</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 907</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 314</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 999</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 337</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Right of use assets obtained in exchange for new operating lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 282</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 55</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth data regarding the Company&#x2019;s operating leases as of September 30, 2019:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Weighted average remaining lease term (in years)</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.6
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Weighted average discount rate</font></p>
				</td>
				<td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 12.55</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity analysis of operating leases</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth a maturity analysis of the Company&#x2019;s operating lease liabilities as of September 30, 2019:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2019 (excluding the nine months ended September&nbsp;30,&nbsp;2019)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 300</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2020</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1,128</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2021</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 949</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2022</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 826</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2023</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 803</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">After 2023</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 6,656</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Total undiscounted cash flows</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 10,662</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Less: imputed interest</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 4,908</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:80.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Present value of&nbsp;&nbsp;operating lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 5,754</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6746642688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,567)<span></span>
</td>
<td class="num">$ (21,023)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">599<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses (income), net (mainly exchange differences)</a></td>
<td class="nump">371<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">51<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Net loss in connection with conversions of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">2,197<span></span>
</td>
<td class="nump">1,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes', window );">Issuance of shares for interest payment in connection with conversions of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contracts liability (including non-current portion)</a></td>
<td class="num">(2,697)<span></span>
</td>
<td class="nump">18,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable and other assets</a></td>
<td class="num">(4,767)<span></span>
</td>
<td class="num">(3,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in right of use assets</a></td>
<td class="num">(92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="nump">1,044<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="nump">4,905<span></span>
</td>
<td class="num">(1,805)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Increase in other long term liabilities</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,671)<span></span>
</td>
<td class="num">(3,738)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(599)<span></span>
</td>
<td class="num">(498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Increase in restricted deposit</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(59)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(912)<span></span>
</td>
<td class="num">(675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Net payment for convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,752)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">217<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(16,366)<span></span>
</td>
<td class="num">(9,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">37,808<span></span>
</td>
<td class="nump">51,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">21,442<span></span>
</td>
<td class="nump">41,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible notes conversions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 2,172<span></span>
</td>
<td class="nump">$ 2,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for interest payment regarding conversion of convertible notes,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfSharesForInterestPaymentRegardingConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6760608960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="num">$ (3,205)<span></span>
</td>
<td class="num">$ (1,917)<span></span>
</td>
<td class="num">$ (7,945)<span></span>
</td>
<td class="num">$ (7,024)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES (1)</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(10,071)<span></span>
</td>
<td class="num">(35,021)<span></span>
</td>
<td class="num">(23,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)</a></td>
<td class="num">(2,587)<span></span>
</td>
<td class="num">(4,088)<span></span>
</td>
<td class="num">(6,885)<span></span>
</td>
<td class="num">(8,744)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(1,544)<span></span>
</td>
<td class="num">(3,741)<span></span>
</td>
<td class="num">(12,917)<span></span>
</td>
<td class="num">(15,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="num">(2,050)<span></span>
</td>
<td class="num">(1,811)<span></span>
</td>
<td class="num">(5,877)<span></span>
</td>
<td class="num">(5,824)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES, NET</a></td>
<td class="num">(2,016)<span></span>
</td>
<td class="num">(1,581)<span></span>
</td>
<td class="num">(5,650)<span></span>
</td>
<td class="num">(5,387)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
<td class="num">$ (3,560)<span></span>
</td>
<td class="num">$ (5,322)<span></span>
</td>
<td class="num">$ (18,567)<span></span>
</td>
<td class="num">$ (21,023)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE-BASIC AND DILUTED</a></td>
<td class="nump">148,382,299<span></span>
</td>
<td class="nump">148,187,513<span></span>
</td>
<td class="nump">148,382,299<span></span>
</td>
<td class="nump">146,752,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
<td class="nump">$ 5,126<span></span>
</td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">$ 12,086<span></span>
</td>
<td class="nump">$ 7,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
<td class="nump">$ 9,122<span></span>
</td>
<td class="nump">$ 11,672<span></span>
</td>
<td class="nump">$ 24,848<span></span>
</td>
<td class="nump">$ 16,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6751795728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Statements of operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=plx_PfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,701<span></span>
</td>
<td class="nump">$ 4,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BR', window );">Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,385<span></span>
</td>
<td class="nump">2,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 5,126<span></span>
</td>
<td class="nump">$ 663<span></span>
</td>
<td class="nump">12,086<span></span>
</td>
<td class="nump">7,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 9,122<span></span>
</td>
<td class="nump">$ 11,672<span></span>
</td>
<td class="nump">$ 24,848<span></span>
</td>
<td class="nump">$ 16,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6746681392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - Additional Information (Details) - Fair Value, Inputs, Level 3 [Member] - Seven Point Five Percentage Convertible Notes [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="nump">$ 57.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">$ 57.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6761820208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 23, 2018</div></th>
<th class="th"><div>Oct. 19, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,547,287<span></span>
</td>
<td class="nump">73,280,977<span></span>
</td>
<td class="nump">78,269,464<span></span>
</td>
<td class="nump">73,310,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 341,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 341,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,442<span></span>
</td>
<td class="nump">$ 41,868<span></span>
</td>
<td class="nump">$ 21,442<span></span>
</td>
<td class="nump">$ 41,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,808<span></span>
</td>
<td class="nump">$ 51,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientsPackage', window );">Lease, Practical Expedients, Package [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaintainOfMinimumCashBalance', window );">Maintain of Minimum Cash Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable', window );">Upfront Nonrefundable Non-Creditable Payment Receivable</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable', window );">Upfront Nonrefundable Non-Creditable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaintainOfMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance required to be maintained under long term debt agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaintainOfMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNonCreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientsPackage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=119364159&amp;loc=SL77916155-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=119364159&amp;loc=SL77916155-209984<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientsPackage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6759277568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) - Employee Stock Option [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value | $</a></td>
<td class="nump">$ 97,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">66.48%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">1.695%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">Chief Financial Officer [Member] | 2006 Employee Stock Incentive Plan Member</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6637612832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">NOTE&nbsp;2&nbsp;- INVENTORIES</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> a.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Inventories at September 30, 2019 and December&nbsp;31, 2018 consisted of the following:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Raw materials</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,691</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,792</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Work in progress</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 233</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Finished goods</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,601</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 4,777</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Total inventory</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 7,525</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 8,569</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> b.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">During the&nbsp;year ended December&nbsp;31, 2018 and the nine&nbsp;months ended September 30, 2019, the Company recorded approximately $1.1 million and $29,000, respectively, for write-down of inventory under cost of goods sold.</font></p></td></tr></table></div><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6638354704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> a.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Inventories at September 30, 2019 and December&nbsp;31, 2018 consisted of the following:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">(</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Raw materials</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,691</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,792</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Work in progress</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 233</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Finished goods</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 3,601</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 4,777</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Total inventory</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 7,525</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 8,569</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6749601376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">NOTE&nbsp;5&nbsp;&#x2013; REVENUES</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes the Company&#x2019;s disaggregation of revenues:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Nine Months Ended September&nbsp;30,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">(U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Pfizer</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 4,701</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 4,649</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Brazil</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 7,385</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 2,573</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Total revenues from selling goods</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 12,086</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 7,222</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Revenues from license and R&amp;D services</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 24,848</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 16,665</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth data regarding the Company&#x2019;s contracts liability:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:31.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Nine Months Ended September&nbsp;30,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">(U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Contracts liability at the beginning of the period</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 42,895</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 25,015</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Additions during the period</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 22,151</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 34,929</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Revenue recognized during the period</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (24,848)</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (16,665)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Contracts liability at the end of the period</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 40,198</font></p>
				</td>
				<td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 43,279</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table represents the Company&#x2019;s unsatisfied performance obligation:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:26.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;font-size:8pt;">(U.S. dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Unsatisfied performance obligation</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 50,584</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 76,969</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6759921072">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2019</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (67,485)<span></span>
</td>
<td class="num">$ (42,742)<span></span>
</td>
<td class="num">$ (52,881)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (29,457)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">196<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,291<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange', window );">Convertible notes exchange</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,560)<span></span>
</td>
<td class="num">(5,322)<span></span>
</td>
<td class="num">(18,567)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(21,023)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(70,849)<span></span>
</td>
<td class="num">(47,943)<span></span>
</td>
<td class="num">(70,849)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(47,943)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 144<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">148,382,299<span></span>
</td>
<td class="nump">148,183,591<span></span>
</td>
<td class="nump">148,382,299<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">143,728,797<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock award (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29,898<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible notes conversions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,928,907<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange', window );">Convertible notes exchange</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange', window );">Convertible notes exchange (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,613,636<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 148<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">148,382,299<span></span>
</td>
<td class="nump">148,301,238<span></span>
</td>
<td class="nump">148,382,299<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">148,301,238<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 269,927<span></span>
</td>
<td class="nump">$ 268,907<span></span>
</td>
<td class="nump">$ 269,524<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 266,495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">196<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,289<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange', window );">Convertible notes exchange</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,148<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">270,123<span></span>
</td>
<td class="nump">269,028<span></span>
</td>
<td class="nump">270,123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">269,028<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(337,560)<span></span>
</td>
<td class="num">(311,797)<span></span>
</td>
<td class="num">(322,553)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(296,096)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,560)<span></span>
</td>
<td class="num">(5,322)<span></span>
</td>
<td class="num">(18,567)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(21,023)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (341,120)<span></span>
</td>
<td class="num">$ (317,119)<span></span>
</td>
<td class="num">$ (341,120)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (317,119)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common Stock, $0.001 par value; Authorized&#160;- as of September 30, 2019 and 2018&#160;- 350,000,000 and 250,000,000, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents an amount less than $1.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The numbers of shares issued in exchange for outstanding notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesConvertibleNoteExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueConvertibleNoteExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of outstanding notes exchanged with the company for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueConvertibleNoteExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6751706800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Nov. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,382,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>82</ContextCount>
  <ElementCount>244</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>27</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeases</Role>
      <ShortName>OPERATING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30403 - Disclosure - OPERATING LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesTables</Role>
      <ShortName>OPERATING LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeases</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30503 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40202 - Disclosure - INVENTORIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails</Role>
      <ShortName>INVENTORIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40401 - Disclosure - OPERATING LEASES - Lease, Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesLeaseCostDetails</Role>
      <ShortName>OPERATING LEASES - Lease, Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40402 - Disclosure - OPERATING LEASES - Lessee, Operating Lease, Liability, Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesLesseeOperatingLeaseLiabilityMaturityDetails</Role>
      <ShortName>OPERATING LEASES - Lessee, Operating Lease, Liability, Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40403 - Disclosure - OPERATING LEASES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>OPERATING LEASES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40501 - Disclosure - REVENUES - Statements of operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesStatementsOfOperationsDetails</Role>
      <ShortName>REVENUES - Statements of operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40502 - Disclosure - REVENUES - Contract With Customer Asset And Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesContractWithCustomerAssetAndLiabilityDetails</Role>
      <ShortName>REVENUES - Contract With Customer Asset And Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40503 - Disclosure - REVENUES - Unsatisfied Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesUnsatisfiedPerformanceObligationsDetails</Role>
      <ShortName>REVENUES - Unsatisfied Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40601 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="plx-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40701 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>32</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>plx-20190930.xml</File>
    <File>plx-20190930.xsd</File>
    <File>plx-20190930_cal.xml</File>
    <File>plx-20190930_def.xml</File>
    <File>plx-20190930_lab.xml</File>
    <File>plx-20190930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6749661856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVENUES - Unsatisfied Performance Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Unsatisfied performance obligation</a></td>
<td class="nump">$ 50,584<span></span>
</td>
<td class="nump">$ 76,969<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6760215680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="nump">$ 426<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GrantsAndReimbursementsReceivedOrReceivable', window );">Grants</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(1,810)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrantsAndReimbursementsReceivedOrReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GrantsAndReimbursementsReceivedOrReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6749618304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">NOTE&nbsp;1&nbsp;- SIGNIFICANT ACCOUNTING POLICIES</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">a.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>General</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Protalix BioTherapeutics,&nbsp;Inc. (collectively with its subsidiaries, the &#x201C;Company&#x201D;) and its wholly-owned subsidiaries, Protalix&nbsp;Ltd. and Protalix B.V. (the &#x201C;Subsidiaries&#x201D;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;"> protein expression system (&#x201C;ProCellEx&#x201D;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name alfataliglicerase in Brazil and certain other Latin American countries and Elelyso</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;"> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s product pipeline currently includes, among other candidates:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">pegunigalsidase alfa, or PRX&#8209;102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">alidornase alfa, or PRX&#8209;110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (3)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">OPRX&#8209;106, the Company&#x2019;s oral antiTNF product candidate which is being developed as an orally-delivered anti-inflammatory treatment using plant cells as a natural capsule for the expressed protein.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company, together with its commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201C;Chiesi&#x201D;), plans to file a biologics license application (&#x201C;BLA&#x201D;) for PRX-102 for the treatment of Fabry disease by April 2020 through the Accelerated Approval pathway of the U.S. Food and Drug Administration (&#x201C;FDA&#x201D;). This decision is the result of a series of meetings and correspondence between the Company and Chiesi, on the one hand, and the FDA, on the other hand. The Company and Chiesi have initiated preparations for the BLA submission based on clinical data generated in the one-year completed phase I/II clinical trials of PRX-102 and from the ongoing phase III BRIDGE clinical trial, as well as safety data from all on-going studies. The BLA will also include extensive data from the Company&#x2019;s completed nonclinical program, as well as information regarding production of PRX-102. </font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On October&nbsp;19, 2017, Protalix&nbsp;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201C;Chiesi Ex-US Agreement&#x201D;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&nbsp;23, 2018, Protalix&nbsp;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201C;Chiesi US Agreement&#x201D;) with respect to the commercialization of pegunigalsidase alfa in the United States.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively,&nbsp;the &#x201C;Chiesi Agreements&#x201D;), Chiesi made an upfront payment to Protalix&nbsp;Ltd. of $25.0&nbsp;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&nbsp;Ltd. is entitled to additional payments of up to $25.0&nbsp;million in pegunigalsidase alfa development costs, capped at $10.0&nbsp;million per&nbsp;year, and to receive additional payments of up to $320.0&nbsp;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&nbsp;Ltd. is entitled to payments of up to a maximum of $20.0&nbsp;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&nbsp;million per&nbsp;year, and to receive an additional up to a maximum of $760.0&nbsp;million, in the aggregate, in regulatory and commercial milestone payments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under the terms of both of the Chiesi Agreements, Protalix&nbsp;Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer Inc. ("Pfizer") in accordance with the exclusive license and supply agreement entered into&nbsp;between Protalix&nbsp;Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October&nbsp;2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On June 18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201C;Brazil Agreement&#x201D;) with Funda&#xE7;&#xE3;o Oswaldo Cruz (&#x201C;Fiocruz&#x201D;), an arm of the Brazilian Ministry of Health (the &#x201C;Brazilian MoH&#x201D;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with alfataliglicerase in Brazil.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Going Concern</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;">Since the Company is engaged in research and development activities, it has not derived significant income from its activities and has incurred accumulated losses in the amount of $341.0 million through September 30, 2019 and cash outflows from operating activities. As of September 30, 2019, the Company has outstanding $57.9 million aggregate principal amount of its 7.50% convertible promissory notes due 2021 (the &#x201C;2021 Notes&#x201D;) which are secured with a perfected lien on all of the Company&#x2019;s assets. Under the terms of the indenture governing the 2021 Notes, the Company is required to maintain a minimum cash balance of at least $7.5 million. As of September 30, 2019, the Company had cash and cash equivalents of $21.4 million. Based on its current cash resources and commitments, the Company may not be able to meet its current planned development activities and the corresponding level of expenditures for the next 12 months from the date of approval of the financial statements as of September 30, 2019 absent a refinancing or restructuring. These factors raise substantial doubt as to the Company&#x2019;s ability to continue as a going concern.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;">The Company&#x2019;s management is in the process of evaluating refinancing and restructuring alternatives, including a restructuring of its outstanding convertible notes, and related transactions.&nbsp;&nbsp;However, there is no certainty about the Company&#x2019;s ability to obtain such funding.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:normal;">The financial information has been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business.&nbsp;&nbsp;If the Company does not complete a refinancing or restructuring, it will need to curtail or cease operations.&nbsp;&nbsp;These financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">b.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Basis of presentation</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201C;GAAP&#x201D;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full&nbsp;year.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2018, filed by the Company with the U.S Securities and Exchange Commission (the &#x201C;Commission&#x201D;). The comparative balance sheet at December 31, 2018 has been derived from the audited financial statements at that date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">c.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Net loss per share</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Basic and diluted loss per share (&#x201C;LPS&#x201D;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s common stock, par value $0.001 per share (the &#x201C;Common Stock&#x201D;), outstanding for each period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The calculation of diluted LPS does not include 73,310,911 and 78,269,464 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of outstanding convertible notes for the nine&nbsp;months ended September 30, 2018 and 2019, respectively, and 73,280,977 and 78,547,287 shares of Common Stock for the three months ended September 30, 2018 and 2019, respectively, because the effect would be anti-dilutive.</font>
		</p>
		<p style="margin:0pt 0pt 1pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">d.<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 12pt 0pt 0pt;"></font>Recently adopted standards</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February&nbsp;2016, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued ASU No.&nbsp;2016&#8209;02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). The new standard requires a lessee to record assets and liabilities on its balance sheet for all leases with terms longer than 12&nbsp;months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the lessee&#x2019;s income statement. The Company adopted this standard as of January&nbsp;1, 2019 on a modified retrospective basis and will not restate comparative periods. The Company elected the package of practical expedients permitted under the transition guidance within the new standard which, among other things, allows the Company to carryforward the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12&nbsp;months or less off of its balance sheet. The Company recognized those lease payments in its statements of operations on a straight-line basis over the lease period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of the adoption date, the Company recognized an operating lease asset and liability of $5.9&nbsp;million and $5.7 million, respectively, as of January&nbsp;1, 2019 on its balance sheet.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Newly issued accounting pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In June&nbsp;2018, the FASB issued ASU 2018&#8209;07, &#x201C;Compensation&nbsp;&#x2013; Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting&#x201D; that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in ASU 2018&#8209;07. The guidance is effective for fiscal&nbsp;years beginning after December&nbsp;15, 2018, including interim reporting periods within that fiscal&nbsp;year. Early adoption is permitted, but no earlier than an entity&#x2019;s adoption date of Topic 606. The Company does not expect the adoption of ASU 2018&#8209;07 to have a material impact on its financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6637511808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member', window );">Notes 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of liability component based on income approach</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company prepared a valuation of the fair value of the Company&#x2019;s outstanding 2021 Notes&nbsp;(a Level 3 valuation) as of September 30, 2019. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 35.3pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2021&nbsp;Notes</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Stock price (USD)</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 0.21</font></p>
				</td>
				<td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Expected term</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 2.13</font></p>
				</td>
				<td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Risk free rate</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1.62</font></p>
				</td>
				<td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Volatility</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 74.99</font></p>
				</td>
				<td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:85.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Yield</font></p>
				</td>
				<td valign="bottom" style="width:04.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 10.53</font></p>
				</td>
				<td valign="bottom" style="width:04.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_Notes2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6632301504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;">NOTE 6 - STOCK TRANSACTIONS</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In September 2019, the Company granted to its new chief financial officer 10-year options to purchase, in the aggregate, 800,000 shares of Common Stock under the Company&#x2019;s 2006 Employee Stock Incentive Plan, as amended (the &#x201C;Plan&#x201D;).&nbsp;&nbsp;The options have an exercise price equal to $0.2 per share and vest over a four-year period in 16 equal quarterly increments.&nbsp;&nbsp;Vesting of the options is subject to acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions.&nbsp;&nbsp;The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $97,000 based on the following weighted average assumptions: share price equal to $0.2; dividend yield of 0% for all years; expected volatility of 66.48%; risk-free interest rates of 1.695%; and expected life of six years.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6902540128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES - Lease, Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 314<span></span>
</td>
<td class="nump">$ 907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">10 years 7 months 6 days<span></span>
</td>
<td class="text">10 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">12.55%<span></span>
</td>
<td class="nump">12.55%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6927224576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,691<span></span>
</td>
<td class="nump">$ 3,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">3,601<span></span>
</td>
<td class="nump">4,777<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 7,525<span></span>
</td>
<td class="nump">$ 8,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6746527744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Contract With Customer Asset And Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contracts liability at the beginning of the period</a></td>
<td class="nump">$ 42,895<span></span>
</td>
<td class="nump">$ 25,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Additions during the period</a></td>
<td class="nump">22,151<span></span>
</td>
<td class="nump">34,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized during the period</a></td>
<td class="num">(24,848)<span></span>
</td>
<td class="num">(16,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contracts liability at the end of the period</a></td>
<td class="nump">$ 40,198<span></span>
</td>
<td class="nump">$ 43,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>52
<FILENAME>0001104659-19-060804-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-19-060804-xbrl.zip
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MV'H")YSZWN^"Z8:G[=:O'\/OPA$2[_SZ,:!>V:0\UW4#F82:M]30KZP+.C-
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M_3&SX2?/<$2N:AGN,@43JPQIIQL9TO<!E5@<QEEXZ\,=,Z9/ON.*BQSNF,:
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M\U=?)C#BVZG]8C$],TX(5 S#-T]O\C=C>)O_ *BR,]XGQDE-VR!@8,B38<_
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MYT\Q[H._3=MU8U<U=F1_:G>49HM$P6^P!70/P8KH4-EN<=T[%/$%=2?HPX]
M_%T!A!VVD4@F<]&LP^#SH\R+OIUHF?53M]\<1K!$(2QXS; F8X:;I1'@N'@(
MKL&<:O&I(?2O<>L% UV+'[7200[5EJK,ZU+^+3]FE-'WW#5"S\=E@,A(<C%J
M'_$#\>"D@49$"&/+GY]PYZTTDKY%%*;B!W%( J/-,28<K%"9Q9!EM5@FIA$G
MG3 Q((XZ"?H\!0>T4+-[!&M%/)Z'"!&[/G4"@D>4Q\G!\0^#IY]4I=F)1_T<
M[G7QC=.P'Q:^!XQO@UU@;I1],+P@5$Y..*6<:J@T>74)KI%!.)8<#S=+\81#
MOOA$*<EXAQ"1:N+#D=L%$3+@/-ZRL["CIZ*2*8CUQ(TWL+@%1"2&\4Y MA&6
MY?#DB1N>'.6[Z;DHA96X'$9TV<6+&$\ZO*;<\3'9 %_P313,N<-2; ?(3 WX
MA*<XL#$I3J7;_I/'?7Q[K0V>R CQ;7ZQF:<)[;P'#[ 2ZGEA934,0,7!-12Q
M0$4&M>^<:X#X/@TJT6,B"@\[0470!R#?%C^+@)K<"IUXFGDN4%]VNEM@I,0L
M(?IB?*&^>>Q#M:":/0HWX[_^;K\ DSM<H#!H0PL2.FC $1"Y^=Y:C)/<Y!OY
M'+AC9IA8V),;TE%J0]0 "+67$3/<^T>_,[ GV-J"N2E]QY-_26\1/$6^><8-
MN^@!Q5T%PP6?VAF+'\SXU'+(JP)HW!!V7*ZRGH)F=[FL<I6R6*!9F' WPKWY
M%;J*NR@<="L(S$$W \^8^*3&RTKLZ+1E+@"!KLM3HQ!'(2AA;0%/ .C_Z[O"
M7(AC(V@FGI*;UN[$]DT]M2CXW;="([*A+@R+(#]F:YA(\H,XH[KRG&E\)#4X
MBGUC73/O'O.'"SIF[?5&RA4MKUK-=E<L?,EJ=K/DTNY^7;ED9:M+WO7]RBN7
MVVE58KDEW5]>,G6C[VY&^?WTOJ,S:;[=X5/F;;CC4*!7RPK*K[&@D'Z;P;KO
MQ2;IOG2Q;=YSJ]\M:[7H]S'=_0IA0*I%R\TH;-^W6&?UHK4E/H5,BX>I(8*"
MH2Z?F>A@G>HTD_F](,NOV\&RE^BLL,9:\Q&#@G$SNA6;64OP,4CA8Q 3.WCU
MQKEGSK.AL;@18S9!]F '";@,/BJ!S:!-[CPVTPB*D8C-?3"#>J[;$"GJ]^C^
M4T?/>@NR205_4*]#DXJ0I."H<IH2-R1JC79:KBSRE3TY/KC3J<W,X/3"U\A7
M/]=XV2FZT!'SDL\V_)/9^SB__YS.JQD0 6$Q^?T/<FTWT[,D3DQ@.3W7TR[Y
M\&#/#(T,.NHO81C%CX>[3 \BJ>B$^-@WQ-8Q)G7$\2@:03H_8.L74;9J 2I#
M<H6Y-8P13#S[$(1DN&V1C,:2\5>0[ HS;NX$TU7A5IPI)A6;V3SO9]J@;3#I
M1"V@<*)XAV>>FB&8/+AZPC/Y,"W>^<)/?#"#5ZB+L(EAL!6E7AMBDO#YX*0
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M^@-VP(\.:HJFFBXS3=ZLP;8SS3$.P_&O#=6K'1+@F7UL=VJR]^S@5A/S.]G
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M]YJIS_UN8DKUN> (0+?14MY5_%K/&.589/D<EHDWK+M$]YVP6O9@0XZ*4?7
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M.ZA'Q(Y-C60=/0$M\'%-/\Q3Q4M)&ZQOM_>9W@>.8',_V%S4C6>#1U-6B)1
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ML1T@W5]X$OP)('KF1_R0K+Z5^,+@3:3XZ4>D0X"TY, 04MC!H?$GQZ; %G@
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MV9:]*/;2!41I=@82\_O _+"I2I[?"^:EMI':YM@P+[5--;L][=UGE=V>ZF=
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M(/SB,[/8R/!P3'<+OI+:[J>EN63H=KWT MJUU^I59.7!6-O8D1D46&,:C.W
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MP <(73/JX"&>(*\ 5V(YQU\*G,SFCBRX]VS*\.1+8>Z\%*4?RY?G99G]UY$
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M?^&[L["]RFU-3?<1#\$CG<D$6\J1W4\N1"X].Q:RX -&GPBHYV9Y#]+KNNN
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M&:T<L8X.Z9%@MJJLOV@VKW9)K93-K"<ICY1N"#1QR)72K9U1RYMH#V'<=OO
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MN#3M"W(L, %SC='ZV7U;@Z\G&*[6%N61?;=$8!XE>Z[C)S8(49>%KJ\9%N?
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M;=5/.?<(&%$ CMV%4,<VAX22[3>[9T>EKTWF7A29I:3*&-D"FY7!"JY(6$*
MH7#S>/1G%0Q63M7:W'H08:CBE?6[K.DEVJF08+2.E;TJL3E-5_;B&I6.-=?I
M^GUAT?-[.@8SYQXZ!O+^$AJ:Y$>:/MJ8JHA4.E:4"^A%W]V]H)+<G1THL4DT
M@0796J.I79S\:DC(,0 P\3UA;P+@ZLE#F(T]FM,0G(WW"IJD?DJ)390I<$K-
M4-5%;W=HF.ITJW!H Q(0B#=68B=A#L''^<@5]/UR3ONG,>:__S]02P,$%
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M57V0@B+H10,?*OW(4(C (2F2:0?Q1'V_33^J0&CN0<+JD7<H06 XA]KP2M\
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M-S-R]DETH&YGV^A%";<^HX?0LK*-#F30JCDZ\Z@NC4A)\84J)48PC%.[_F-
MV?<EV1T@YOBQ/=;+ZU3TRJ6D&%98HTR(!JLK@V-;5YV75BL:B>(B2RJE].5
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M9AB5%V?$<YHLMM=AM*5><HAJ+4=/IF;^1'< X;,3WA-(H9SXGLQOW3/LPD/
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MMZ=5X;,*V :-/F9=K=49)+)F5]EHU^X,W@X-;^&>-V_DR3F>JD^[47E!^F2
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M-5()EP-8J@-4WXJ]ZDP!AR%OPW1/G [;#?04F[36#(>RO/-8&CQ.-(2EJ1Y
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M=?E:P*2YK_%7)W)E#=S/0!_IN&'H":H<5 Q%W/P1Q["<UP]'4OH0+W/LBP=
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MAREULP;94\H:&F2$4D1$TQU,FJ19FO3O&S8\^S?[%_L#*GK^[?\!4$L#!!0
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M584 *L@D+E=I@NE K.H$;7YX!:*(H8([K]*?R?4E,7+='3#N=@Y:6 2VV#?
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M-'D)GCL86<,W?8U?S+BW';[$225:;(@>B99 0U(O)"%_!UA*P.BC,8#6/3.
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M?L$=QV=>?_M_4$L! A0#%     @ >S=G3[*+4E$$=   4J@& !
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M              "  2?A  !P;'@M,C Q.3 Y,S!?<')E+GAM;%!+!08
..!@ & (0!  "3"P$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
